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Abstract 
The health of our bones is maintained by two major cell types in a delicate 
balance of active bone remodelling through bone resorption by osteoclasts and bone 
formation by osteoblasts. An imbalance in the processes leads to osteoporosis, which 
is a metabolic disorder of the bones that shows increased incidence in post-
menopausal women, where estrogen deficiency plays a significant role in its 
development. Hormone and hormone responsive molecules have emerged as playing 
a critical role in immunity, metabolism and cell differentiation and their activation is 
associated with many human diseases. The aim of this project is to investigate 
hormone and hormone responsive molecules associated with the development of 
osteoporosis in post-menopausal women. Firstly, a hormone-responsive cell model 
system was established using osteosarcoma [osteoblast-like] cell lines, Mg-63, TE-
85 and Saos-2, which represent three different stages of bone maturation. Secondly, 
the effect of steroid hormones on these cultured cells was analysed using RNA 
sequencing to identify differentially-expressed hormone responsive genes. Thirdly, 
the identified genes were further analysed in peripheral blood mononuclear cells 
(PBMCs), an osteoclast precursor, from osteoporosis patients, female >40 years, to 
assess potential diagnostic values for osteoporosis. Furthermore, some functions of 
selected genes and their protein products were investigated using cultured cells. 
A panel of differentially expressed hormone responsive genes was identified 
using RNA sequencing from established osteosarcoma cell line, Mg-63 after β-
estradiol treatment. 154 genes were up-regulated and 108 genes were down-
regulated compared to non-treated controls. Further analysis showed that 5 
differentially expressed genes were associated with the development of osteoporosis 
in clinical samples using RT-qPCR. 
The levels of annexin A1 (ANXA1), calcium binding protein (S100A4), and 
X-box binding protein transcription factor (XBP1) mRNAs were significantly 
decreased in PBMCs associated with reduced T-score in osteoporosis patients 
compared to osteopenia and non-osteoporotic participants (p = 0.0291, p=0.00034, 
p=0.0001, respectively). Increasing levels of Cathepsin Z (CTSZ), translocation 
associated membrane protein 2 (TRAM2), and Gasdermin D (GSDMD) mRNAs in 
PBMCs significantly correlated with reduced T-score in osteoporosis patients 
XVI 
 
compared to osteopenia and non-osteoporotic participants (p = 0.0011, p=0.0161, 
p=0.0019 respectively). The levels of microRNAs miR-100-5p and miR-99a-5p were 
significantly decreased in PBMCs associated with the reduced T-score in 
osteoporosis patients compared to osteopenia and non-osteoporotic controls (p = 
0.0002 and p= 0.0270 respectively). However, the levels of miR-196b-3p, miR-1260 
and miR-1290 were significantly increased in PBMCs associated with the reduced T-
score in osteoporosis patients compared to osteopenia and non-osteoporotic controls 
(p = <0.0001, p=0.0072 and p=0.0004 respectively).  
Furthermore, through a follow-up cellular functional study, suppression of 
Cathepsin Z (CTSZ) mRNA/protein expression using RNAi significantly inhibited 
proliferation, migration and invasion of Mg-63 and TE-85 cells.  
This is the first report of the presence of cathepsin Z mRNA/protein in 
osteosarcoma cells and the first demonstration of an association between CTSZ and 
osteoporosis in PBMCs. The results suggest that CTSZ might be a valuable 
diagnostic and therapeutic target for osteoporosis in postmenopausal women in the 
future. 
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1.1 Bone  
1.1.1 Function and Structure of Bone 
Bone is a rigid organ that creates the vertebrate skeleton which has a variety of 
functions. First, it provides structural support to the whole body. Second, it helps in 
locomotion and movement, through the provision of levers to muscle. Thirdly, bone 
protects vitals structures and internal organs such as the skull protecting the brain or the 
ribs protecting the heart and lungs. Fourthly, in response to acidic conditions, bone 
tissue will dissolve to release neutralizing calcium carbonate into the blood stream 
which eventually maintains the body's proper pH levels. Lastly, bone provides 
maintenance of mineral homeostasis particularly of calcium and phosphorus (Robling et 
al., 2006).  
There are two types of bone tissue composed of osteons, cortical and trabecular 
bone, as shown in Figure 1-1. The cortical bone (compact) is dense, solid, and surrounds 
the marrow space. It comprises 80% of bone in the human skeleton (Clarke, 2008). The 
trabecular bone (cancellous or spongy) comprises 20% of bone in the human skeleton, 
and is found sandwiched between cortical bone layers. It is composed of a honeycomb-
like network of trabecular plates and rods interspersed in the bone marrow compartment 
(Clarke, 2008). 
Cortical and trabecular bone is comprised of organic and mineral components. The 
organic component (Osteoid) contain 25% of total bone mass and is composed mostly of 
cross linked type I collagen (90%), where the rest contain proteoglycan and non-
collagenous proteins such as osteocalcin, osteopontin and osteocalcin. The menial 
components contain 65% of the bone mass, is mainly calcium and phosphorus in the 
  Chapter 1 
3 | P a g e  
 
form of hydroxyapatite as well as other ions, Mg2+, Na+, K+, Cl-, HCO3- and the 
remaining 10% is water. These components provide the rigidity to the structure and the 
collagen provides resilience and ductility (Florencio-Silva et al., 2015) 
 
Figure 1-1: Cortical and cancellous bone structure. 
Bone section of the proximal femur in the frontal plane illustrating cortical 
and trabecular bone. This figure is adapted from 
(www.servier.com/Powerpoint-image-bank) 
1.1.2 Bone Cells 
There are four cell types of cell found in bone: osteocytes, osteoblasts, osteoclasts, 
and lining cells (Downey and Siegel, 2006, Buckwalter et al., 1996).  
4.2.3.1 Osteoblasts 
Osteoblasts are the cells that responsible for bone formation and they are located 
along the outside of the bone surface (Capulli et al., 2014). They arise when 
mesenchymal stem cells express the transcription factor RUNX2, a master gene 
regulator of osteoblast differentiation, forming osteoprogenitor cells or pre-osteoblasts in 
bone marrow (Figure 1-2). They are found in large numbers in the periosteum, which is 
a membrane that covers the cortical tissues (Figure 1-1) (Darvin et al., 2013). 
Osteoblasts are responsible for direct production and secretion of the organic 
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components of bone, type 1 collagen, and non-collagen protein such as osteocalcin and 
osteopontin, known as osteoid (Alghazali et al., 2015), which then mineralizes to 
become bone. On completion of bone formation, the mature osteoblasts can undergo 
apoptosis (Jilka et al., 1998) or become osteocytes or bone lining cells (Florencio-Silva 
et al., 2015).  
4.2.3.2 Osteoclasts  
Osteoclasts are large cells with multiple nuclei that are responsible for bone 
resorption (Yavropoulou and Yovos, 2008). Osteoclasts are differentiated from 
hematopoietic stem cells, the monocyte–macrophage lineage in bone marrow (Boyle et 
al., 2003), (Figure 1-2.). Bone resorption process is very important in bone health 
because it allows, along with the osteoblasts, for bone remodelling. The formation of 
osteoclasts is regulated by cytokines and hormones through several transcription factors, 
which control osteoclast proliferation, survival, differentiation, and function (Xia et al., 
2011). Osteoclast activation occurs on binding of osteoblast membrane-bound Receptor 
Activator for Nuclear Factor k B Ligand (RANKL) and macrophage colony-stimulating 
factor (M-CSF) to their receptors on the surface of osteoclasts (Figure 1-3). RANK 
signalling is regulated by a decoy receptor for RANKL, osteoprotegerin (OPG), which is 
produced by osteoblast lineage cells that inhibit the formation of osteoclasts (Lacey et 
al., 1998), as shown in Figure 1-3. Bone resorption process is controlled by hormones in 
the bloodstream which instruct the osteoclasts when and where to break down bone 
tissue through releasing RANKL that activate osteoclasts under the influence of 
parathyroid hormone (Florencio-Silva et al., 2015, Alghazali et al., 2015) 
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Figure 1-2: Schematic diagram of the source of bone cells  
Osteoblasts are derived from MSCs cells that differentiate first to 
committed pre-osteoblast cells where they form the new bone, and then 
become osteocyte or lining cells. Osteoclasts originate from HPSCs which 
differentiate, first to a mononuclear pre-osteoclast cell that then fuses to 
form the osteoclast cells. This figure is adapted from 
(www.servier.com/Powerpoint-image-bank) 
 
 
Figure 1-3: Osteoclast activation 
The activation of osteoclast starts from binding of Receptor Activator for 
Nuclear Factor k B Ligand (RANKL) on osteoblast surface to receptor 
activator for nuclear factor k B (RANK) on the surface of pre-osteoclast 
cells. The activation is controlled by osteoprotegerin (OPG) which inhibits 
the formation of mature osteoclasts by preventing the binding between 
RNAK/RANKL, PTH = parathyroid hormone. This figure is adapted from 
(www.servier.com/Powerpoint-image-bank)  
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4.2.3.3 Osteocytes  
Osteocytes, which comprise 90–95% of the total number of bone cells, are the 
most abundant cell type in the bone. They originate from osteoblasts that have migrated 
into and become trapped inside of the bone matrix (Florencio-Silva et al., 2015). 
Osteocytes lie within lacunae, within the mineralized bone and have long thin 
cytoplasmic processes that occupy tiny canals called canaliculi, Figure 1-2. These cells 
have the ability to form a fine network of connections in the bone matrix with other 
osteocytes, and with the bone lining cells located at the surface of the bone (Capulli et 
al., 2014). Therefore, it is thought that these connections are extremely important in 
cellular communication by facilitating the intercellular transport of small signalling 
molecules such as prostaglandins and nitric oxide among these cells within the 
mineralized matrix as well as allowing cell-mediated exchanges of minerals between the 
fluids in the bone and the vascular supply (Downey and Siegel, 2006, Buckwalter et al., 
1996). Recently, however, it has been suggested that osteocytes can alter the rate of bone 
remodelling by controlling osteoclast formation via production of RANKL (Dallas et al., 
2013) and osteocytes also control the balance between formation and resorption of bone 
by regulating osteoblast formation via production of sclerostin (SOST), which stimulates 
RANKL expression by osteocytes leading to inhibiting the Wnt signalling pathway (Li 
et al., 2005) and eventually decreasing the osteoblast formation (Poole et al., 2005, 
Wijenayaka et al., 2011, Xiong and O'Brien, 2012). 
4.2.3.4 Lining Cells 
This type of cell is derived from osteoblast cells and has an elongated and flattened 
form (Miller et al., 1989). These cells exhibit a thin and flat nuclear profile and cover the 
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bone surfaces and separate the bone surface from the bone marrow, thereby protecting 
bone surfaces from inappropriate resorption (Alghazali et al., 2015), (Figure 1-2). Bone 
lining cells functions during bone resorption, removing the thin layer of organic 
component that covers the mineralized matrix once exposed to parathyroid hormone. 
Also, lining cells prevent the direct interaction between osteoclasts and bone matrix, 
when bone resorption should not occur, and participate in osteoclast differentiation by 
producing OPG and RANKL (Alghazali et al., 2015, Everts et al., 2002) 
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1.1.3 Bone Remodelling 
 Bone tissue is metabolically active and undergoes continuous remodelling 
throughout life although it appears to be inert and static (Crockett et al., 2011). Bone 
remodelling is a process whereby old bone is removed from the skeleton through bone 
resorption by osteoclasts, and new bone is replaced through bone formation by 
osteoblasts in a coordinated fashion (Frost, 1990). These processes also could control the 
reshaping and replacement of bone during growth and following injuries such as 
fractures and microdamage, which can occur during normal activity. The property of 
bone remodelling makes the bone a very dynamic tissue that permits the repair of 
damaged tissue, the maintenance of bone tissue, and the homeostasis of the 
phosphocalcic metabolism (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b).  
4.2.3.1 Bone Remodelling Phases 
At a cellular level, bone remodelling occurs in small areas of the cortical and 
trabecular surface, known as basic multicellular units (BMUs) (Hauge et al., 2001). The 
bone remodelling process resorbs the old bone, which is replaced by new bone to 
prevent accumulation of bone microdamage (Xiao et al., 2016). Under normal 
conditions, the rate of resorbed bone in the mature skeleton is proportional to rate of 
production of the newly formed bone (Crockett et al., 2011). Therefore, it is referred to 
as a balanced process and continues up to the third decade of life in humans, when the 
bone mass is at its maximum, and this is maintained with small variations until the age 
of ~50 in humans. From then on, resorption predominates, causing a decrease in the 
bone mass (Clarke, 2008).  
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The bone remodelling cycle involves sequential phases that depend on the 
interactions of osteoclasts and osteoblasts. The process occurs over several weeks and 
approximately 5 to 10% of total bone is renewed per year (Alghazali et al., 2015). Bone 
remodelling can be divided into the following six phases, namely, quiescent, activation, 
resorption, reversal, formation, and mineralization (Fernandez-Tresguerres-Hernandez-
Gil et al., 2006b), as summarized in Figure 1-4. 
1.1.3.1.1 Quiescent Phase 
This state describes the bone when at rest. The factors that initiate the remodelling 
process remain unknown (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b). 
1.1.3.1.2 Activation Phase 
The bone surface is activated prior to resorption, through the retraction of the bone 
lining cells and the digestion of the endosteal membrane by collagenase action 
(Teitelbaum, 2007). The activation stage involves recruitment and activation of 
osteoclast precursor cells from the circulation, mononuclear monocyte-macrophages, 
leading to interaction of osteoclast and osteoblast precursor cells (Bruzzaniti and Baron, 
2006). This results in the differentiation, migration, and fusion of the large 
multinucleated osteoclasts in response to macrophage colony-stimulating factor (M-
CSF) and RANKL that is released from osteoblasts (Fixe and Praloran, 1998, 
Fernandez-Tresguerres-Hernandez-Gil et al., 2006b). 
1.1.3.1.3 Bone Resorption Phase 
Osteoclasts start to dissolve the mineral matrix by secreting hydrogen ions that 
create an acidic microenvironment and decompose the osteoid matrix by secretion of 
lysosomal enzymes, particularly cathepsin K, making the mineralised component 
  Chapter 1 
10 | P a g e  
 
dissolve. Macrophages complete this process and permit the release of growth factors 
contained within the matrix, essentially platelet derived growth factor (PDGF), 
transforming growth factor beta (TGF-β), insulin-like growth factor I and II (IGF-I and 
II) (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b) 
1.1.3.1.4 Reversal Phase 
At this stage, bone resorption shifts to bone formation. Once bone resorption is 
complete, resorption cavities contain mononuclear cells, including monocytes, 
osteocytes, and preosteoblasts, recruited to begin new bone formation (Wu et al., 2015). 
1.1.3.1.5 Bone Formation Phase 
Osteoclasts are replaced by preosteoblast which synthesize a cementing 
substances, which consists of organic components, type 1 collagen, and non-collagen 
protein such as osteocalcin and osteopontin, all together known as osteoid (Canalis et al., 
2003). A few days later, the resorption cavity is then filled with the osteoid synthesized 
by the osteoblasts (Lind et al., 1995, Fernandez-Tresguerres-Hernandez-Gil et al., 
2006b). 
1.1.3.1.6 Mineralization Phase 
This phase begins thirty days after deposition of the osteoid, ending at 90 days in 
the trabecular, and at 130 days in the cortical bone (Fernandez-Tresguerres-Hernandez-
Gil et al., 2006a). Calcium hydroxy phosphate crystals, secreted from osteoblasts, is 
deposited in the resorption cavity of triple helical fibrils “hole regions” of collagen 1 
under the influence of non-collagenous proteins (Gajjeraman et al., 2007, Sapir-Koren 
and Livshits, 2011). The quiescent phase then begins again after completely cover the 
newly formed bone surface and link with the osteocytes through a network of canaliculi 
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in the bone matrix (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b). When the cycle 
is completed, the amount of bone formed should equal the amount of bone resorbed. 
Abnormalities of bone remodelling process are associated with a variety of skeletal 
disorder such as osteoporosis, which the rate of bone resorption is more than bone 
formation.  
 
Figure 1-4: Phases of bone remodelling: 
Bone remodelling requires the coordination of six sequential, but distinct, 
phases of the process namely, quiescence, activation, resorption, reversal, 
formation, and mineralization. The quiescent phase involves detection of 
an initiating remodelling signal, which is described as resorption by 
osteoclasts. In the resorption phase, osteoblasts respond to signals 
generated by osteocytes or direct endocrine activation signals, recruiting 
osteoclast precursors to the remodelling site. The limited duration of the 
resorption phase depends on the level of the stimulus responsible for 
osteoclast differentiation and activity. The osteoclasts are replaced by 
osteoblast in the reversal phase. The formation phase is distinct by forming 
the osteoid matrix by osteoblastic cells. The mineralization phase includes 
the crystallization of calcium hydroxy phosphate secreted from osteoblast. 
This figure is adapted from (www.servier.com/Powerpoint-image-bank) 
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4.2.3.2 Regulatory Factors of Bone Remodelling 
Some interrelated factors influence the balance between bone resorption and 
formation processes. These factors are, mechanical, nutritional, local, hormonal and 
genetic factors (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b). 
1.1.3.2.1 Mechanical Factors 
Growing bones are more responsive to physical activity, since it increases bone 
mineral mass build-up in both children and adolescents (Bonjour et al., 2009). The 
increased gain in BMD in young athletes compared with less active controls is localized 
in weight bearing bones. Therefore, in adult athletes, increased bone mass gain from 
intense physical activity during childhood and adolescence are maintained after training 
attenuates or even completely ceases in adult athletes (Bonjour et al., 2009). Physical 
activity influences bone metabolism not only locally, but also systemically (Jacobs et al., 
2010). In response to mechanical stimuli early signals produced, include nitric oxide, 
prostaglandins and IGF-I, which stimulate the osteoblast activity proteins. On the other 
hand, the absence of physical activity, rest or weightlessness has an adverse effect on 
bone, accelerating resorption (Jacobs et al., 2010). 
1.1.3.2.2 Nutritional Factors 
Generally, the supply of calcium is sufficient to avoid the occurrence of bone 
disorders during growth (Bonjour et al., 2009). From the last decade, attention has 
focussed on variations of the intake of certain nutrients that affect bone mass 
accumulation by healthy children and adolescents (Prentice et al., 2006). Most studies 
have focused on the intake of calcium to the studies (Moynihan and Holt, 1996, Whitton 
et al., 2011). Thus, the recommended daily calcium intake, for children aged 6-10 years, 
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is set at 500 mg, while for female adolescents aged 11-17 it is set at 800 mg in the UK.  
Nowadays, it is reasonable and safe to recommend food intake that would have about 
1000 mg of calcium daily from prepuberty to the end of adolescence, and after that age, 
and menopause should be at least 1.5 g per day. Similarly, it is known that toxic habits, 
such as smoking, caffeine, alcohol and excess salt are risk factors for osteopenia, a 
precursor condition of osteoporosis (Fernandez-Tresguerres-Hernandez-Gil et al., 
2006b). Not only an adequate calcium intake is important, but the skin and food supply 
of vitamin D must be adequate to enhance the mineralization of osteoid and regulate the 
expression of several bone proteins, particularly osteocalcin (Holick, 1996). Vitamin D 
expect that bone mass gain can be increased during childhood and adolescence and thus 
optimal bone mass peak can be achieved (Bonjour et al., 2009). The consequence of 
reduced level of vitamin D is bone loss, leading to osteoporosis and fractures (Lips and 
van Schoor, 2011) 
1.1.3.2.3 Local Factors 
Bone remodelling is also regulated by local factors. These factors include growth 
factors, cytokines, and the bone matrix proteins as describe in Table 1-1. They influence 
in bone remodelling by stimulating bone formation, stimulate bone resorption or inhibit 
bone resorption. Bone acts as an endocrine organ through the production of 
prostaglandins and nitric oxide, as well as cytokines and growth factors (Crockett et al., 
2011). 
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Table 1-1:  Regulatory local factors in bone remodelling 
 Stimulate bone formation Stimulate bone resorption Inhibit bone 
resorption 
Growth 
Factors 
• Bone Morphogenetic 
Proteins: BMP-2, 4, 6 
and 7 
• Insulin-like growth 
factor I and II: (IGF-I 
and IGF -II) 
• Transforming Growth 
Factor-β (TGF- β) 
• Fibroblastic Growth 
Factor (FGF) 
• Platelet-Derived 
Growth Factor (PDGF) 
• Tumor Necrosis Factor 
(TNF) 
• Vascular Endothelial 
Growth Factor (Yue et 
al.) 
•  Platelet-Derived Growth 
Factor (PDGF) 
• Fibroblastic Growth 
Factor (FGF) 
• Macrophage-Colony 
Stimulating Factor (M-
CSF) 
• Granulocyte/Macrophage
-Colony Stimulating 
Factor (GM-CSF) 
 
Cytokines 
 • Interleukin: IL-1, IL-6, 
IL-8, IL-11.  
• Prostaglandins: PGE2, 
PGE1, PGG2, PGI2, PGH2. 
➢ Interleukin 
IL-4 
1.1.3.2.4 Hormonal Factors 
The endocrine system plays a significant role in the normal development of bone. 
The most important hormones that involved in bone physiology are: 
1.1.3.2.4.1 Thyroid Hormones 
Thyroid Hormones (TH) can stimulate bone resorption and formation by 
stimulating the synthesis of the osteoid matrix by the osteoblasts and its mineralization. 
Therefore, in congenital hypothyroidism (cretinism) short stature is produced by the 
inhibition of the long bone formation. Also, thyroid hormones can stimulate resorption 
with the increase in number and function of the osteoclasts as bone loss in 
hyperthyroidism (Kawaguchi et al., 1994). 
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1.1.3.2.4.2 Parathyroid hormone 
Parathyroid hormone (PTH) produced in the parathyroid glands in response to 
hypocalcaemia to stimulate the bone resorption by synthesis of RANKL from osteoblast. 
It controls the homeostasis of calcium by stimulating renal production of 1,25 
dihydroxyvitamin D to increase Ca+2 absorption from kidneys and intestine. Also, PTH 
stimulates bone formation through the synthesis of IGF-I and TGF-β and decreases 
apoptosis of osteoblasts (Lombardi et al., 2011, Dempster et al., 1993).  
1.1.3.2.4.3 Calcitonin 
Calcitonin is produced by the C cells of the thyroid, or parafollicular. It 
counteracts PTH through inhibiting bone resorption by reducing the number and activity 
of the osteoclasts (Fernandez-Tresguerres-Hernandez-Gil et al., 2006b). High 
concentrations of calcitonin might be able to increase urinary excretion of calcium and 
phosphate, via actions on the kidney tubules (Carney, 1997). 
1.1.3.2.4.4 1.25(OH)2 vitamin D3 or calcitriol 
Calcitriol is a steroid hormone responsible for increasing the release of calcium 
and phosphate into the blood from bone by absorption of calcium and phosphate from 
gastrointestinal tract and kidneys. Thus, it acts in concert with parathyroid hormone 
(Raisz, 1999). 
1.1.3.2.4.5 Insulin 
Insulin stimulates matrix synthesis of insulin like growth factor (IGF-I and II) by 
the liver and osteoblasts, and found abundantly in the osteoid matrix. They increase the 
activity of the osteoblasts stimulating collagen synthesis (Guicheux et al., 1998). 
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1.1.3.2.4.6 Glucocorticoids 
Glucocorticoids increase bone resorption through stimulating osteoclastogenesis 
by increasing the expression of RANK ligand and decreasing the expression of OPG as 
well as increasing the apoptosis of mature osteoblasts (Canalis and Delany, 2002). 
1.1.3.2.4.7 Growth hormone 
Growth hormone (GH) acts directly on the osteoblasts by with stimulating the 
activity hormone receptors, thus increasing the synthesis of collagen, osteocalcin and 
alkaline phosphate (ALP). GH, through an indirectly action, increases in synthesis of 
IGF-I and II by the osteoblasts (Harvey and Hull, 1997). 
1.1.3.2.4.8 Androgens 
Androgens have an anabolic effect by increasing cortical bone size through 
stimulation of both longitudinal. However, androgen deficiency is associated with lower 
bone density. Androgens protect men against osteoporosis by maintenance of cancellous 
bone mass and expansion of cortical bone. Both testosterone and 5α-dihydrotestosterone 
stimulate proliferation of osteoblast precursors (Clarke and Khosla, 2009). 
1.1.3.2.4.9 Estrogen 
Estrogens play an important role in the regulation of osteoblastogenesis and 
osteoclastogenesis, by increasing the number and function of the osteoblasts and 
decreasing the number and function of the osteoclasts in female mice and humans (Imai 
et al., 2010, Maatta et al., 2013). The decreased levels of estrogen after the menopause 
plays an important role in the development of osteoporosis in postmenopausal women. 
The effect of estrogen is mediated by estrogen receptor α and/or β (ERα, ERβ), which 
have been described in human osteoblasts, osteocytes and osteoclasts (Fitzpatrick, 
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2006). Estrogen can increase the levels of OPG that inhibits resorption (Hofbauer et al., 
1999), so they play an important role in the regulation of osteoclastogenesis. Also, 
estrogens enhance osteoblast survival and block the osteoblast's synthesis of IL-6 that is 
a potent stimulator of bone resorption, thus, estrogen deficiency during the menopause is 
the most important pathogenic factor in bone loss associated with osteoporosis (Nilsson 
et al., 2001). Estrogen inhibits bone resorption rate in which bone mass decrease and 
continues to occur years after menopause (Cummings et al., 1998). This would occur 
through imbalanced production of some cytokines, interleukins and growth factors, 
which are important in bone development, as will be mentioned in Section 1.2.3. 
Understanding the basic biology of bone development is important for 
understanding the molecular and cellular mechanisms underlying bone disorders caused 
by abnormality in bone remodelling (Table 1-2) (Raisz, 1999, Feng and McDonald, 
2011). The bone remodelling process may be derailed at different points leading to 
various metabolic bone diseases. These diseases, such as osteoporosis, may reflect 
hereditary or acquired disorders in the mineral phase, the organic matrix, the cellular 
processes of remodelling, or the endocrine, nutritional, or other factors that regulate 
skeletal and mineral homeostasis (Xiao et al., 2016). The acquired metabolic bone 
disorders include: osteoporosis, osteomalacia, the skeletal changes of 
hyperparathyroidism and chronic renal failure (renal osteodystrophy) and Paget’s 
disease (Feng and McDonald, 2011, Xiao et al., 2016).  
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Table 1-2: Abnormalities of bone remodelling in disease   
Diseases 
Bone 
resorption 
Bone 
formation 
1 Primary Osteoporosis 
• Menopause associated 
• Age related 
increased  increased 
2 Secondary Osteoporosis 
• Glucocorticoid induced 
• Immobilization induced 
increased decreased 
3 Renal osteodystrophy increased  increased  
4 Paget’s disease increased  increased  
5 Osteopetrosis decreased  increased  
  
  Chapter 1 
19 | P a g e  
 
1.2 Osteoporosis 
Osteoporosis is a systemic skeletal disorder that characterized by low bone mass, 
resulting in increased bone fragility and increased fracture risk (Taxel, 1998, Tuck and 
Francis, 2002), (Figure 1-5). Osteoporosis affects 200 million individuals worldwide and 
is considered as a silent disease that often remains asymptomatic and undetected and 
becomes apparent only after bone fracture has occurred (Lin and Lane, 2004). Loss of 
bone mass and bone strength is mediated by (a) failure to reach the optimal peak bone 
mass in a young adult, (b) excessive bone resorption, or (c) an impaired bone formation 
response during bone remodelling (Parra-Torres et al., 2013). Osteoporosis is classified 
into primary and secondary types. Primary osteoporosis has been divided into two 
subtypes: failure to reach the optimal peak bone mass in a young adult, (b) excessive 
bone resorption, or (c) an impaired bone formation response during bone remodelling 
(Parra-Torres et al., 2013). Osteoporosis is classified into primary and secondary types. 
Primary osteoporosis has been divided into two subtypes: type I osteoporosis which is a 
common bone disorder in postmenopausal women caused by estrogen deficiency 
resulting from menopause or type II osteoporosis, which is associated with aging in both 
women and men (Feng and McDonald, 2011). Secondary osteoporosis is a group of 
bone disorders that are complications of various other medical conditions ( Table 1-2), 
physical activity consequences, or the negative outcome of therapeutic interventions for 
some disorders (Marcus, 1996). 
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Figure 1-5: Difference between normal bone tissue (trabecular) and 
osteoporotic bone tissue. This figure is redrawn from 
(www.servier.com/Powerpoint-image-bank) 
1.2.1 Epidemiology of Osteoporosis 
Osteoporosis is considered a major public health crisis around the world because it 
is not diagnosed until the occurrence of fractures, which result in substantial morbidity 
and mortality (Tuck and Francis, 2002). In 2010, 22 million women and 5.5 million men 
were estimated to have osteoporosis in Europe (EU), of which 2.5 million women and 
680,000 men are in the UK (Hernlund et al., 2013). Fractures caused by osteoporosis 
affect 1 in 2 women and 1 in 5 men aged >50 years in the UK (Poole and Compston, 
2006, Svedbom et al., 2013). 15% of white people of age over 50 and 70% of those over 
80 have osteoporosis are affected (Wade et al., 2014). This costs around £3.5 billion 
annually for health service and treatment with monitoring of fracture patients in the UK 
(Svedbom et al., 2013). There is an expectation of an increase in cost of treatment of 25 
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% by 2025 (Hernlund et al., 2013). Svedbom et al (2013) reported that, in 2010, 536,000 
new osteoporotic fragility fractures were sustained in the UK, comprising 14.7% hip 
fractures, 12% vertebral fractures, 12% forearm fractures and 60% other fractures (i.e., 
fractures of the fibula, clavicle, scapula, rib, humerus, sternum and other femoral 
fractures). 
1.2.2 Risk Factors for Osteoporosis 
The most important risk factor for osteoporosis is advanced age in both men and 
women which is 3-fold higher for each standard deviation (SD) decreased in BMD 
(Compston et al., 2017). Figure 1-6 shows that women lose bone mass more quickly 
than men, due to estrogen deficiency following the menopause or surgical removal of 
the ovaries (Bonjour et al., 1994). In men, a decrease in testosterone levels has a 
comparable effect (Sinnesael et al., 2013). Race also is a factor where people from 
European or Asian ancestry are more likely to suffer from osteoporosis than African 
people (Curtis et al., 2016). Some additional clinical risk factors have been identified. 
These include: a history of a prior fracture, a parental history of hip fracture, smoking, 
alcohol intake, malnutrition, and rheumatoid arthritis, which increases fracture risk 
independently of BMD (Compston et al., 2017).  
Genome-wide association studies (GWAS) have proven to be very successful in 
identifying common genetic variants associated with BMD adjusted for age, gender and 
weight, however a large portion of the genetic variance for this trait remains unexplained 
(Liu et al., 2014b, Mori, 2016). Recently, there is evidence to suggest significant genetic 
correlation between body size traits and BMD and unintended bias can be introduced as 
a result of adjusting a phenotype for a correlated trait (Mullin et al., 2016). Based on 
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GWAS data, it was found that there are at least 15 confirmed genes (VDR, ESR1, ESR2, 
LRP5, LRP4, SOST, GRP177, OPG, RANK, RANKL, COLIA1, SPP1, ITGA1, SP7, 
and SOX6) and potentially another 30 genes or more that could be osteoporosis related 
genes (Ralston, 2010). Particularly, these genes are clustered into three biological 
pathways: the estrogen endocrine pathway, the Wnt/β-catenin signaling pathway and the 
RANK/RANKL/OPG pathway (Li et al., 2010).  
 
Figure 1-6: Age-related changes in bone mass in men and women 
The general pattern of bone mass accrual and loss over the three phases of 
bone development: (I)growth (green), (II) modelling or consolidation 
(blue), and (III) remodelling (red). This figure is redrawn from (Bonjour et 
al., 1994) 
1.2.3 Osteoporosis in Post-menopausal Women 
The pathogenesis of postmenopausal osteoporosis is primarily caused by the 
reduced level of estrogen following the menopause (Feng and McDonald, 2011). 
Albright et al. (1941), for the first time, demonstrated that estrogen deficiency led to a 
reduced bone formation in postmenopausal women (Albright et al., 1941). However, 
subsequent studies (Garnero et al., 1996, Eriksen et al., 1990) indicated that estrogen 
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deficiency leads to an increase in bone resorption rather than to impaired bone 
formation. Nevertheless, it is well known that both bone resorption and bone formation 
are increased in postmenopausal osteoporosis; with the increased of bone resorption rate 
(Raisz, 2005). The past decades have focused on the understanding of the molecular and 
cellular mechanisms underlying the role of estrogen deficiency in the pathogenesis of 
postmenopausal osteoporosis. 
Indeed, in vitro and in vivo studies revealed that estrogen suppresses the 
expression of IL-1, TNF, and IL-6, which promote osteoclast differentiation, the in 
monocytes and/or osteoblasts (Pacifici, 1998, Girasole et al., 1992). Pacifici et al (1991) 
showed that human peripheral-blood monocytes cells (PBMCs) from ovariectomized 
premenopausal women secrete more IL-1 and TNF (Pacifici et al., 1991). Later Roggia 
et al (2001) confirmed the pathological role for TNF in postmenopausal osteoporosis by 
suppressing either TNF or TNF receptor 1 in mice which then showed a resistant to 
ovariectomy induced bone loss (Roggia et al., 2001). IL-1 and TNF either directly target 
osteoclasts to enhance its activity or indirectly stimulate osteoclastogenesis by 
upregulating the expression of IL-6 in osteoblasts (Feng and McDonald, 2011). Overall, 
these studies confirmed the idea that estrogen exerts protective effects on bone via 
inhibition of IL-1 and TNF expression. Recent investigations have shown that the 
increased levels of these three cytokines augment bone resorption by distinct 
mechanisms. 
The RANKL/RANK/OPG system plays an important role in bone remodelling in 
which any imbalance can lead to bone disorders, including postmenopausal 
osteoporosis. Osteoblast lineages express both M-CSF and RANKL (Suda et al., 1999), 
which bind to their receptors, Colony stimulating factor 1 receptor (CSF1R) and RANK, 
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result in stimulating osteoclast formation (Lacey et al., 1998). RANK regulates 
osteoclast formation and function in part through recruiting TNF receptor–associated 
factors (TRAFs), which sequentially regulate osteoclast formation, function, and/or 
survival (Feng, 2005, Boyle et al., 2003, Takayanagi et al., 2002). OPG, produced from 
osteoblasts, acts as an antagonist of RANKL functions by competing with RANK for 
binding of RANKL (Bucay et al., 1998). It has become clear that estrogen exerts bone-
sparing effects by targeting the RANKL/RANK/OPG axis through stimulating OPG 
expression in mouse osteoblasts and stromal cells (Saika et al., 2001). Also, the RANKL 
expression on osteoblast cells from postmenopausal osteoporosis women was more than 
that expressed in osteoblast cells from premenopausal controls (Eghbali-Fatourechi et 
al., 2003). This indicates that RANKL plays an important role in the pathogenesis of 
postmenopausal osteoporosis. Furthermore, the RANK-activated JNK pathway, plays a 
role in cellular apoptosis pathway, in osteoclast cells is inhibited by estrogen (Shevde et 
al., 2000, Srivastava et al., 2001). As discussed above, deficiency of estrogen results in 
an increase of IL-1 and TNF secretion, that enhances osteoclastogenesis by increased IL-
6 expression. RANKL gene expression in osteoblasts and stromal cells is also stimulated 
by IL-1 and TNF (Yasuda et al., 1998), which shows the complexity of the action of 
these two cytokines in the development of postmenopausal osteoporosis. 
1.2.4 Diagnosis of Osteoporosis 
Dual-energy X-ray (DXA) is the most common technique used for assessing the 
risk of osteoporosis. It is used to measure hip and spine bone density, and can also 
measure bone density of the whole skeleton (Kanis et al., 2008). The spine or hip 
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fracture could be also diagnosis through high resolution peripheral quantitative 
computed tomography (HR-pQCT) (Nishiyama and Shane, 2013). 
The World Health Organization (WHO) has categorised osteoporosis into four 
groups as shown in Table 1-3. The reference measurement results from bone density 
measurements in a population of healthy young adults (called a T-score). Osteoporosis is 
diagnosed when a person’s BMD is equal to or more than 2.5 standard deviations below 
this reference measurement (Kanis, 1994) 
Table 1-3: WHO classification for osteoporosis based on DXA 
Status BMD 
Normal T-score of -1 or above 
Osteopenia T-score lower than -1 and greater than -2.5 
Osteoporosis T-score of -2.5 or lower 
Severe Osteoporosis 
T-score of -2.5 or lower, and presence of at least one fragility 
fracture 
 
There are a few other methods for diagnosing osteoporosis that have been used 
extensively in clinical trials. These include bone biomarkers. 
1.2.5 Biomarkers of Bone 
Bone biomarkers can be measured in blood or urine. Since bone remodelling 
processes are coupled and tend to change in parallel, these biomarkers are detected in 
either in formation and resorption markers that express the metabolic activity of 
osteoblasts or osteoclasts respectively. Some markers can be used to monitor both 
processes, e.g. osteocalcin (OC). Also, some of these markers are non-specific for being 
present in tissues other than bone and may be influenced by non-skeletal processes 
(Wheater et al., 2013). 
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4.2.3.1 Bone Formation Biomarkers 
Bone formation biomarkers are either by-products of active osteoblasts expressed 
during the various phases of bone remodelling or osteoblastic enzymes. These markers 
are widely used and measured in serum or plasma and include: bone specific alkaline 
phosphatase (ALP), osteocalcin (OC) and the carboxy- and amino-terminal propeptides 
of type 1 collagen (P1CP, P1NP).  
1.2.5.1.1 Total alkaline Phosphatase 
Alkaline Phosphatase (ALP) is an enzyme found in the bloodstream, which is 
produced in liver, intestines and kidneys. 50% of total ALP is called bone-specific 
alkaline phosphatase (BALP) that is a glycoprotein produced from the surface of 
osteoblasts bone (Masrour Roudsari and Mahjoub, 2012). Abnormal level of ALP 
isoenzyme in blood indicates an issue with liver, gall bladder, or bones which could be 
used for diagnosis of bone problems such as rickets, osteomalacia and Paget’s disease. 
The measurement of BALP is also used as an indicator of osteoblastic activity for the 
assistance of the management of osteoporosis in women (Kuo and Chen, 2017). 
1.2.5.1.2 Osteocalcin  
Osteocalcin (OC) is synthesized by mature osteoblasts, odontoblasts and 
hypertrophic chondrocytes (Lee et al., 2007). It plays an important role for metabolic 
regulation, bone mineralization and calcium ion homeostasis. Serum OC is used as 
biomarker for osteoblast function for evaluation of bone formation rate in osteoporosis 
(Kuo and Chen, 2017). The mean level of OC is significantly different between the 
postmenopausal non-osteoporotic women (11.26 ± 3.07 ng/ mL) and osteoporotic (16.16 
± 4.5 ng/ mL) (Singh et al., 2015) 
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1.2.5.1.3 Procollagen type 1 N-terminal and C-terminal Propeptide  
Type 1 collagen included (P1NP& P1CP) can be found in the organic bone matrix, 
which is synthesized by fibroblasts and osteoblasts. P1CP and P1NP are released during 
the formation of type 1 collagen (Hassager et al., 1991). P1NP has been demonstrated to 
be a more sensitive for measuring the bone formation rate in osteoporosis (Garnero, 
2008). P1NP has functional advantages where it has low interindividual variability and 
is relatively stable in serum at room temperature (Wheater et al., 2013).  
4.2.3.2 Bone Resorption Biomarkers  
Most bone resorption markers are considered degradation products of bone 
collagen. Earlier research identified bone resorption markers which were measured in 
urine sample such as pyridinoline (PYD) and deoxypyridinoline (DPD). These 
biomarkers were time-consuming and cumbersome and relied on second morning void/ 
creatinine ratios, or complete 24 h urine collections, increasing the imprecision of the 
measurement (Rosano et al., 1998, Lo Cascio et al., 1999). However, now serum/ 
plasma markers are available, such as Osteopontin (OP), Tartrate-resistant acid 
Phosphatase 5b (TRAP-5b), cathepsin K (CTSX), Carboxy-terminal Crosslinked 
Telopeptide of type 1 collagen (CTX-1), and Amino-terminal Crosslinked Telopeptide 
of type 1 collagen (NTX-1) (Wheater et al., 2013) 
1.2.5.2.1 Osteopontin  
Osteopontin (OP) is expressed in different cells include bone cells. The plasma 
level of OP was used to evaluate the treatment of intermittent parathyroid hormone in 
menopausal osteoporosis (Chiang et al., 2011). Chiang et al found that women with high 
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level of OP were less resistant to postmenopausal osteoporosis than women with normal 
OP levels (Chiang et al., 2011) 
1.2.5.2.2 Carboxy-terminal Crosslinked Telopeptide of type 1 collagen  
Telopeptides of type 1 collagen, included carboxy-terminal crosslinked (CTX-1) 
and aminoterminal crosslinked (NTX-1), are used as bone resorption biomarkers 
(Chiang et al., 2011). They are released during collagen degradation. CTX-1 was found 
to be a s sensitive and specific biomarker of bone resorption that can rapidly indicate the 
response to bisphosphonate therapy for postmenopausal osteoporosis. However, blood 
withdrawal must take place in the fasting state because food intake substantially 
decreases the levels of CTX-1 (Christgau, 2000).  
1.2.5.2.3 Cathepsins 
Cathepsins are lysosomal proteases found in all animal cells and have 
approximately different members of this family, which are distinguished by their 
structure, catalytic mechanism, and which proteins they cleave (Turk et al., 2012). 
Cathepsins play a critical role in driving cancer progression, proliferation, invasion and 
metastasis (Olson and Joyce, 2015), and have ability to catabolize elastin, collagen, and 
gelatine allow it to break down bone (Brömme and Lecaille, 2009). Some of these 
cathepsins are expressed highly in specific cell types such as Cathepsin K (CTSK) in 
osteoclasts and Cathepsin S (CTSS) in immune cells (Mohamed and Sloane, 2006). 
CTSK plays a role in cancer metastasis through the degradation of the extracellular 
matrix (Gocheva and Joyce, 2007). The organic bone matrix is degraded by not only 
cathepsin K, but also by matrix metalloproteinases or other cathepsins (Goto et al., 
2003). Each cathepsin is specifically localized in the osteoclast, result in that each 
cathepsin cooperatively participates to the bone resorption (Goto et al., 2003). CTSK is 
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an important factor in process of bone resorption where osteoclasts secrete CTSK to 
degrade the bone matrix proteins included type 1 collagen (Holzer et al., 2005, Troen, 
2004). Robust genetic and pharmacological preclinical studies revealed that suppression 
of CTSK result in increasing the bone mass (Duong le et al., 2016). CTSK level was 
revealed to be significantly different between non-osteoporotic and osteoporosis patient 
(Duong le et al., 2016, Holzer et al., 2005) which indicate that CTSK level in the serum 
could serve as a potential biomarker for fracture prediction and BMD (Kuo and Chen, 
2017).  
4.2.3.3 Bone Turnover Biomarkers  
1.2.5.3.1 Receptor activator of NF-κB ligand  
RANKL is produced by osteoblasts to control the differentiation and maturation of 
osteoclasts at bone remodelling process. RANKL in serum were studied in fracture risk 
prediction and evaluation of the response from osteoporosis treatment (Kuo and Chen, 
2017). However, more work needs to assess the clinical application of RANKL in 
osteoporosis diagnosis (Rogers and Eastell, 2005). 
1.2.5.3.2 Sclerostin and Dickkopf-1  
Sclerostin (SOST) and Dickkopf-1 (DDK1) are produced by osteoblasts and 
inhibit the Wnt signalling that responsible for osteoblastic differentiation. DKK1 were 
positively correlated with the BMD of the femoral neck and of the total hip (Wheater et 
al., 2013). Also, more clinical trial is needed for using SOST as a biomarker of bone 
turnover (Kuo and Chen, 2017). 
The use of these biomarkers as routine test remains a challenge because of their 
wide biological and analytical variation (Lewiecki, 2010, Sandhu and Hampson, 2011). 
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Even with identical assays and methods, the results of different bone markers, including 
ALP, OC, DPD, and PYD, differed by up to 7.3-fold between 73 laboratories once 
analysed in two serum and two urine pools (Seibel et al., 2001). The analytical 
variability is influenced by non-modifiable and modifiable factors. The non-modifiable 
factor includes: age, sex and ethnicity, geographical location, medication such as 
glucocorticoids, and Hormone Replacement Therapy (HRT) (Naylor and Eastell, 2012),  
whereas, the modifiable factors include seasonal changes, phase of menstrual cycle of 
the patient, level of exercise and the meal intake which found that patients have reduced 
serum CTX‑I levels (20%) 1 hour after breakfast, attributed to the production of the gut 
hormone, glucagon-like peptide 2 (Henriksen et al., 2003, Naylor and Eastell, 2012).   
Overall, these bone biomarkers can be used in monitoring treatment efficiency for 
osteoporosis, but are not useful as a diagnostic tool (Sandhu and Hampson, 2011). Also, 
although variation of markers was seen, abnormal levels of some of these markers may 
result from other bone pathologies, not just osteoporosis (Vasikaran and Chubb, 2016)    
1.2.6  Hormone-Responsive Genes in Osteoporosis 
The accurate and early identification of osteoporosis, commonly in 
postmenopausal women, would be critical to reduce the physical and economic 
consequences of this disease, since the current biomarkers, based on normal bone 
metabolism are ineffective in predicting osteoporosis (Mendoza et al., 2012). Recently, 
identification of the development of osteoporosis can be achieved through genetic 
studies since they correlate with the degree of bone mass lost (Mendoza et al., 2012). 
Thus, the attempt to determine new markers genetically of osteoporosis are necessary 
because the expression of genes that change during the onset of osteoporosis might be 
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more effective at detecting the disease in its early stages. However, the identification of 
genes responsible for the development of osteoporosis is difficult because of the 
multifactorial nature of the illness, sex and fracture history, and the heterogeneity of 
different populations, age and ethnicity. To date, more than 150 genes related to 
osteoporosis have been described, with the three most studied being the vitamin D 
receptor, estrogen receptors, RANKL and LDL Receptor Related Protein 5 (LRP5) 
(Mendoza et al., 2012). However, the influence of estrogen deficiency on the pattern of 
gene expression in the bone of postmenopausal women, which might be associated with 
the development of osteoporosis, is still unknown. 
Estrogen is important in the development of bone by inhibiting bone resorption 
and inducing bone formation by osteoblasts through its cognate receptors, ERα or ERβ 
(Hofbauer et al., 1999, Fitzpatrick, 2006). Table 1-4 shows the genes that are possible 
targets of hormones in human bone cells or associated with low BMD or osteoporosis, in 
which some them were involved in the estradiol pathway (Karasik et al., 2010). For 
example, single-nucleotide polymorphism (SNPs) of ESR1 were found to be decreased 
with low BMD, bone remodelling, and fragility fractures (Binh et al., 2006, Langdahl et 
al., 2000). Moreover, analysis of genes related to the estrogen signalling pathway, 
Estrogen receptor 2 (ESR2), Bone Morphogenetic Protein 15 (BMP15), and Nuclear 
receptor interacting protein 1 (NRIP1), more likely to be related to hip osteoporosis 
(Mendoza et al., 2012). However, Zhao et al showed that interaction of osteoporosis and 
some genes, such as ESR1 and LRP4 might influence the age at menopause (Zhao et al., 
2011). It was found that the interactions between some genes, BMP15, follicle-
stimulating hormone receptor (FSHR), Cytochrome P450 Family 19 Subfamily A 
Member 1 (CYP19A1), and Nuclear Receptor Interacting Protein 1 (NRIP), seem to be 
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most related to osteoporosis predisposition. However, although osteoporosis has been 
considered a polygenic disease modulated by environmental factors, the predisposition, 
pathology and treatment response of the osteoporosis depend on interaction between 
different genes or between genes and environmental factors. Not only this but also 
microRNAs are also involved in the pathogenesis of osteoporosis since many reports 
have recently highlighted the involvement of microRNAs as key regulators of osteoblast 
mediated bone development, homeostasis and osteoporosis (Lian et al., 2012a). 
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Table 1-4: Hormone-related genes in bone cells  
 Hormone Gene Function  Reference 
1 Estrogen 
IGF-1 and 
–II 
Regulate OB differentiation 
(Guntur and Rosen, 
2013) 
2 Estrogen ESR1 Promote OB differentiation 
(Almeida et al., 
2013) 
3 Estrogen ESR2 
Oppose actions of ESR1, act 
together with ESR1, or substitute 
for ESR1 in its absence 
(Galea et al., 2013b) 
4 Estrogen RANKL Stimulate osteoclast differentiation (Martin et al., 2015) 
5 Estrogen ALP Increase mineralization of bone 
(Scheven et al., 
1992) 
6 Estrogen OPG Inhibits OC differentiation 
(Hofbauer et al., 
1999) 
7 Estrogen RUNX2 Inhibits OB formation (Martin et al., 2015) 
8 Estrogen IL-1, IL-6 Stimulate of OC activity (Nilsson et al., 2001) 
9 Estrogen 
Cathepsin 
B, L, K 
Stimulate of OC activity 
(Pennypacker et al., 
2011, Kremer et al., 
1995) 
10 Estrogen DKK1 
Inhibits osteoblastogenesis, lowers 
OPG levels, DKK1 enhances 
RANKL levels 
(Pinzone et al., 2009) 
11 Estrogen FasL Induces OC apoptosis (Krum et al., 2008) 
12 Estrogen MMP3 
Preserved OC differentiation and 
survival 
(Garcia et al., 2013) 
13 Estrogen TNFα, β3 
Induced OB apoptosis, inhibits OC 
differentiation  
(Matsuda et al., 
2001, Krum, 2011) 
14 Estrogen Bcl2 Induced OB apoptosis 
(Pantschenko et al., 
2005) 
15 Estrogen SOST Regulate OB formation (Galea et al., 2013a) 
16 Estrogen 
BMP-2, 4, 
6  
increases OB differentiation 
(Zhou et al., 2003, 
Krum, 2011) 
17 Estrogen 
C-fos and 
c-jun 
increases OC differentiation 
(Oursler et al., 1991, 
Krum, 2011) 
18 
Parathyroid 
hormone 
RANKL Stimulate bone formation 
(Dempster et al., 
1993) 
19 
Parathyroid 
hormone 
IGF-I Decrease OB apoptosis  
(Lombardi et al., 
2011) 
20 
Parathyroid 
hormone 
TGF-β 
Decrease osteoblasts apoptosis and 
decreases bone resorption 
(Lombardi et al., 
2011) 
21 
Parathyroid 
hormone 
1.25(OH)2 
vitamin D3 
Increase Ca absorption from 
kidneys and intestine 
(Lombardi et al., 
2011) 
22 Insulin 
IGF-I and 
II 
Stimulate OB to synthesis collagen 
(Guicheux et al., 
1998) 
23 
Glucocortic
oids 
RANK and 
OPG 
Stimulate of OC activity 
(Canalis and Delany, 
2002) 
24 
Growth 
hormone 
IGF-I and 
II 
Increase the synthesis of collagen, 
osteocalcin and alkaline phosphate 
(Harvey and Hull, 
1997) 
 (OB=osteoblast, OC= osteoclast) 
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1.3 microRNA  
microRNAs (miRNAs) are small non-coding RNA molecule containing about 22 
nucleotides. miRNAs are involved in signalling pathways, such as control of cellular 
development, proliferation, and apoptosis (Ambros, 2004, Bartel, 2004). miRNAs 
function in post-transcriptional regulation of 60% of human protein-coding gene 
expression through inhibiting the translation of target messenger RNA (mRNA) (Li et 
al., 2013) or promoting messenger mRNA degradation (Friedman et al., 2009). On the 
other hand, miRNAs may function to induce gene expression by targeting specific sites 
in gene promoters (Place et al., 2008). It was demonstrated that miRNAs can activate 
mRNA translation through the AU-rich element binding protein and conserved miRNA 
target site in 3' untranslated region (3'UHR) (Vasudevan et al., 2007). The majority of 
miRNAs are located within the cell, but some have also been found in the extracellular 
environment or in the circulation (Sohel, 2016). The complexity of miRNA is that a 
single miRNA can regulate many genes and a single gene can be targeted by different 
miRNAs (Doench and Sharp, 2004). miRNAs are recognized as major regulators of 
gene expression, as well as key controllers of different biological and pathological 
processes (Flynt and Lai, 2008). 
1.3.1 microRNA Biogenesis 
More than 50% of mammalian miRNAs have been found to be encoded within 
introns of either protein-coding or noncoding transcription units and approximately 10% 
by exons of long nonprotein-coding transcripts (Ambros, 2004, Bartel, 2004). miRNA 
genes are transcribed by RNA polymerase II (Lee et al., 2004) or RNA polymerase III 
(Cai et al., 2004) forming long primary transcripts, pri-miRNAs. Pri-miRNAs are then 
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cleaved in the nucleus to form hairpin pre-miRNAs (70–100 nt in length) and are 
transported to the cytoplasm via Exportin-5 for further processing to form double-
stranded RNAs of 19–25 nt (Guay and Regazzi, 2013). Pre-miRNAs undergoes cleavage 
by the endonuclease, Dicer, to form double-stranded RNAs of 19–25 nt (Guay and 
Regazzi, 2013). One strand is then incorporated into a protein complex called RNA-
induced silencing complex (RISK) (Friedman et al., 2009). MiRNA binding can lead to 
repression of translation or mRNA degradation as shown in Figure 1-7. 
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Figure 1-7: microRNA biogenesis 
pri-miRNA is cleaved by Ribonuclease III Drosha enzyme into pre-
miRNA in the nucleus and then transported into the cytoplasm by Exportin 
5. pre-miRNA is cleaved by Dicer enzyme yielding 21-23 nucleotide 
duplexes in which one strand binds to RISC and guides translational 
repression of target mRNAs. This figure is adapted from (Guay and 
Regazzi, 2013) 
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1.3.2 microRNA Associated with Bone Formation and Bone 
Resorption 
The roles of miRNAs have been demonstrated by many studies in osteoblasts, 
osteoclasts, and osteocytes (Moore and Xiao, 2013, Tang et al., 2014, Chen et al., 2015, 
Ji et al., 2016, Suttamanatwong, 2017). miRNAs are associated with the development, 
growth, and metabolism of bone and then can cause bone metabolism disorder, resulting 
in osteoporosis and other bone disease (Bartel, 2004).  
1.3.3 Regulation of Osteoblast Differentiation by miRNAs  
Many studies revealed that some miRNAs stimulate and others inhibit 
osteoblastogenesis, and some miRNAs inhibit osteoblastogenesis. Mesenchymal stem 
cells differentiation to preosteoblast and mature osteoblasts is regulated by runt-related 
transcription factor 2 (RUNX2) (Zhang et al., 2011b). The differentiation of hMSCs is 
regulated by miRNAs since Dicer or Drosha knockdown inhibits ALP activity and then 
decrease the osteogenic differentiation (Oskowitz et al., 2008). A list of miRNAs 
regulating osteoblastogenesis in human cells is shown in Table 1-5.  
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Table 1-5: miRNAs regulating osteoblastogenesis in human cells  
miRNA Target Gene(s) Cell Type(s) Function Reference  
miR-15b BMPER, PDAP1*, 
FGF2* 
Human MSCs Stimulate OB 
Differentiation 
(Gao et al., 
2011) 
miR-20a PPAR-, Bambi, 
Crim1 
Human MSCs Stimulate OB 
Differentiation 
(Zhang et al., 
2011a) 
miR-1228 BMP2K Human primary 
osteoblasts 
Stimulate OB 
Differentiation 
(Lisse et al., 
2013) 
miR-29a DKK1, Kremen2, 
SFRP 
Human primary 
osteoblasts/FOB
1.19 cells 
Stimulate OB 
Differentiation 
(Kapinas et al., 
2010) 
miR-26a Smad1 Human ADSCs Stimulate OB 
Differentiation 
(Luzi et al., 
2008) 
miR-20a BMP2*, RUNX2* Human ligament 
fibroblasts 
Inhibit OB 
Differentiation 
(Zhang et al., 
2011a) 
miR-31 RUNX2, BMPR2 Human MSCs Inhibit OB 
Differentiation 
(Gao et al., 
2011) 
miR-100 BMPR2 Human ADSCs Inhibit OB 
Differentiation 
(Zeng et al., 
2012) 
miR-106a BMP2*, BMPR1A*, 
BMPR2*, RUNX2* 
Human MSCs Inhibit OB 
Differentiation 
(Gao et al., 
2011) 
miR-148a BMP3*, BMP8B*, 
BMPR2*, RUNX2* 
Human MSCs Inhibit OB 
Differentiation 
(Gao et al., 
2011) 
miR-221 Wnt signaling 
molecules 
Human USSCs Inhibit OB 
Differentiation 
(Bakhshandeh 
et al., 2012) 
miR-221 TGF-β Human USSCs Inhibit OB 
Differentiation 
(Bakhshandeh 
et al., 2012) 
miR-
1274a 
Wnt signaling 
molecules 
Human USSCs Inhibit OB 
Differentiation 
(Bakhshandeh 
et al., 2012) 
miR-106a CBFB* Human MSCs Inhibit OB 
Differentiation 
(Gao et al., 
2011) 
miR-138 PTK2 Human MSCs Inhibit OB 
Differentiation 
(Eskildsen et 
al., 2011) 
miR-146a IRAK1 Human ADSCs Inhibit OB 
Differentiation 
(Cho et al., 
2010) 
miR-
1274a 
TGF-β Human USSCs Inhibit OB 
Differentiation 
(Bakhshandeh 
et al., 2012) 
miR-424 CBFB* Human MSCs Inhibit OB 
Differentiation 
(Gao et al., 
2011) 
*Putatively predicted target genes that have not been validated 
experimentally. (OB = osteoblast) 
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1.3.4 Regulation of Osteoclast Differentiation by miRNAs 
There are some miRNAs that regulate the proliferation and differentiation of 
osteoclasts. The function and effect of miRNA on osteoclast differentiation have been 
less well studied compared to that in osteoblasts (Franceschetti et al., 2013, Chen et al., 
2015). Mammalian miRNAs involved in regulating of osteoclast differentiation are 
shown in Table 1-6. 
Table 1-6: miRNAs regulating osteoclastogenesis in human cells  
miRNA Target Gene(s) Cell Type(s) Function References 
miR-214 Pten BMMs Stimulate OC 
differentiation 
(Zhao et al., 
2015) 
miR-29 CDC42, SRGAP2 BMMs Stimulate OC 
differentiation 
(Franceschetti 
et al., 2013) 
miR-21 Fasl BMMs Stimulate OC 
differentiation 
(Sugatani and 
Hruska, 2013) 
miR-148a MAFB PBMCs Stimulate OC 
differentiation 
(Cheng et al., 
2013) 
miR-26a CTGF BMMs Inhibit OC 
differentiation 
(Kim et al., 
2015a) 
miR-34a TGIF2 BMMs Inhibit OC 
differentiation 
(Krzeszinski et 
al., 2014) 
miR-7b DC-STAMP BMMs Inhibit OC 
differentiation 
(Dou et al., 
2014) 
miR-503 RANK PBMCs Inhibit OC 
differentiation 
(Chen et al., 
2014) 
miR-124 NFATcL, RhoA BMMs Inhibit OC 
differentiation 
(Lee et al., 
2013) 
miR-125a TRAF6 PBMCs Inhibit OC 
differentiation 
(Guo et al., 
2014) 
miR-223 NFIA, 1KKα PBMCs Inhibit OC 
differentiation 
(Shibuya et al., 
2013) 
(OC= osteoclast) 
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1.3.5 miRNAs as Molecular Biomarkers and Therapeutics for 
Osteoporosis 
Recently, the number of miRNAs associated with osteoporosis has expanded, 
based on the increasing body of research on miRNAs. However, most of these studies 
were carried out using cultured cells or animal model systems (van Wijnen et al., 2013), 
with the exception of a few studies in clinical samples from patients who have 
osteoporosis fractures in small pilot experiments. MiR-133a is a potential biomarker of 
osteoporosis and its level in circulating monocytes was significantly increased in 10 
osteoporotic postmenopausal Caucasian women compared to 10 non-osteoporotic 
women (Wang et al., 2012). Seeliger et al (2014) reported that the expression of speciﬁc 
miRNAs (miR-21-5p, miR-23-3p, miR-24-3p, miR-25-3p, miR-100-5p, and miR-125b-
5p) in bone tissue significantly increased in osteoporotic compared to that in non-
osteoporotic fractures (Seeliger et al., 2014). Also, it was found that 6 miRNAs (miR-
133b, miR-328-3p, let-7g-5p, miR-10a-5p, miR-10b-5p and miR-22-3p) in serum from 
post-menopausal women who had recently suffered osteoporotic fractures at the femoral 
neck, which were not detectable in control samples (Weilner et al., 2015). However, 
there is only one study of circulating estrogen related-miRNAs study in 
osteoclastogenesis and this showed that estrogen down regulates miR-21 in osteoclasts 
leading to promote the apoptosis is by a FasL mechanism (Sugatani and Hruska, 2013). 
Thus, it is important to identify differential miRNAs changes relevant to the 
development of osteoporosis in postmenopausal women who are more susceptible to this 
disease where estrogen is lost. 
RNA sequencing has become quickly a powerful alternative way to measure 
mRNA expression and uses developed deep-sequencing technologies (Wang et al., 
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2009). This technique has several advantages although it is still under active 
development. First, RNA-seq is not limited to detect transcripts which correspond to 
existing genomic sequences unlike hybridization-based approaches. This makes RNA-
seq able to revel the precise location of transcription boundaries (Vera et al., 2008). 
Second, it has very low, if any, background signal because DNA sequances can be 
unambiguously mapped to unique regions of the genome (Mortazavi et al., 2008). 
Taking these advantages into account, RNA seq is the accurate method to identify 
differentially expressed genes in osteosarcoma cells (Mg-63, TE-85, and Saos-2) which 
represent three different stages of bone maturation treated with Estradiol.  
In conclusion, although there are many studies reporting the estrogen-regulation of 
specific genes in osteoblast cells, and several studies have done on local gene expression 
in osteoporotic compared to non-osteoporotic bone samples (Krum et al., 2008, Kassem 
et al., 1996, Chen et al., 2002). However, the link with estrogen deficiency in 
postmenopausal women is not well understood. This could facilitate understanding of 
the molecular changes occurring in osteoporosis in post-menopausal women compared 
to pre-menopausal, by detecting the genes responsible for increasing the risk of 
osteoporosis once estrogen levels were decreased. 
1.4 Hypothesis 
The hypothesis underlying this study is that a deficiency of estrogen is responsible 
for changing genes expression which result in the development of osteoporosis in post-
menopausal women. 
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1.5 Aim  
The aim of this project is to investigate hormone and hormone responsive 
molecules associated with the development of osteoporosis post-menopausal women.   
1. A hormone responsive cell model system will be established using osteosarcoma 
[osteoblast-like] cell lines, Mg-63, TE-85 and Saos-2, which represent three 
different stages of bone maturation (Pacheco-Pantoja et al., 2011).  
2. The effect of steroid hormones on these cultured cells will be analysed using RNA 
sequencing to identify differentially expressed hormone responsive genes.  
3. The identified genes will be further analysed in clinical samples from osteoporosis 
patients to assess potential diagnostic values for osteoporosis.  
4. Some functions of selected genes and their protein products will be investigated 
using cultured cells. 
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2 Chapter 2 Materials and Methods 
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2.1 Equipment and Materials 
2.1.1 Laboratory Equipment Materials 
All equipment used in this study are listed in Table 8-1 and all consumable used in 
this study are listed in in Table 8-2 in the Appendix. Materials for blood collection and 
molecular biology in this study are listed in Table 8-3 in the Appendix. 
2.1.2 Antibodies 
All antibodies used in this study are listed in Table 2-1 and Table 2-2with dilutions 
used for western blotting (Towbin et al.). All species are indicated by the following 
abbreviations:  
Table 2-1 Primary antibodies used for W.B 
Antibody 
name 
Antigen Concentration Company Cat. number 
β-Actin Human Actin 1 µg/mL R & D System MAB8929 
ERα Estrogen Receptor alpha 1 µg/mL R & D System MAB57151 
ERβ Estrogen Receptor beta  2 µg/mL R & D System MAB7106 
CTSZ Cathepsin Z  1 µg/mL R & D System AF934 
 
Table 2-2 Secondary antibodies used for W.B 
Antibody  Species  Antigen  Concentrat
ion 
Company  Cat. number 
α-M-HRP Sheep Mouse IgG 1 µg/mL Fisher Scientific 10106134 
α-R-HRP Donkey Rabbit IgG 1 µg/mL Fisher Scientific 10710965 
α-G- HRP Donkey Goat IgG 1 µg/mL Fisher Scientific 11596752 
 
2.1.3 Primers Used  
Table 2-3 All primers used for RT-qPCR in this study were from QIAGEN 
Accession 
Number  
Gene 
Symbol  
Cat. no. Band 
Size 
Reference 
Position  
mRNA 
size 
NM_000691.4  ALDH3A1 PPH07009A 166 705 1794 
NM_000700.2 ANXA1 PPH02882E 71 395 1399 
NM_001001786.2  BLID PPH57804A 124 444 862 
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Accession 
Number  
Gene 
Symbol  
Cat. no. Band 
Size 
Reference 
Position  
mRNA 
size 
NM_004342.6  CALD1 PPH21139A 107 1547 4476 
NM_001317184.1 CDH1 PPH00135F 153 2617 4815 
NM_001408.2 CELSR2 PPH09555A 110 3925 10540 
NM_000088.3 COL1A1 PPH01299F 75 3760 5927 
NM_000089.3 COL1A2 PPH01918B 142 4322 5411 
NM_000090.3 COL3A1 PPH00439F 95 4287 5490 
NM_001336.3  CTSZ PPH06136B 72 963 1517 
NM_001920.4  DCN PPH01900A 81 1378 2305 
NM_001018057.1 DKK3 PPH05547F 155 917 2587 
NM_001423.2 EMP1 PPH16632B 155 2391 2804 
NM_001135554.1 EPB41L2 PPH20930B 61 2301 3473 
NM_000125.3 ESR1 PPH01001A 162 245 6330 
NM_024939.2 ESRP2 PPH18162A 123 2184 4021 
NM_000138.4 FBN1 PPH06948A 88 8681 11695 
NM_021939.3  FKBP10 PPH07225A 88 1774 2888 
NM_007085.4 FSTL1 PPH20210A 108 827 3840 
NM_001136007.1 FXYD3 PPH16470A 189 875 1588 
NM_001145453.1 GFRA1 PPH01108A 143 1473 9235 
NM_014668.3  GREB1 PPH20761F 93 1110 8482 
NM_001166237.1  GSDMD PPH11430A 143 1030 2326 
NM_001206567.1 IFI16 PPH01330F 74 2105 2750 
NM_001130080.2  IFI27 PPH02866B 83 129 681 
NM_006820.3  IFI44L PPH05811G 131 424 5889 
NM_002038.3  IFI6 PPH01322C 63 448 836 
NM_001256282.1 KRT8 PPH02214F 72 516 1807 
NM_001015002.1  LLGL2 PPH07188A 139 803 1440 
NM_001042544.1  LTBP4 PPH10314F 156 4526 5163 
NM_052886.2 MAL2 PPH10025A 88 2609 2831 
NM_001042467.2 MLPH PPH16367B 142 1308 3703 
NM_001127891.2  MMP2 PPH00151B 69 1452 3416 
NM_001144925.2 MX1 PPH01325A 184 2542 3444 
NM_000909.5 NPY1R PPH01837A 172 1215 2974 
NM_001032731.1 OAS2 PPH05813A 139 363 2123 
NM_032789.3  PARP10 PPH17400A 183 1460 3525 
NM_001270393.1  PKIB PPH17903B 156 1343 1828 
NM_001170690.1 SCUBE2 PPH20500B 109 1971 4058 
NM_001042422.2  SLC16A3 PPH18809E 169 580 2086 
NM_001008539.3 SLC7A2 PPH00484E 191 7189 7584 
NM_004598.3  SPOCK1 PPH10509A 128 1166 4841 
NM_003222.3 TFAP2C PPH06080A 180 1467 2895 
NM_000358.2 TGFΒI PPH01904D 191 2480 2805 
NM_022152.4  TMBIM1 PPH20239B 81 705 2375 
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Accession 
Number  
Gene 
Symbol  
Cat. no. Band 
Size 
Reference 
Position  
mRNA 
size 
NM_001008495.3 TMEM64 PPH10400A 67 1017 4819 
NM_001003395.1 TPD52L1 PPH08107A 92 406 1409 
NM_012288.3  TRAM2 PPH58037A 66 1119 7065 
NM_001005207.2  TRIM37 PPH07602A 94 2899 3623 
NM_003380.3  VIM PPH00417F 92 1545 2151 
NM_017523.3  XAF1 PPH58211A 172 889 3638 
NM_001040275 ESR2       PPH00992C 81 941  2470 
NM_020529 NFKBIA    PPH00170F 133 835  1579 
NM_000478 ALP PPH01311F 63  37  2606 
NM_002961 S100A4 PPH01313E 57 249 512 
NM_005978 S100S2 PPH00423E 113 834 970 
NM_001015151 RUNX2 PPH01897C 102 1555 5487 
NM_005080 XBP1 PPH02850A 133 740 1820 
NM_001256799 GAPDH PPH0050F 130 856 1455 
 
Table 2-4 All miRNAs used for RT-qPCR in this study were from QIAGEN 
NO
. 
miRNA miRBase microRNA database/Forward Primer 
Sequence 
QIAGEN 
miScript Cat. 
1 hsa-miR-1281 MIMAT0005939: 5'UCGCCUCCUCCUCUCCC MS00014455 
2 hsa-miR-1290 MIMAT0005880: 5'UGGAUUUUUGGAUCAGGGA MS00014518 
3 hsa-miR-143-3p MIMAT0000435: 
5'UGAGAUGAAGCACUGUAGCUC 
MS00003514 
4 hsa-miR-4516 MIMAT0019053: 5'GGGAGAAGGGUCGGGGC MS00037555 
5 hsa-miR-409-3p MIMAT0001639:5’ 
GAAUGUUGCUCGGUGAACCCCU 
MS00006895 
6 hsa-miR-1260 MIMAT0005911: 5’AUCCCACCUCUGCCACCA MS00014329 
7 hsa-let-7c-5p MIMAT0000064: 5’ 
UGAGGUAGUAGGUUGUAUGGUU 
MS00003129 
8 hsa-miR-100-5p MIMAT0000098: 
5'AACCCGUAGAUCCGAACUUGUG 
MS00003388 
9 hsa-miR-450a-5p MIMAT0001545: 
5'UUUUGCGAUGUGUUCCUAAUAU 
MS00006937 
10 hsa-miR-196b-3p MIMAT0009201: 
5’UCGACAGCACGACACUGCCUUC 
MS00031570 
11 hsa-miR-373-5p MIMAT0000725: 
5'ACUCAAAAUGGGGGCGCUUUCC 
MS00006867 
12 hsa-miR-99a-5p MIMAT0000097: 
5'AACCCGUAGAUCCGAUCUUGUG 
MS00003374 
13 hsa-miR-145-3p MIMAT0004601: 
5'GGAUUCCUGGAAAUACUGUUCU 
MS00008708 
14 hsa-SNORD96A CCTGGTGATG ACAGATGGCA TTGTCAGCCA 
ATCCCCAAGT GGGAGTGAGG ACATGTCCTG 
CAATTCTGAA GG  
MS00033733  
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2.2 Cell Culture 
2.2.1 Cell Culture Technique 
Cell culture work was carried out in a sterile cell culture hood class II. Medium 
was warmed at 37oC in the water bath before use. All flasks were labelled properly, 
covered loosely, and kept at 37oC in a humidified atmosphere of 95% air, 5% CO2 
incubator. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % (v/v) foetal bovine serum (FBS), 2 % (v/v) 200 mM L-
glutamine, 1 % (v/v) 100IU penicillin/streptomycin and 1 % (v/v) of MEM Non-
Essential Amino Acid Solution. This medium is referred to as ‘complete medium’ in this 
study. All routine culture media were replaced every alternate day. 
2.2.2 Cell Lines  
Three types of the osteosarcoma cell lines were used, Mg-63, TE-85, and Saos-2 
represent three different stage of maturity (Pacheco-Pantoja et al., 2011, Clover and 
Gowen, 1994, Rodan et al., 1987) based on measuring alkaline phosphatase activity and 
osteocalcin production, markers that are representative of early and late stages of 
osteoblast maturation (Clover and Gowen, 1994). The Mg-63 cell line, which was 
derived from an osteosarcoma of a 14 years old male, is considered as an 
undifferentiated initial osteoblast phenotype (Clover and Gowen, 1994, Pacheco-Pantoja 
et al., 2011, Heremans et al., 1978). The TE-85 cell line, which was derived from a 
sarcoma of a 13 years old Caucasian female, represents osteoblasts with a higher level of 
maturity than Mg-63 (Clover and Gowen, 1994, Pacheco-Pantoja et al., 2011, 
McAllister et al., 1971). The Saos-2 cell line, which was derived from an osteosarcoma 
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from an 11-year-old Caucasian female, represents the most mature osteoblasts (Pautke et 
al., 2004, Pacheco-Pantoja et al., 2011). The MCF-7 cell line is a breast cancer cell line 
isolated in 1970 from a 69- year-old Caucasian woman (Soule et al., 1973). This cell line 
was used in this study as an estrogen receptor positive control cell line (Levenson and 
Jordan, 1997). 
2.2.3 Thawing of Cell Stocks 
Stocks of frozen cells in freezing medium were removed from liquid nitrogen 
and thawed rapidly at 37oC in a water bath. The cells were immediately transferred to a 
sterile tube containing 10 mL of complete medium. The tube was centrifuged at 100 g 
for 5 mins at room temperature in a bench-top centrifuge, after which the cell pellets 
were resuspended in the appropriate volume of required complete medium for plating at 
a density of approximately 2.5x104 cells per cm2. All flasks or plates were then kept as 
mentioned in 2.2.1. 
2.2.4 Routine Cell Culture  
All cells were cultured in a humidified atmosphere of 95% air, 5% CO2 at 37oC 
in complete medium until about 70-80% confluent. The cells were washed twice with 10 
mL Dulbecco's phosphate-buffered saline (PBS), then incubated with 0.01% (w/v) 
Trypsin-EDTA at 37oC for 2 min until approximately 90% of the cells had detached 
from the surface of the flask. The trypsin solution was inactivated by adding 10 mL of 
complete medium. The cells were then transferred into a sterile universal tube and 
centrifuged at 100 g for 5 minutes. The supernatant was removed, Cells were re-
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suspended in the appropriate volume of required medium and replaced at a dilution of 
1:4, (see Table 2-5). 
Table 2-5 Routine Cell Culture and Passaging 
Cell Medium  Ratio Passage (from-to) 
Mg-63 DMEM containing 10% FBS 1:4 every 2 days P3-P9 
TE-85 DMEM containing 10% FBS 1:4 every 2 days P2-P11 
Saos-2 DMEM containing 10% FBS 1:4 every 2 days P2-P9 
MCF-7 DMEM containing 10% FBS 1:4 every 2 days P10-P18 
2.2.5 Cell Counting 
Cells were counted using a ScepterTM cell counter according to manufacturer’s 
recommendations. Briefly, cell pellets were resuspended and mixed well with 1 mL of 
PBS in a 2 mL sterile microcenterfuge tube. 50 µl of the cell suspension was drawn into 
a disposable 60 µm sensor and cell number was calculated. 
2.2.6 Freezing of Cultured Cells 
Cells were selected for freezing when they were approximately 70-80% 
confluence. The cells were detached as described in 2.2.4 and resuspended in 10 mL of 
medium containing 10% FBS. The cells were re-centrifuged at 100 g for 5 min. The 
cells were resuspended in the appropriate volume of freezing medium containing 7.5% 
(v/v) DMSO to give a concentration of 1x106 cells/mL. One mL aliquots of cell 
suspensions were frozen in sterile cryogenic vials in a Nalgene cryo-preserver box 
containing 250 mL of isopropyl alcohol stored in a –80oC freezer overnight, before 
being transferred to liquid nitrogen for long-term storage. 
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2.2.7 Cell Culture with Hormone-Stripped Serum 
2.2.7.1 Preparation of “Steroid hormone-stripped” Serum 
Steroid–stripped serum was prepared from FBS as follow. The FBS was treated 
with dextran-coated charcoal containing 2% (w/v) of activated charcoal (Sigma, UK) by 
incubation at 56oC for 45 min initially, then overnight at 4oC with gently rocking. The 
charcoal was removed by centrifugation at 500 g for 30 min at 4oC. The procedure was 
then repeated once and the serum finally sterilized by filtration through both 0.45 um 
and a 0.22 m filter and stored frozen at -80oC. 
2.2.7.2 Optimization the Concentrations of “Steroid Hormone-
Stripped” FBS Medium  
The cells were grown in complete medium until reaching about 60 % confluency 
and transferred to phenol red-free Roswell Park Memorial Institute Medium (RPMI) 
supplemented with 0.0, 0.25, 0.5, 1, 2.5, or 5% concentrations of hormone-stripped FBS 
for 6 days followed by collection of the cells. Medium was changed daily, and cells were 
washed once with PBS prior to each medium change. 
2.2.7.3 Culture of Cells in 0.5% “Steroid hormone-stripped” medium 
The cells were grown to 60% confluence, washed twice with PBS and transferred 
into RPMI containing 0.5% ‘hormone-stripped’ FBS and cultured for 3 days to deplete 
the endogenous steroids. Medium was changed daily, and cells were washed once with 
PBS prior to each medium change. Estrodial was added to a final concentration of 10-8 
M to the medium on the 3rd day of being cultured in a stripped medium followed by 
collection cells after 48h. 
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2.3 Isolation of RNA  
2.3.1 Isolation of total cellular RNA  
Total cellular RNA was prepared using a combination of TRIzol® reagent and 
PureLink® RNA Mini Kit, according to manufacturer’s recommendations (Ambion, 
UK). Generally, for isolation of total cellular RNA, when cells reached 70-80% 
confluence, they were harvested and washed with PBS, which was removed by 
centrifuging at 1000 g for 5 min. 1 mL of TRizol® reagent was added to the cell pellet 
and mixed with 200 µL of chloroform followed by mixing the tube vigorously and 
centrifuging at 14,000 g for 30 min. RNA was precipitated by adding an equal volume of 
70% ethanol and then aspirated onto a RNA spin cartridge tube. The column was 
washed with wash buffer I and wash buffer II supplied by the manufacture (Ambion, 
UK) followed by spin at 8000 g for 15 seconds. The column was transferred to a new 1.5 
mL recovery tube, subsequently adding 30 µL pre-warmed RNase-free PCR water 
directly onto the column to get the 1st RNA elution. The resulting purified RNAs were 
stored frozen at -80oC until use. 1.5 µL of every sample was taken to determine the RNA 
concentration using a Nano Drop 2000 Spectrophotometer. 
2.3.2 RNA Extraction from PBMCs Using miRCURY Kit 
Total RNA from clinical samples PBMC was extracted using miRCURY Kit 
according to manufacturer’s recommendations [Exiqon]. PBMC cell pellets were lysed 
in 350 μl of Lysis solution containing 1% of 2-mercaptoethanol and vortexed for 15 secs 
followed by the addition of 200 μl of 100% ethanol. The suspension was transferred to a 
column provided with a collection tube and then centrifuge the column at 3500 × g for 1 
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minute. The column was washed twice by 400 µl of wash solution and centrifuged for 1 
min at 5000 g. RNA was then collected by adding 50 µl of elution buffer to the column 
followed by centrifuged for 2 min at 200 g, followed by 1 min at 14,000 g. 1.5 µ1 of 
every sample was taken to determine the RNA concentration using a Nano Drop 2000 
Spectrophotometer. 
2.3.3 RNA Concentration and Purity 
The RNA concentration was measured using a NanoDrop 2000 spectrophotometer 
(Thermo Scientific). The measurement of RNA concentration was expressed as in ng/µl 
calculated from absorbance at 260 nm using the modified Beer-Lambert equation 
(Evans), and the ratio of the absorbance at 260/280 and 260/230 nm ratios were also 
calculated to assess the purity of nucleic acids (RNA) from either protein or phenol 
contaminant. While the ratio of the absorbance at 260/230 was used to measure the 
nucleic acid purity from residual phenol, residual guanidine from the Trizol reagent used 
for precipitation of the RNA. These ratios are used to assess the purity of RNA, where 
values of 2 or above are considered as RNA pure for further experimentation (Johnson et 
al., 2012). 
2.4 RNA Sequencing 
6 µg of RNA was sent to The Genome Analysis Centre TM (TGAC) (Norwich, 
UK) for RNA sequencing in order to identify differentially expressed mRNA between 
control and treated cells. The quality of RNAs was checked using the Agilent 
Bioanalyser 2100. Illumina TruSeq RNA libraries from a total of 8 RNA samples were 
constructed and RNA sequencing of the resulting 8 libraries on a HiSeq2000 DNA 
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sequencer with a 100bp paired-end read-metric performed by TGAC. Bioinformatics 
analysis of RNA sequencing was carried out by TGAC including RNA sequencing data 
QC, filtering and mapping, transcript assembly, normalization and differential 
expression analysis. Alignment of RNA-Sequencing reads to transcriptome reference 
[Human genome build 38] was carried out using TopHAt software followed by 
transcript reconstruction and differential expression of RNA sequencing using Cufflinks 
software.  
2.5 Transient Transfection using RNAi Technology 
Cells were transiently transfected with siRNA using HiPerFect® Transfection 
Reagent (QIAGEN #1301702). Transient transfections were performed using 6-well cell 
culture plates. One well contained parental cells, scrambled RNA, transfection reagent 
only, while cells in another well were treated with the 4 siRNAs. Cells were seeded at 1 
× 105 per well 24 h before the transfection which was carried out when the cells reached 
50-60 % confluence. 1 µl of siRNA was diluted in 100 µl of medium without serum and 
3 µl of HiPerFect® Transfection Reagent, to give a final concentration of 5 nM in a 2 mL 
final volume after adding the complexes to cells. The mixture was then mixed by 
vortexing followed by incubation for 5-10 mins at room temperature to allow the 
formation of transfection complexes. The medium containing the transfection complexes 
was added drop-wise onto the cells and the plate gently swirled to ensure uniform 
distribution of the transfection complexes. Cells were incubated under their normal 
growth condition and gene silencing was monitored after 24 hr. Cells were then used 
experimentally to extract RNA or to prepare protein samples.  
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2.6 Cell Invasion Assay 
Invasion assays were performed using the (Yue et al.) MatrigelTM Invasion Chamber 
(BD Biosciences, USA) according to manufacturer’s recommendations. Briefly, 0.5 mL 
of warm culture medium was added to the interior of the inserts and allowed to rehydrate 
for 2 h in a humidified tissue culture incubator at 37°C, 5% CO2 atmosphere. After 
rehydration, medium was carefully removed without disturbing the GFR MatrigelTM 
Matrix layer on the membrane. 2.5×104 cells in 0.5 mL serum free medium were loaded 
into every upper compartment of chambers while 1 mL of complete medium was placed 
in the lower compartments of each well, (Figure 2-1). A negative control was set up for 
each cell line by using serum-free medium in the lower compartment. The matrigel 
invasion chambers were incubated in a humidified tissue culture incubator for 24 h. 
Non-invading cells were removed from the upper surface of the membrane by scrubbing 
using a cotton wool swab. The scrubbing was repeated with a second swab moistened 
with medium. The cells on the lower surface of the membrane were stained with 
Shandon™ Kwik-Diff™ Stains by incubating each insert for approximately 30 seconds 
in each solution followed by washing 2 time with PBS and allowed to air dry for 
minimum of 60 minutes.  
The results were presented as the percentage of cells invaded through the GFR 
MatrigelTM MatrixTM membrane relative to the control. 
% Invasion = 
Mean # of cells invading through GFR Matrigel insert membrane 
Mean # of cells migrating through control insert membrane
X 100 
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Figure 2-1: Schematic diagram illustrating invasion assay using the 
(Yue et al.) MatrigelTM Invasion Chamber.  
Cells were seeded in serum free medium and then leaving 
overnight to penetrate through the membrane follow by staining the 
membrane and count cells using inverted microscope.  
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2.7 Wound Healing Assay 
A scratch wound healing assay was carried out by capturing images at regular 
intervals by time lapse microscope (Rodriguez et al., 2005, Kramer et al., 2013). Cells 
were seeded at 1 × 105 per well in a 6-wells plate for 24 h and then treated with the 
transfection complex as mention in section 2.5. After achieving confluence, the cellular 
layers in all plates were scratched using sterile 200 ul pipette tips and rinsed with PBS. 
Cell migration at the edge of the scratch was analysed at 0, 24, 48, and 72 h. Images 
were captured using a 4x objective lens of Nikon Diaphot inverted microscope/D50 
camera with an ToupTek ToupView software. The width of the wound between the two 
edges was measured in triplicate using Image J software.  
2.8 Cell Proliferation Assay 
2.8.1 Preparation of growth curve  
Proliferation assays were carried out using an MTT assay. Parental Mg-63 and TE-
85 cells were grown to 70-80% confluence, harvested as previously outlined and 
resuspended in 10mL of complete medium. Each cell line was made up in 5x105 
cells/mL in 4 mL of complete medium. One well was set up as the blank that contained 
culture medium only. A standard growth curves was prepared by serial dilution of cells 
at: 6.25x103/mL, 1.25x104/mL, 2.5x104/mL, 5x104/mL, 1x105/mL, and 2.5x105/mL. 200 
μl of cell suspension from each dilution was transferred into a 96-wells plate in 
triplicate. After overnight incubation with 5% CO2 at 37
oC, the cells were stained with 
MTT assay as described in section 2.8.2. The cell proliferation assay was run for six 
days at one plate per day. 
  Chapter 2 
 
57 | P a g e  
 
2.8.2 Assessing Cell Numbers Using MTT Assay 
MTT stock solution was prepared at a concentration of 5 mg/mL and stored at 4oC. 
50 μl of MTT stock solution, at each time point, was added to each well and the cells 
were incubated at 37oC, 5% CO2 for 4 h. 200 μl of DMSO was added to each well, 
including the blank control wells after, which the medium was removed. The plate was 
incubated for 10 minutes at 37oC, in 5% CO2 and the optical density read at 570 nm in a 
SPECTROstar Nano plate reader. The growth rate for each cell line was compared 
against the standard curve to obtain the number of cells/well each day for six days. 
Graphs of cell number/time were plotted. 
2.9 Blood Sample Collection and Preparation 
This study has been carried out under ethical approval from the England Health 
Research Authority National Research Ethics Service Committee, North West-Greater 
Manchester West [REC reference: 11/NW/0593] and East of England-Essex [REC 
reference 15/EE/0051] Ethics Committees. Informed consent was obtained for all 
participants prior to sample collection. Blood samples were drawn by phlebotomists in 
the blood collection area at the RLBUHT, following a standard safety protocol. Samples 
of blood (approximately 25mL) were obtained, using one 9mL S-Monovette® K3E, 
Potassium EDTA tubes and were inverted gently for 10 times, and kept in a standing 
position at room temperature. The date of collection and time were written on the 
participant’s medical form and on the collected tubes. All samples were labeled with a 
unique identification number (ID) composed of six digits, made up from the year, month 
and the date of collection, followed by two letters, either OP for osteoporosis or HC for 
healthy volunteer, and two digits from the participant serial number.  
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2.10  Isolation of Peripheral Blood Mononuclear Cells 
[PBMCs]  
Plasma was isolated from the blood specimens by centrifuging the EDTA tube 
containing samples at 1000 g using Thermo Heraeus Mµltifuge 3SRT centrifuge at room 
temperature for 30 min. The upper layer containing the rest of the plasma, the buffy 
coat, and red blood cells were then transferred to 15 mL Tubes and diluted with the same 
volume of Dulbecco's Phosphate-Buffered Saline (DPBS). 3 mL of Ficoll-premium 
(1.077g/mL) solution was added into the bottom of a Greiner Bio-One 10 mL 
Leucosep® tube and centrifuged at room temperature for 1 min at 1000 g, (Figure 2-2). 
6 mL of PBS-diluted blood samples were carefully added down the side of the 
Leucosep® tube held at 45 degrees and the tube was centrifuged at 200 g at RT for 30 
min. The interface layer containing the PBMCs was then collected into a new sterile 15 
mL Tubes, and washed with PBS at room temperature, followed by centrifuging at 200g 
at RT for 5 min and the supernatant was discarded. Cell pellets were then suspended 
with 10 mL of cold ammonium-chloride-potassium lysing buffer, and incubated at 4C 
for 1 mine, followed by centrifugation at 200 g for 5 min at 4C. The pellets were 
washed twice using 10 mL PBS, and centrifuged at 1000g at room temperature for 5 
min. Finally, the cell pellets were suspended in 0.5 mL PBS, and transferred into 1.5 mL 
Microcentrifuge tubes and centrifuged at 1000 g at 4C for 2 min to form a tight cell 
pellet, which was stored at -80°C until further analysis. 
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Figure 2-2: Isolation of PBMCs using ficoll density gradient. 
Tube was centrifuged to obtain the buffy coat which was then transfered to a 
new tube containing Ficoll. The remaining PBS was removed and PBMCs were 
collected in 1.5 mL Microcentrifuge tubes 
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2.11  Real-Time Quantitative PCR (RT-qPCR) 
2.11.1  First-strand cDNA Synthesis  
First-strand cDNA was synthesized from purified RNAs using the RT-PCR kit 
(Qiagen) according to the manufacturer’s methodology. 500 ng of purified total RNA 
was mixed with 2 μl Buffer GE, and RNase-free water added to a final volume of 10 μl 
in a 0.5 mL tube (Table 2-6) and incubated in a Bio-Rad T100 thermal cycler at 42°C for 
5 min, then placed immediately on ice for at least 1 min. 10 μl of reverse-transcriptase 
mixture, as shown in Table 2-7, were added to each tube containing genomic DNA 
elimination mix and gently mixed by pipetting up and down. Reverse Transcriptase (RT) 
was replaced by RNase-free water for the no reverse transcription control (NRT) 
preparation. The RNA reverse transcription reaction mixtures, of final volumes of 20 
µL, were incubated at 42°C for exactly 45 min. and immediately the reaction was 
stopped by incubating at 95°C for 5 min, then centrifuged for 10 seconds to bring the 
contents to the bottom of the tubes. The resulting first-strand cDNA products were 
stored frozen at -20oC and samples were used as a template for RT-qPCR amplification.  
 
Table 2-6 Reaction mixture for genomic DNA elimination 
Component Amount 
Total RNA 500 ng µL Variable 
 Buffer GE  2 μl 
 RNase-free water  Variable 
Total volume 10 μl 
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Table 2-7 Reaction mixture for preparing reverse-transcription  
Component 
Volume for 1 
reaction 
 RNase-free water  3 μl 
 Control P2  1 μl 
 RE3 Reverse Transcriptase Mix  2 μl 
 5x Buffer BC3  4 μl 
 Total volume  10 μl 
First-strand cDNA for RT-qPCR of microRNAs was synthesized from purified 
RNAs using miScriptII RT-PCR kit (Qiagen).: 500 ng of total RNA was mixed with 4 µl 
of 5x miScript HiSpec Buffer and 2 µl of 10x miScript Nucleics Mix in a final volume 
of 20 µl with Reverse Transcriptase (RT) as describe in Table 2-8. RT was replaced by 
RNase-free water for the no-RT control preparation. The reaction mixtures were 
incubated at 37oC for 60 min followed by incubation for 5 min at 95ºC. The resulting 
reverse transcription products were stored frozen at -20oC and were used as a template 
for RT-qPCR amplification of microRNAs. 
Table 2-8: First-strand cDNA reaction mixture for preparing microRNA 
Component 
Volume for 1 
reaction 
RNase-free water µL Variable 
5x miScript HiSpec Buffer  4 µL 
10x miScript Nucleics Mix 2 µL 
500 ng of Total RNA  µL Variable  
miScript Reverse Transcriptase 
Mix 
2 µL 
Total Volume 20 µL 
2.11.2  Real-Time Quantitative PCR (RT-qPCR) 
RT-qPCR of mRNAs was performed by adding 1 µl of diluted (1:20) RNA reverse 
transcription products to 1x RT2 SYBR Green Mastermix, 0.4uM of RT2 qPCR Primer 
in a final volume of 10 µl (Table 2-9). The RT-qPCR mixtures were incubated in 96 
well plates at. at 95oC for 10 min followed by 35 cycles of 2 steps cycling; annealing at 
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95oC for 15 second followed by an extension step for 15 seconds at 60oC. Melting curve 
analysis was performed (10 seconds at 95oC, 65oC for 60 seconds and 97oC for 1 
seconds) to detect the presence of nonspecific products and the primer dimers. All RT-
qPCR reactions were performed in duplicate and a No-Reverse Transcriptase (NRT) 
control was included. RT-qPCR amplification was performed using a Roche Lightcycler 
96® real-time PCR system. All primers used for RT-qPCR in this study were from 
QIAGEN as shown in Table 2-3. 
Table 2-9: Reaction mixture for detection of mRNA 
Component 
Volume for 1 
reaction 
RT2 SYBR Green Mastermix 5 µl 
Diluted cDNA synthesis reaction (1:20) 1 µl 
RT2 qPCR Primer Assay (10 uM stock) 0.4 µl 
RNase-free water 3.6 µl 
Total 10 µl  
Detection of the expression of miRNAs was performed by RT-qPCR using 
miScript SYBER kit [Qiagen] according to manufacturer’s recommendation. 1µl of 
diluted cDNA (1:20) was mixed with 5µl of 2x QuantiTect SYBR Green PCR Master 
Mix, 1µl of 10x miScript Universal Primer (reverse primer), 1 µl of 10x Primer Mix 
(forward miScript primer), with a final volume of 10 µl, (Table 2-10). The RT-qPCR 
mixture were incubated at 95oC for 15 min followed by 45 cycles of 3 steps cycling; 
denaturation s at 94oC for 15s, annealing at 55oC for 30s and an extension at 70oC for 
30s, melting step (95oC for 10s, 65oC for 60s and 97oC). All RT-q PCR reactions were 
performed in duplicate for the miRNA of interest and a No-Reverse Transcriptase 
(NRT) control was included. RT-qPCR ammplification was performed using a Roche 
Lightcycler 96® real-time PCR system. All miRNAs used for RT-qPCR in this study 
were from QIAGEN as shown in Table 2-4.  
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Table 2-10 Reaction mixture for detection of miRNA 
Component 
Volume for 1 
reaction 
2x QuantiTect SYBR Green PCR Master Mix 5 µl 
10x miScript Universal Primer 1 µl 
10x miScript Primer Assay 1 µl 
RNase-free water 2 µl 
Template of diluted cDNA (1:20) 1 µl 
Total Mix 9 µl 
2.11.3  Analysis of RT-qPCR Data 
Relative quantities of mRNA/miRNA were calculated using the Ct methods after 
normalization to the controls including Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) for mRNA or Small Nucleolar RNA, C/D Box 96A (SNORD96A) for 
microRNAs.  The expression levels of mRNAs or MiRNA between the osteopaenia, 
osteoporosis and non-osteoporosis control were calculated using the Ct equation as 
well as the fold change (2-CT) for each mRNA/miRNA  (Bustin et al., 2005). Since Ct 
values greater than 35 were considered to be below the detection level of the reaction, 
(indicated as N/A, not detected), all mRNA/miRNA RT-qPCR reactions with Ct > 35 
were included in the analysis as undetected and assigned the Ct values of 35. 
ΔCt = Ct Treated - Ct control  
ΔCt = Ct Untreated - Ct control  
ΔΔCt = ΔCt Treated - ΔCt Untreated 
 Fold change = 2-(ΔΔCt) 
  Chapter 2 
 
64 | P a g e  
 
2.12  Western Blotting 
2.12.1  Preparation of Cell Lysates  
After washed twice with PBS, 5×106 cells were lysed with 1 mL of cold RIPA 
buffer (ThermoFisher, UK) and incubated on ice for 5 min with slight swirling of the 
plate occasionally. The lysate was then gathered to one side, using a cell scraper to be 
collected in 1.5 mL microcentrifuge tube before centrifuging at 100 g for 15 min to 
pellet the cell debris. The supernatant was resuspended in an equal volume of 2x 
Laemmli lysis buffer and then transferred to a new microcentrifuge tube. Protein 
samples were heated for 5 min at 95oC, chilled on ice for 2 min and centrifuged before 
loading onto an SDS polyacrylamide gel or stored at -20oC until further analysis. 
2.12.2  Quantification of Total Protein in Cell Lysates  
The total protein content of cell lysate was determined using the Qubit® Protein 
Assay Kit (Invitrogen Ltd, Paisely, UK) according to manufacturer’s recommendation. 
Briefly, a stock QubitTM working solution containing Qubit dye was prepared by diluting 
the QubitTM protein reagent 1:200 in the dilution buffer. 10 µl of standard sample was 
added to 190 µl of working solution, while 1 µl of each experimental sample was added 
to 199 µl of working solution. All tubes were vortexed for 2-3 seconds and incubated at 
room temperature for 15 min. The fluorescence signal was measured on the Qubit® 
Flurometer 2.0. 
The protein concentration was calculated based on the amount of fluorescence 
signal directly proportional to the concentration of protein in the solution using a 
calibration of protein standards of known concentration. 
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2.12.3  Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out on 12% Mini-PROTEAN® TGX™ Precast Protein 
Gels using the Bio-Rad mini protean gel system. 20 µg of protein were loaded per lane 
of the gel alongside a lane containing protein molecular weight markers (Precision Plus 
ProteinTM Dual Color Standard, BioRad). Gels electrophoresis was carried out at 200V 
and 30 mA for 40 min. After gel electrophoresis, proteins were electroblotted onto a 
PVDF membrane which had been activated by soaking in 100% methanol then 
equilibrated in transfer buffer. The blotting unit was assembled by placing components 
as shown in Figure 2-3. It was necessary to roll out the components to ensure there were 
no air bubbles between layers within the cassettes. Once the stacks were positioned on 
the cassette base, transfer was carried out at 1.5mA, 25 V, for 7 min.  
 
Figure 2-3: Schematic diagram illustrating the order to transfer protein 
from gel to PVDF membrane using Trans-Blot® TurboTM.  
The order started from bottom by 2 Filter papers then the PVDF membrane then 
the gel and lastly 2 filter papers) 
  Chapter 2 
 
66 | P a g e  
 
After electroblotting, the PVDF membrane was shaken continuously in 5% (w/v) 
non-fat milk in Tris-Buffer Saline Tween-20 (TBST) for 1 hour at room temperature to 
block non-specific binding sites on the membrane. The membrane was then incubated 
with primary antibody in an appropriate concentration diluted in 5% non-fat milk in 
TBST overnight at 4°C under continuous shaking (list of primary antibodies, Table 2-1). 
The membranes were then washed three times in TBST for 10 mins each time with 
gentle rocking to remove unbound primary antibodies. The membrane was then 
incubated for one hour at room temperature with gentle shaking with the appropriate 
secondary antibody in an appropriate concentration, (Table 2-2), made up in 5% non-fat 
milk /TBST. The membrane was again washed three times in TBST for 10 min each 
time. 
The levels of protein were detected using an enhanced Chemiliminescent 
Substrate kit (SuperSignal™ West Femto Chemiliminescent Substrate, Fisher Scientific) 
which measures the horseradish peroxidase (HRP) activity from the secondary 
antibodies. The ECL substrate kit contains ECL reagents 1 and 2 which were mixed in a 
1:1 solution and applied to the membrane for 2-3 mins. The membrane was enclosed in a 
clear plastic sheet protector to prevent drying and signals were measured using BioRad 
ChemiDOCTM digital imager (BioRad, UK). Densitometric values of band intensity 
were taken using the BioRad Image Lab program. β-Actin was used as control to 
evaluate equal loading of samples.  
2.13  Statistical Analyses 
A variety of statistical tool were used to measure the numerical analytical data 
including IBM SPSS Statistic 22.0 (UK Head Office IBM United Kingdom Limited PO 
  Chapter 2 
 
67 | P a g e  
 
Box 41, North Harbour Portsmouth Hampshire, PO6 3AU) and GraphPad Prism version 
7 (GraphPad Software, Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA).  
Student’s t-test was used to compare any differences observed between each 
experimental group and the control group. One-way ANOVA with ‘Bonferroni's 
multiple comparisons test’ was used to compare the mean between three or more groups. 
Two-way ANOVA ‘Dunnett's multiple comparisons test’ was used to compare the mean 
between different groups when different treatments were compared with the control. 
SPSS Ver. 22.0 was used to calculate the area under the receiver operating 
characteristic (ROC) curve (AUC) diagnostic value of mRNAs and miRNAs of clinical 
samples. The cut‐off points with the highest sensitivity and specificity were determined. 
Statistical significance was set at a p-value less than 0.05.  In Figures P values were 
indicated by *: (*) <0.05, (**) <0.01, (***) <0.001, (***), <0.0001(****). 
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3 Chapter 3: Identification of Differentially-
Expressed Hormone-Responsive Genes in 
Cultured Osteosarcoma Cells by RNA 
Sequencing 
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3.1 Introduction 
Osteoporosis is a common bone disease among the elderly that occurs when the 
body loses bone mass, which results in bone weakness and fracture. Until a fracture 
occurs there are no symptoms (Rachner et al., 2011). In postmenopausal women, 
osteoporosis is mainly caused by a deficiency of estrogen resulting in a high risk of 
suffering from the disease (Nih Consensus Development Panel on Osteoporosis 
Prevention and Therapy, 2001). Estrogen plays a significant role in the growth and 
maturation of bone and in the regulation of bone remodelling (Hofbauer et al., 1999). 
The major physiological effect of estrogen is to inhibit bone resorption by osteoclasts 
and induce bone formation by osteoblasts (Hofbauer et al., 1999) (Riggs, 2000). The 
effect of estrogen, on bone and other target tissues, is mediated by estrogen receptors α 
and/or β (ERα, ERβ), and these receptors are encoded by different genes, located on 
human chromosomes 6 and 14, respectively (Fitzpatrick, 2006). Once estrogen bind to 
these receptors in the nucleus, gene expression is modulated, either by the complex 
binding directly to specific response elements, or indirectly by protein-protein 
interaction in the regulatory regions of the estrogen-target genes (Tsai and O'Malley, 
1994). However, the influence of these receptors on the pattern of gene expression in the 
bones of postmenopausal women, which might be associated with the development of 
osteoporosis, is still unknown (Chen et al., 2004).  
Due to the difficulty of isolating, in an intact state, the cellular components of bone 
(Damien et al., 1998, Aguirre et al., 2007), cultured osteosarcoma cells can be used as a 
bone related system (Denger et al., 2008, Pacheco-Pantoja et al., 2011). The in vitro 
osteosarcoma cells used in this study, (Mg-63, TE-85, and Saos-2), represent different 
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stages of osteoblastic development, where Mg-63 is identified as the cell line being the 
least mature, Saos-2 as the most differentiated and TE-85 may have a level of maturity 
somewhere between Mg-63 and Saos-2 (Pacheco-Pantoja et al., 2011).  
3.1.1 Aim 
The purpose of this chapter is to identify differentially-expressed estrogen- 
responsive genes using cultured osteosarcoma cells by RNA sequencing. This aim will 
be achieved by performing the following experiments: 
• Establishing an estradiol (-estradiol) responsive model of cultured osteosarcoma 
cells (Mg-63, TE-85, and Saos-2). 
• Investigating the effect of -estradiol on the proliferation of the cultured 
osteosarcoma cells. 
• Identifying, using RNA-sequencing, mRNAs of genes that are differentially-
expressed when the osteosarcoma cells are treated with estradiol. 
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3.2 Result 
3.2.1 Establish a Hormone-Responsive Model in Cultured 
Osteosarcoma Cells 
Different batches of foetal bovine serum (FBS) from different companies were tested 
to identify the serum batch that is suitable to support the growth of cultured osteosarcoma 
cells. The results showed that 10 % Bio Sera FBS did not increase the number of cells at all 
over 24 h. 10 % of LabTech serum in the medium showed an increase in cell number by 
only 60 %. However, 10 % of Gibco FBS in the culture medium increased the accumulation 
of all three cultured cells by more than two-fold over 24 h, compared to the starting number 
of cells (Figure 3-1).  Therefore, 10 % of Gibco FBS was used for the rest of the project.  
 
Figure 3-1: Change in cell numbers of osteosarcoma cell lines tested with 
different batches of foetal bovine serum. 
Three osteosarcoma cell lines were cultured and the number of cells was 
determined after 24h of culture and compared with the number of cells at 
the start, which was set at 100. Each bar represents the mean ±SD of 
triplicate experiments. 
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3.2.2 Estrogen Receptors α and β in the Cultured 
Osteosarcoma Cells 
The purpose of this part of this study was to detect the presence of ER α and β 
mRNAs/proteins in the Mg-63, TE-85, and Saos-2 osteosarcoma cell lines, as well as in 
MCF-7 cells, a positive control for ERα, using real-time reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) and western blot.  
3.2.2.1 The Levels of Estrogen Receptors α and β mRNAs in the 
Cultured Osteosarcoma Cells 
Total RNAs were isolated from the Mg-63, TE-85 and Saos-2 osteosarcoma cell 
lines and the MCF-7 cells and treated with DNase to remove traces of genomic DNA 
contamination before reverse transcription. Levels of ER α and β mRNAs were 
determined by RT-qPCR using specifically designed primers (Table 2-3). The levels of 
mRNA in cultured osteosarcoma cell lines were compared to the positive control, MCF-
7 cells, using the 2-∆Ct method with GAPDH as a housekeeping control gene. The results 
showed that the ER α mRNA was detected in Mg-63, TE-85 and Saos-2 cells (Figure 
3-2A), but at less abundant levels than in the positive control cells, MCF-7. However, in 
contrast, the levels of ER β mRNA were much higher in all three osteosarcoma cell lines 
than that in the MCF-7 cells, (Figure 3-2B). The results show that both ER α and β 
mRNAs are present in the cultured osteosarcoma cells, with ER β being more abundant 
than ER . 
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Figure 3-2: The relative expression levels of estrogen receptor α and 
β mRNAs in osteosarcoma cell lines and control MCF-7 cells 
mRNAs for ERα (A) and ERβ (B) were detected using RT-qPCR 
and relative expression levels of mRNA compared to MCF-7 cells 
were determined using the 2-∆Ct method with GAPDH as a 
constitutively-expressed control mRNA. Each bar represents the 
mean ±SD (n=3). All RT-qPCR data were logarithmically 
transformed. 
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3.2.2.2 Estrogen Receptor α and β Proteins in the Cultured 
Osteosarcoma Cells 
The presence of estrogen receptor α and β proteins in osteosarcoma cell lines was 
determined by western blot, using antibodies for estrogen receptors α or β. A β-actin 
antibody was used as a housekeeping control to standardise between samples, (Table 2-1 
and Table 2-2). 
Immunoblotting for ER α and β protein in the osteosarcoma cell lines, Mg-63, TE-
85 and Saos-2, and control MCF-7 cells, revealed distinct bands at 65 and 46 kDa 
corresponding to the sizes of the ER α and β proteins, respectively (Figure 3-3) (Wang et 
al., 2014, Park et al., 2017). The results showed that, as with the mRNA measurements 
by RT-qPCR, the levels of ER α protein in the osteosarcoma cells were not as abundance 
as in the positive control cells, MCF-7. The ER α protein is present in the cultured 
osteosarcoma cell line Mg-63 cells, but the levels of ER α protein were much lower in 
both TE-85 and Saos-2 cells compared to Mg-63 cells. The ER β protein was detected in 
all three cultured osteosarcoma cell lines, Mg-63, TE-85 and Saos-2 cells, and showed 
similar/greater levels as those in MCF-7 cells (Figure 3-3). 
 
Figure 3-3 Western blot analysis of estrogen receptor α and β in 
osteosarcoma and MCF-7 cell lines.  
ER α and β protein bands at 65 and 46 kDa, respectively, were detected in 
osteosarcoma and MCF-7 cell lines.  
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3.2.3 The Effect of Estradiol on the Proliferation of the 
Cultured Osteosarcoma Cells  
The effect of Estradiol on the proliferation of osteosarcoma cell lines and MCF-7 
cells was evaluated using phenol red-free medium (RPMI) containing steroid-free FBS 
(Materials and Methods, Section 0). 
3.2.3.1 Optimization of the Rate of Growth on Osteosarcoma Cells 
Using In-house Hormone-Stripped FBS. 
The purpose of this optimization is to find the minimum concentration of 
hormone-stripped FBS that allows cell survival for a period of 6 days in the absence of 
steroid hormones, to ensure that cells can survive over this period without growing. 
It was found that in 0.5 % hormone-stripped FBS, none of the cells showed any 
significant change in number compared to the starting number (all p > 0.99) Thus, the 
cells stayed alive for 6 days without cell proliferation or cell death, whereas higher and 
lower concentrations of hormone-stripped FBS generally resulted in an increase or 
reduction in cell number relative to the starting number (Figure 3-4 and Table 3-1). The 
result demonstrates that RPMI supplemented with 0.5 % hormone-stripped FBS kept 
cells in a life state without any growth in Mg-63, TE-85, Saos-2 and MCF-7 cells 
compared to the starting number. Thus, 0.5% hormone stripped FBS was used in 
subsequent experiments. 
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Figure 3-4: The effect of hormone-stripped medium on the growth of cell 
lines  
1×104 cells/ cm2 were grown initially to 60 % confluence in complete 
medium, washed twice with PBS and then transferred into RPMI 
containing different concentrations of hormone-stripped FBS to deplete the 
endogenous steroids for 6 days. Medium was changed daily. The number 
of cells was calculated by counting cells after 6 days (A. Mg-63, B. TE-85, 
C. Saos-2 and D. MCF-7). Each bar represents the mean percentage 
change ±SD (n=3). The control is the mean number of cells before 
treatment with stripped FBS, which was normalised to 100%. ns=non-
significant, * p < 0.05, ** p < 0.01, **** p < 0.0001. 
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Table 3-1: The effect of hormone-stripped FBS on the growth of cell lines  
Cells 
Hormone-stripped 
FBS concentrations  
Rate of growth 
(Mean Difference 
to the Control %) 
P Value 
Mg-63 
0.00% vs. Control -60.46 <0.0001 
0.25% vs. Control -23.09 0.048 
0.50% vs. Control <1 >0.99 
1% vs. Control 23.15 0.0474 
2.50% vs. Control 89.89 <0.0001 
5% vs. Control 252.1 <0.0001 
TE-85 
0.00% vs. Control -56.17 <0.0001 
0.25% vs. Control -29.19 0.006 
0.50% vs. Control -2.16 >0.99 
1% vs. Control 18.15 0.2102 
2.50% vs. Control 115.8 <0.0001 
5% vs. Control 274.1 <0.0001 
Saos-2 
0.00% vs. Control -60.85 <0.0001 
0.25% vs. Control -16.66 0.3134 
0.50% vs. Control <1 >0.99 
1% vs. Control 23.69 0.0398 
2.50% vs. Control 89.44 <0.0001 
5% vs. Control 236.8 <0.0001 
MCF-7 
0.00% vs. Control -52.86 <0.0001 
0.25% vs. Control -20.35 0.1122 
0.50% vs. Control <1 >0.99 
1% vs. Control 24.33 0.0323 
2.50% vs. Control 117 <0.0001 
5% vs. Control 284.9 <0.0001 
The control is the mean number of cells for each cell line before treatment 
with stripped FBS which was normalised to 100%. Two-way ANOVA, 
(Dunnett’s multiple comparisons test) was used to calculate the rate of 
growth compared to the control  
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3.2.3.2 The Effect of Estradiol on the Proliferation of Osteosarcoma 
Cells  
The effectiveness of the step-down period prior to adding -estradiol was 
optimised by incubating cells at a density of 1×104 cells/ cm2 for 1 or 3 days in phenol-
free RPMI medium containing 0.5% hormone-stripped FBS, followed by the addition of 
1 nM of β-estradiol (Dohi et al., 2008) into the step-down medium and incubation for 
48hr (Materials and Methods, Section 0). Step-down medium without β-estradiol was 
used for control cells. The results (Figure 3-5 and Table 3-2) showed that incubating 
cells for 1 day in the step-down medium, followed by 48 h in the presence of β-estradiol, 
was insufficient for estrogen to stimulate cell numbers of Mg-63 and MCF-7 cells 
compared to untreated controls (p = 0.07 and 0.4 respectively). In contrast, TE-85 and 
Saos-2 cells showed a significant increase in cell number compared to the control 
untreated cells (p = 0.03 and 0.0016) On the other hand, following step-down, 
incubation of the cells for 3 days with 1 nM β-estradiol significantly increased cell 
numbers of all four cell lines Mg-63, TE-85, Saos-2 and MCF-7 (p = 0.006, <0.0001, 
0.0002 and <0.0001 respectively).  
In order to produce more cells for later RNA isolation, larger dishes with 25 cm2 
growth area were used. Cells were seeded (3×104 cells/ cm2) equally to each flask and 
the same protocol was followed as with the 9.5 cm2 dishes. There was a significant 
increase in cell numbers for all 4 cell lines after treatment with β-estradiol for 48 h 
compared with untreated cells ( Figure 3-6; Mg-63, p<0.0001; TE-85, p =0.0034; Saos-
2, p = 0.0003; MCF-7, p <0.0001). Therefore, the results obtained with the larger dishes 
were consistent with those obtained with the pilot 6-well plates. 
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Figure 3-5: The effect of 1 nM β-estradiol on the proliferation of cell lines. 
The indicated cell lines were incubated in step-down medium for 1 or 3 
days before treatment with 1 nM β-estradiol for 48 h. Control cells were 
incubated for 48 h without β-estradiol normalised to 100%. White bars, 
cells incubated for 1 day; Black bars, cells incubated for 3 days. Each bar 
represents the mean ±SD (n=3). * p < 0.05, *** p < 0.001, **** p < 
0.0001. 
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Table 3-2: β-estradiol on Proliferation of Osteosarcoma Cells: 
Cells Incubation Time  
Rate of growth 
relative to the 
Control %) 
P Value 
Mg-63 
1 Day  110 0.0737 
3 Days 124 0.0006 
TE-85 
1 Day  111 0.0306 
3 Days 136 <0.0001 
Saos-2 
1 Day  117 0.0016 
3 Days 124 0.0002 
MCF-7 
1 Day  105 0.408 
3 Days 129 <0.0001 
 1 nM β-Estradiol induced the proliferation of cells incubated in 0.5% 
hormone-stripped medium for 1 or 3 days using 6 well-plates.   
 
Figure 3-6: The effect of 1 nM β-estradiol on the proliferation of cell lines 
scaled up in TC-25 dishes. 
The indicated cell lines were incubated in -estradiol stripped medium in 
TC-25 flasks for 3 days before adding β-estradiol. Control cells were 
incubated for 48 without β-estradiol, which was set at 100. Live cell 
numbers were counted after 48 h. Each bar represents the mean ±SD 
(n=3)** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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3.2.4 Identify Differentially Expressed Estrogen-Responsive 
Genes in Cultured Osteosarcoma Cells by RNA-
Sequencing 
3.2.4.1 RNA Purity and Quality Control  
Total RNAs were extracted from cells lines by using a combination of TRIzol® 
reagent and PureLink® RNA Mini Kit (Ambion, UK) (Materials and Methods, Section 
2.3.1) and were checked for purity and yield using a NanoDrop™ 2000 
spectrophotometer (Materials and Methods, Section 2.3.3). All isolated RNAs exhibited 
260/280 and 260/230 ratios that exceeded the benchmark of 2 (Evans, Chomczynski and 
Sacchi, 2006) (Table 3-3), a requirement for successful RNA sequencing.  
In order to identify differentially-expressed mRNA between control (untreated) 
and β-estradiol-treated osteosarcoma and MCF-7 cells, 6 µg of the total RNA for each 
cell line was subjected to RNA sequencing by The Genome Analysis Centre (TGAC) 
(Norwich, UK). Additional RNA quality assessment was performed using an RNA6000 
Nano LabChip on an Agilent 2100 bioanalyzer by TGAC (Table 3-3, Figure 3-7 and 
Figure 3-8). The data showed that all the isolated RNAs from all cell lines exceeded the 
benchmark ratio of 28S to 18S ribosomal RNA ratio of >2 (Table 3-3) (Skrypina et al., 
2003). The fluorescence plots with two peaks representing 18S and 28S ribosomal 
RNAs of control and treated cell lines are shown in Figure 3-8. The RNA integrity 
number (RIN), which was calculated by TGAC for each isolated RNA, showed at least 
9.4 out of 10. The conclusion is that the total RNA was intact and no degradation was 
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observed (Schroeder et al., 2006) and these high quality RNAs purified from all the 
experimental treated or control cultured cells were used for RNAs sequencing. 
Table 3-3: Quality check of RNA isolated from control and treated cell lines 
Sample ID A260/280 A260/230 RIN 
rRNA Ratio 
[28S/18S] 
TE-85-Control 2.06 2.04 9.9 2.33 
TE-85-Treated 2.02 2.02 9.6 2.28 
Saos-2-Control 2.05 2.07 9.5 2.05 
Saos-2-Treated 2.04 2.03 9.7 2.2 
Mg-63-Control 2.1 2.12 9.4 2.05 
Mg-63-Treated 2.1 2.07 9.5 1.93 
MCF-7-Control 2.11 2.22 9.5 2.0 
MCF-7-Treated 2.09 2.25 9.7 2.06 
Benchmark value 2 (Evans) 2 (Evans) 
10 (Schroeder et 
al., 2006) 
2 (Skrypina et 
al., 2003) 
The quality check of RNA was performed using a NanoDrop™ 2000 
spectrophotometer and an Agilent 2100 Bioanalyzer. The RIN and rRNA 
ratios were determined by TGAC     
 
 
Figure 3-7: Quality of RNA isolated from both control and treated cells 
using Agilent 2100 Bioanalyzer. 
The gel electropherogram images for Ladder (Lane 1), TE-85 Control 
(Lane 2), TE-85 Treated (Lane 3), Saos-2 Control (Lane 4), Saos-2 
Treated (Lane 5), Mg-63 Control (Lane 6), Mg-63 Treated (Lane 7), MCF-
7 Control (Lane 8) and MCF-7 Treated (Lane 9). Data generated by 
TGAC.  
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Figure 3-8: Quality check of total RNA samples by the Agilent 2100 
bioanalyzer. 
Horizontal axis (Monroe et al.) denotes the aligned time in seconds, and 
the vertical axis (FU) denotes the fluorescent units (measure of the 
intensity). All panels showed two peaks of 18S and 28S ribosomal RNAs 
of each control sample, whereas right plots with two peaks of 18S and 28S 
ribosomal RNAs of each treated sample. Data generated by TGAC. 
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3.2.4.2 RNA sequencing Quality Control (QC) 
Following cDNA synthesis, 8 Illumina TruSeq RNA libraries, both control and 
treated for each of the 4 cell lines, were generated by TGAC and sequenced across two 
lanes of a HiSeq2000 with 100 bp paired-end reads. Reads were mapped to the reference 
human genome, using Tophat software version 2.0.12. 
An initial step in the analysis of RNA-Seq data evaluated the quality of 
sequencing, trimming and mapping, using the MultiQC tool of RNA-seq QC software. 
The mapping of the sequencing data is a useful quality control step to evaluate the 
quality of the individual RNA libraries. Alignment of RNA-Sequencing reads to 
transcriptome reference [Human genome build 38] was carried out as shown in Table 
3-4. The table summarizes the mapping result by showing the total number of reads 
obtained and percentage of reads that mapped to the human reference genome. On 
average reads, across all samples, 52.3 ± 8 million reads were obtained for each sample, 
with 88.19 ±2 % identical to the human reference genome. Hence, all samples achieved 
the 70-90 % benchmark (Conesa et al., 2016) for sequences mapping onto the reference 
human genome. 
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Table 3-4: Summary of the mapping results to the reference human genome 
build 38 for each library.  
Sample ID 
Total read 
count 
Mapping 
percentage to the 
Reference 
TE-85-Control 52140759 89 % 
TE-85- Treated 59171549 89.6 % 
Saos-2- Control 54013583 89.3 % 
Saos-2- Treated 46404274 89.4 % 
Mg-63- Control 54445889 88.7 % 
Mg-63- Treated 34771768 83.7 % 
MCF-7- Control 57943863 88.3 % 
MCF-7-Treated 59516355 87.5 % 
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3.2.4.3 Analysis of RNA Sequencing 
3.2.4.3.1 Bioinformatics Analysis of RNA-Seq 
Bioinformatics analysis of the RNA-seq data was performed by TGAC (Norwich, 
UK) using Cufflinks software to identify differentially-expressed genes between control 
and -estradiol -treated cells. The list of differentially-expressed genes was narrowed to 
those significantly changed with q value < 0.05 and ±2 fold changed. The q value is an 
adjusted p-value using Benjamini-Hochberg False Discovery Rate (FDR) approach to 
correct for multiple testing.  
Volcano plots were constructed to provide a quick visual representation of the 
result from RNA Seq (Figure 3-9) for each cell line. There are 2 regions of interest in the 
Volcano plot. Those points that are found near the top of the plot have high statistical 
significance, with q value of <0.05. Points shown as green dots represent genes that are 
significantly changed by ±2 fold. However, dots in red represent genes that are not 
significantly changed with q value of >0.05.  
RNA-Seq identified 154 genes that were up-regulated by at least a 2-fold change 
and 108 genes that were down-regulated by -estradiol in Mg-63 cells, compared to 
untreated cells. TE-85 cells showed just one gene down-regulated when compared to 
non-treated controls. There was one gene that was up-regulated and 2 genes that were 
down-regulated in Saos-2-treated cells compared to untreated cells. In MCF-7 control 
estrogen-responsive cells, 142 genes were found to be upregulated and 137 genes were 
found to be downregulated by -estradiol compared to untreated cells. These results are 
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consistent with the presence of estrogen receptor  protein in the Mg-63 and MCF-7 
cells and the very low levels of this receptor in the TE-85 and Saos-2 cells (Figure 3-3). 
 
 
Figure 3-9:Volcano plot of the fold-change of transcripts in osteosarcoma 
cells treated with β-estradiol compared to untreated control. 
Volcano plots were constructed by plotting –log10 of the q-value on the y-
axis, and the expression fold change between control and cells treated with 
1 nM of β-estradiol on the x-axis. In the plots, each dot represents one 
gene, and control vs β-estradiol treatment was plotted for the cultured 
osteosarcoma cell lines and MCF-7 cells. Genes that pass the filtering of q-
value<0.05 are indicated in green on the plot, and those that do not are in 
red. 
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3.2.4.3.2 Differentially Expressed Estrogen Responsive Genes in Osteosarcoma 
Cells 
From 262 gene found to be differentially expressed in the β-estradiol-treated Mg-
63 cells, 36 genes were increased by over 2-fold (p <0.05, q <0.05) and 19 genes were 
decreased over 2-fold change (p <0.05, q <0.05) in the β-estradiol-treated cells 
compared to the untreated control (Table 3-5).   
12 mRNAs, including DKK3 (Dickkopf-related protein 3), XAF1 (XIAP-
associated factor 1), LSP1 (Lymphocyte-specific protein 1), CREB5 (cAMP responsive 
element binding protein 5), MMP2 (Matrix metallopeptidase 2), COLIA2 (Collagen type 
I alpha 2 chain), FSTL1 (Follistatin-like 1), IFI44L (Interferon-induced protein 44 like), 
DCN (Decorin), IFI16 (Gamma-interferon-inducible protein 16), BLID (BH3-like motif 
containing, cell death inducer) and CALD1 (Caldesmon 1), showed the highest fold 
changed by over 9-fold in expression in the Mg-63 cells treated with β-estradiol 
compared to untreated control.  
7 mRNAs, COL3A1 (Collagen type III alpha 1 chain), VIM (Vimentin), MX1 
(MX dynamin like GTPase 1), IFI27 (Interferon alpha inducible protein 27), GSDMD 
(Gasdermin D), OAS2 (2'-5'-oligoadenylate synthetase 2) and S100A4 (S100 calcium 
binding protein A4), showed over 8-fold increased expression in the β-estradiol-treated 
Mg-63 cells.  
The levels of 13 mRNAs including ALDH3A1 (Aldehyde dehydrogenase 3 
family member A1), FBN1 (Fibrillin 1), PARP10 (Poly(ADP-ribose) polymerase family 
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member 10), TMBIM1 (Transmembrane BAX inhibitor motif containing 1), TGFΒI 
(Transforming growth factor beta induced), IFI6 (Interferon alpha inducible protein 6), 
CTSZ (Cathepsin Z), ANXA1 (Annexin A1), COL1A1 (Collagen type I alpha 1 chain), 
TRAM2 (Translocation associated membrane protein 2), SPOCK1 (SPARC/osteonectin, 
cwcv and kazal like domains proteoglycan 1), FKBP1 (FK506 binding protein 10) and 
EMP1 (Epithelial membrane protein 1) showed an increase in level of over 5-fold 
change in the β-estradiol treated Mg-63 cells compared to the untreated control.  
The levels of 4 mRNAs, S100A2 (S100 calcium binding protein A2), EPB41L2 
(Erythrocyte membrane protein band 4.1 like 2), LTBP4 (Latent transforming growth 
factor beta binding protein 4) and SLC16A3 (Solute carrier family 16 (monocarboxylic 
acid transporters), member 3) were upregulated by over 3-fold change in the β-estradiol-
treated Mg-63 cells compared to the untreated control.  
The levels of 5 mRNAs, FXYD3 (FXYD domain containing ion transport 
regulator 3), MLPH (Melanophilin), LLGL2 (LLGL2, scribble cell polarity complex 
component) ESR1 (Estrogen receptor 1) and ESRP2 (Epithelial splicing regulatory 
protein 2) were decreased by over 8-fold change in the β-estradiol treated Mg-63 cells 
compared to the untreated control.  
The levels of 9 mRNAs, KRT19 (Keratin 19), CELSR2 (Cadherin EGF LAG 
seven-pass G-type receptor 2), GREB1 (Growth regulation by estrogen in breast cancer 
1), MAL2 (Mal, T-cell differentiation protein 2), NPY1R (Neuropeptide Y receptor type 
1), KRT8 (Keratin 8), TFAP2C (Transcription factor AP-2 gamma), GFRA1 (GDNF 
family receptor alpha 1) and TPD52L1 (Tumor protein D52 like 1) were decreased by 
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over 5-fold change in the β-estradiol treated Mg-63 cells compared to the untreated 
control.   
The levels of 5 mRNAs including TMEM64 (Transmembrane protein 64), 
TRIM37 (Tripartite motif containing 37), NFKBIA (NFKB inhibitor alpha), XBP1 (X-
box binding protein 1), RUNX2 (Runt related transcription factor 2) were decreased by 
over 2-fold change in the β-estradiol treated Mg-63 cells compared to the untreated 
control.   
Of these 55 differentially-expressed genes, 51 were significantly changed in 
RNA-sequencing data (p<0.05), but 4 mRNAs, S100A2, RUNX2, XBP1, NFKB1A 
were differentially expresssed between treated and untreated control, but were not 
significant in that data (p = 0.84, p = 0.88, p = 0.46, and p = 0.51 respectively).  
 
Table 3-5: Fold changes of the top 55 identified up and down regulated mRNA 
between control and Estradiol treated Mg-63 cells from RNA-seq generated by 
TGAC.   
Gene name Gene 
symbol  
FPKM 
of 
Control 
FPKM 
of 
Treated 
Fold 
Change 
p-value q- 
Value  
1 Dickkopf-related protein 
3 
DKK3 0.82 784.73 9.91 0.0066 0.0065 
2 XIAP-associated factor 1 XAF1 0.10 92.32 9.87 0.0066 0.0065 
3 Lymphocyte-specific 
protein 1 
LSP1 0.05 48.54 9.83 0.0066 0.0065 
4 cAMP responsive 
element binding protein 5 
CREB5 0.08 76.55 9.82 0.0066 0.0065 
5 Matrix metallopeptidase 
2 
MMP2 1.26 1073.33 9.73 0.0482 0.0481 
6 Collagen type I alpha 2 
chain 
COL1A2 1.56 1295.90 9.70 0.0066 0.0065 
7 Follistatin like 1 FSTL1 1.15 897.09 9.61 0.0066 0.0065 
8 Interferon induced 
protein 44 like 
IFI44L 0.41 323.98 9.61 0.0298 0.0298 
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9 Decorin DCN 0.17 130.86 9.60 0.0066 0.0065 
10 Gamma-interferon-
inducible protein 16 
IFI16 0.27 186.49 9.41 0.0066 0.0065 
11 BH3-like motif 
containing, cell death 
inducer 
BLID 0.09 61.24 9.35 0.0298 0.0298 
12 Caldesmon 1 CALD1 0.13 69.11 9.04 0.0066 0.0065 
13 Collagen type III alpha 1 
chain 
COL3A1 2.78 1335.38 8.91 0.0164 0.0163 
14 Vimentin VIM 6.05 2730.81 8.82 0.0066 0.0065 
15 MX dynamin like 
GTPase 1 
MX1 1.78 713.49 8.64 0.0066 0.0065 
16 Interferon alpha inducible 
protein 27 
IFI27 4.37 1618.77 8.53 0.0066 0.0065 
17 Gasdermin D GSDMD 0.47 145.74 8.28 0.0066 0.0065 
18 2'-5'-oligoadenylate 
synthetase 2 
OAS2 0.69 199.89 8.17 0.0429 0.0428 
19 S100 calcium binding 
protein A4 
S100A4 2.55 691.06 8.08 0.0043 0.017 
20 Aldehyde dehydrogenase 
3 family member A1 
ALDH3
A1 
2.83 555.70 7.62 0.0119 0.0119 
21 Fibrillin 1 FBN1 1.66 257.19 7.27 0.0066 0.0065 
22 Poly(ADP-ribose) 
polymerase family 
member 10 
PARP10 1.51 147.67 6.61 0.0066 0.0065 
23 Transmembrane BAX 
inhibitor motif containing 
1 
TMBIM
1 
1.27 123.18 6.60 0.0352 0.0351 
24 Transforming growth 
factor beta induced 
TGFΒI 3.81 349.70 6.52 0.0066 0.0065 
25 Interferon alpha inducible 
protein 6 
IFI6 22.29 2019.69 6.50 0.0298 0.0298 
26 Cathepsin Z CTSZ 2.04 183.08 6.48 0.0119 0.0119 
27 Annexin A1 ANXA1 3.21 282.05 6.46 0.0164 0.0163 
28 Collagen type I alpha 1 
chain 
COL1A1 11.61 733.64 5.98 0.0066 0.0065 
29 Translocation associated 
membrane protein 2 
TRAM2 7.75 454.53 5.87 0.0268 0.0268 
30 SPARC/osteonectin, 
cwcv and kazal like 
domains proteoglycan 1 
SPOCK1 3.93 225.96 5.85 0.0429 0.0428 
31 FK506 binding protein 10 FKBP10 3.72 193.00 5.70 0.0164 0.0163 
32 Epithelial membrane 
protein 1 
EMP1 4.18 145.36 5.12 0.0066 0.0065 
33 S100 calcium binding 
protein A2 
S100A2 0.38 5.65 3.88 0.17 0.84 
34 Erythrocyte membrane 
protein band 4.1 like 2 
EPB41L
2 
14.37 198.02 3.78 0.0482 0.0481 
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35 Latent transforming 
growth factor beta 
binding protein 4 
LTBP4 20.97 265.43 3.66 0.0066 0.0065 
36 Solute carrier family 16 
(monocarboxylic acid 
transporters), member 3 
SLC16A
3 
10.33 112.61 3.45 0.0429 0.0428 
37 Runt related 
transcription factor 2 
RUNX2 1.55 0.39 -2 0.29 0.88 
38 X-box binding protein 1 XBP1 1503.4 120.15 -3.64 0.021 0.46 
39 NFKB inhibitor alpha NFKBI
A 
187.63 12.8 -3.87 0.025 0.51 
40 Tripartite motif 
containing 37 
TRIM37 290.90 14.51 -4.33 0.0429 0.0428 
41 Transmembrane protein 
64 
TMEM6
4 
480.05 17.39 -4.79 0.0268 0.0268 
42 Tumor protein D52 like 1 TPD52L
1 
361.19 10.77 -5.07 0.0066 0.0065 
43 GDNF family receptor 
alpha 1 
GFRA1 116.38 1.74 -6.07 0.0298 0.0298 
44 Transcription factor AP-2 
gamma 
TFAP2C 140.81 2.08 -6.08 0.0298 0.0298 
45 Keratin 8 KRT8 2401.25 32.45 -6.21 0.0268 0.0268 
46 Neuropeptide Y receptor 
type 1 
NPY1R 142.49 1.70 -6.39 0.0268 0.0268 
47 Mal, T-cell differentiation 
protein 2 
MAL2 151.01 1.52 -6.63 0.0352 0.0351 
48 Growth regulation by 
estrogen in breast cancer 
1 
GREB1 154.39 1.47 -6.72 0.0066 0.0065 
49 Cadherin EGF LAG 
seven-pass G-type 
receptor 2 
CELSR2 238.68 1.72 -7.11 0.0268 0.0268 
50 Keratin 19 KRT19 1020.44 6.39 -7.32 0.0066 0.0065 
51 Epithelial splicing 
regulatory protein 2 
ESRP2 94.99 0.28 -8.42 0.0298 0.0298 
52 Estrogen receptor 1 ESR1 133.69 0.38 -8.46 0.0237 0.0236 
53 LLGL2, scribble cell 
polarity complex 
component 
LLGL2 204.89 0.58 -8.47 0.0066 0.0065 
54 Melanophilin MLPH 473.11 1.14 -8.69 0.0298 0.0298 
55 FXYD domain containing 
ion transport regulator 3 
FXYD3 561.10 1.04 -9.08 0.0202 0.0201 
FPKM is Fragments Per Kilobase of transcript per Million mapped reads. The 
ratio ≥2 fold changed for up-downregulated genes by -estradiol with q-
value <0.05 was significant. Bold data represent bone-related genes. 
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3.2.4.3.3 Identification of Common Estrogen Responsive Genes Between Mg-63 
and MCF-7 cells: 
Interrelation analyses between differentially expressed genes were performed 
between Mg-63 and MCF-7 cells to identify common estrogen responsive genes using 
intractiVenn web tool (Heberle et al., 2015). Interestingly, 181 genes, out of 262 that 
were differentially expressed in the Mg-63 cells, were found to be also differentially 
expressed in the MCF-7 cells. Therefore, this 65% of identified -estradiol-responsive 
genes in Mg-63 cells were the same as those in the ER-positive control cells, MCF-7, 
suggesting that these are common estrogen responsive genes. The remaining 81 genes 
differentially expressed in the Mg-63 cells were not differentially expressed by -
estradiol in the MCF-7 cells, possibly reflecting the different origins of the cells, i.e. 
bone and breast cells (Table 3-6) and suggests that these 81 genes might be bone-
specific, estrogen-responsive mRNAs.   
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Table 3-6: Common estrogen responsive genes between Mg-63 and MCF-7 
cells 
Cells 
No of 
Genes 
Genes 
Mg-63 81 GABRE,SPARC,MMP2,COL1A2,TENM2,C4orf22,TNC,CACNA
1A,FAP,ACSL4,DAPK1,VCAN,FBN1,ABCA8,CNN3,MXRA8,OS
BPL3,DDX60,C9,IFI6,ANXA1,NFIX,ALDH1A2,PTPRM,TRAM
2,SPOCK1,RIMS1,AKAP2,EYA4,CADPS,SEMA5A,S100A6,TGF
B1I1,C1orf228,CCDC88A,BTN3A2,PDE4D,PSIP1,EFCAB13,NFA
SC,AUTS2,EPB41L2,IL15RA,SLC16A3,GALT,PALM2AKAP2,R
P11290H9.2,RP1195F19.29,FGF5,KCNE5,DAB2,PALM2,ITGB3,I
L11RA,LINC01515,PPP1R13B,PLXNA3,TMEM64,ST6GALNAC
2,FAM84B,IGF2,RAPGEFL1,RAB17,TFAP2C,NPY1R,VIPR1,C
DYL2,MAL2,GREB1,RBM47,SLC7A2,CELSR2,CDH3,KRT19,
SERPINA3,ESRP2,PKIB,INS-IGF2,INS,SERPINA4,SERPINA5 
Mg-63 and 
MCF-7 
181 MAGI2AS3,BNC2,RP11576C2.1,TXLNGY,DKK3,XAF1,CREB5
,LAMA4,FSTL1,IFI44L,DCN,IFI16,BLID,TCF4,ADD2,CALD1,
COL3A1,VIM,FCGRT,MX1,PIEZO2,MASP1,IFI27,APBB1,GSD
MD,OAS2,ZEB1,PDE4B,C1R,C1RL,CDH11,RAB34,ZEB2,NLRC
5,GPR162,P3H3,ALDH3A1,TPM2,PKNOX2,PRG2,RP11872D17.
8,SLC43A3,LIMS2,ADAMTSL1,LDB2,ABI3BP,NTM,COL14A1,
MEF2C,SPON2,PARP10,ADAMTS10,TMBIM1,NCAM1,EFEMP
2,TGFΒI,CTSZ,EMP3,MYOM2,NR2F1AS1,TMEM173,LAMB1,
SLC14A1,HOXB3,HOXB4,HOXB6,NAV1,TNFRSF14,COL1A1,
BTN3A3,FKBP10,KCNMA1,HOXBAS1,HOXBAS3,TRO,APOL3
,LPIN1,TSPAN32,UCHL1,COL16A1,DGKG,ETV5,EMP1,DDX60
L,IQCJ,IQCJSCHIP1,SCHIP1,KIFC3,ROBO3,FGFR1,GSTM1,GS
TM2,GSTM4,PLSCR1,FIP1L1,PDGFRA,ZNF532,LTBP4,SORBS
2,ENOSF1,TM7SF2,VPS51,SLC25A29,ANKRD18A,RP11392E22.
9,CCDC78,PCDHA1,PCDHA10,PCDHA11,PCDHA12,PCDHA13,
PCDHA2,PCDHA3,PCDHA4,PCDHA5,PCDHA6,PCDHA7,PCDH
A8,PCDHA9,PCDHAC1,PCDHAC2,TMEM132A,TRIM37,TMPR
SS4,DTNA,TMC6,EPS8L1,ANK3,INPP5J,ISYNA1,MCF2L,TPD5
2L1,FER1L4,CNKSR1,MTUS1,FCHO1,PLEKHH1,UGT1A1,UGT
1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,U
GT1A9,SCUBE2,GFRA1,ADGRG1,ICA1,ATP2A3,KRT8,SLAIN
1,LDLRAD4,CATSPERB,TC2N,HID1,SERPINA1,TTC39A,GAL
NT6,NRCAM,PTPN6,LAD1,TNNT2,MYB,AC011513.3,CEACA
M21,CEACAM5,CEACAM6,PRLR,C19orf33,CTB102L5.4,SPINT
2,ESR1,LLGL2,ATP2C2,MLPH,CDH1,FXYD3, LSP1, DMKN 
Out of 262 differentially-changed genes upon -estradiol treatment of Mg-
63, 181 genes were also differentially expressed in MCF-7 cells. 81 genes 
were differentially expressed in the Mg-63 cells but not in the MCF-7 cells 
and thus may be bone-specific estrogen responsive mRNAs. Bold genes are 
those among the list of 55 Mg-63 genes altered by 2-fold or greater. 
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3.2.4.3.4 Functional Analysis of the Identified Differentially Expressed mRNAs 
Functional analysis of the 55 identified differentially-expressed mRNAs in 
treated Mg-63 compared to the control is summarized in Table 3-7. The results show 
that some of these genes are known to be involved in the regulation of bone remodelling, 
such as DKK3, XAF1, MMP2, COL1A2, IFI44L, IFI16, VIM, MX1, PARP10, TGFΒI, 
CTSZ, COL1A1, TRAM2, TMEM64, KRT8, CELSR2 and ESR1. Estrogen is shown to 
be involved in the differential expression of BLID, ANXA1, CALD1, CTSZ, TRAM2, 
EMP1, TFAP2C, GREB1, and ESR1. Others have been suggested to be changed in 
osteoarthritis (OA) like DKK3, FSTL1, CALD1 and COL3A1. Another group of genes 
(XAF1, IFI16, BLID, MX1, IFI27, GSDMD, TMBIMI, and GFRA1) may be involved 
in the apoptosis signalling pathway.  
DKK3 (Dickkopf-WNT signalling pathway inhibitor 3), is a secreted protein 
which has been reported to be associated with cancer development (Kawauchi et al., 
2012) (Kurose et al., 2004, Veeck et al., 2008, Yue et al., 2008). The increased mRNA 
and protein levels of DKK3 in human osteoarthritis cartilage, synovial tissue and 
synovial fluid and may have a positive effect on cartilage integrity by preventing 
proteoglycan loss and helping to restore osteoarthritis-relevant signalling pathway 
activity (Snelling et al., 2016). DKK3 has been reported to be able to inhibit invasion 
and motility of Saos-2 osteosarcoma cells through modulation of the Wnt-beta-catenin 
pathway (Hoang et al., 2004).  
XAF1 (X-linked inhibitor of apoptosis associated factor 1) protein has been 
reported to be involved in the progress of apoptosis signalling pathway (Liston et al., 
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2001), to inhibit cell proliferation and induce cell apoptosis in human lung 
adenocarcinoma cells (Chen et al., 2011) and to inhibit TNF-induced NF-κB activation 
(Lin et al., 2016). MMP2 (matrix metalloproteinase-2) is a protein that is involved in the 
breakdown of extracellular matrix (ECM) in normal physiological processes (Clark et 
al., 2007). MMP-2 plays a direct role in early skeletal development and bone cell growth 
(Mosig et al., 2007). Suppression of MMP-2 in osteoblastic murine increases 
osteopontin (OPN) and bone sialoprotein (BSP) expression and thereby regulates bone 
homeostasis (Mosig and Martignetti, 2013).  
COL1A2 (Collagen type I alpha 2 chain) is found in most connective tissue and 
is a key structural component of the extracellular matrix (Cole, 1994) and involved in 
several cancers (Ibanez de Caceres et al., 2006, Hayashi et al., 2014, Bonazzi et al., 
2011). Mutation of COL1A2 has been found to be associated with low BMD and 
fractures in Icelandic people (Styrkarsdottir et al., 2016). Suppression of COL1A2 may 
be associated with a reduced risk of developing osteoporosis by decrease the ability of 
osteogenesis (Jiang and Hao, 2016). Collagen type I alpha 1 chain (COL1A1) is an 
extra-cellular matrix protein (Kaneto et al., 2014) which was inactivated in most tissues, 
but found to be activated during osteoblast differentiation (Rossert et al., 1995, Stover et 
al.). Also, COL1A1 can be used as markers of increasing maturation within the 
osteoblast lineage (Kalajzic et al., 2005, Glass Ii et al., 2005). 
VIM (vimentin) is a member of the intermediate filament protein family and is 
considered to be a molecular marker of mesenchymal cells (Lian et al., 2012b). TGF-β 
increases VIM expression in osteoblast cells, which leads to suppression of ATF4-
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dependent Ocn transcription and inhibit the osteoblast differentiation (Lian et al., 
2012b). VIM also inhibits endogenous osteocalcin transcription and osteoblast 
differentiation, and inhibits the expression of osteoblast marker genes (Lian et al., 2009).  
Keratin (KRT8) is the largest family of intermediate filament in which play role 
in autoimmune diseases (Toivola et al., 2015) and rheumatoid arthritis (Wang et al., 
2015). It has been reported that suppression of KRT8 could cause osteopenia through the 
reduction of osteoblast differentiation in normal mice by inhibiting NF-κB and Wnt-β-
catenin signals in the bones (Le Henaff et al., 2016).  
Cathepsin Z (CTSZ) is a lysosomal cysteine proteinase and member of the 
peptidase C1 family (Santamaria et al., 1998). and present in the cells of immune 
system, predominantly monocytes, macrophages and dendritic cells (Kos et al., 2005). 
CTSZ enzyme was found also to be secreted from non-hematiopooitic bone marrow 
cells and found predominantly on the surface of primary human osteoblasts 
andsuppression of CTSX in osteoblasts resulted in an enhanced cellular adhesive 
interaction between hematopoietic stem and progenitor cells to osteoblasts (HSPCs) 
(Staudt et al., 2010). The expression of cathepsin B, L and Z were downregulated during 
differentiation of myeloid-derived suppressor cells (MDSCs) from macrophage to 
osteoclast in mice bearing highly metastatic tumours. This might inhibit 
osteoclastogenesis by decreasing the fusion of osteoclast precursors through cleavage of 
proteins needed for membrane fusion (Edgington-Mitchell et al., 2015).  
ANXA1 is a member of the annexin family that play as a mediator of 
glucocorticoid action in the inflammation and under control of hormone released from 
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anterior pituitary hormone release (John et al., 2004). Positive effects of 17β-estradiol on 
the expression of ANXA1 mRNA in which an ovariectomised rat produces a decreased 
level of ANXA1 (Davies et al., 2007). Overall, the result demonstrated that identified 
differentially expressed genes may be involved in bone remodelling once the level of -
estradiol is changed in the culture osteosarcoma cell line, Mg-63.
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Table 3-7: The biological role of the 55 identified differentially expressed genes  
Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
 DKK3 Dickkopf-WNT 
signalling 
pathway 
inhibitor 3 
9.91 11p15.3 This gene encodes a protein that is a member of 
the dickkopf family. The secreted protein 
contains two cysteine rich regions and is 
involved in embryonic development through its 
interactions with the Wnt signaling pathway. 
Wnt 
signalling 
pathway 
(GO:0016
055) 
calcium 
ion 
binding 
(GO:0005
509) 
extracellu
lar space 
(GO:0005
615) 
(Snellin
g et al., 
2016, 
Hoang 
et al., 
2004) 
 XAF1 X-linked 
inhibitor of 
apoptosis- 
associated 
factor 1 
9.87 17p13.1 This gene encodes a protein which binds to and 
counteracts the inhibitory effect of a member of 
the IAP (inhibitor of apoptosis) protein family 
affecting the progress of the apoptosis signalling 
pathway  
apoptotic 
process 
(GO:0006
915) 
zinc ion 
binding 
(GO:0008
270) 
nucleus 
(GO:0005
634) 
(Lin et 
al., 
2016) 
LSP1 lymphocyte-
specific protein 
1 
9.83 11p15.5 This gene encodes an intracellular F-actin 
binding protein. The protein is expressed in 
lymphocytes, neutrophils, macrophages, and 
endothelium and may regulate neutrophil 
motility, adhesion to fibrinogen matrix proteins, 
and transendothelial migration 
movemen
t of cell or 
subcellula
r 
componen
t 
(GO:0006
928) 
actin 
binding 
(GO:0003
779) 
plasma 
membran
e 
(GO:0005
886) 
(Hwang 
et al., 
2015) 
CREB5 cAMP 
responsive 
element binding 
protein 5 
9.82 7p15.1 The product of this gene belongs to the CRE 
(cAMP response element)-binding protein 
family. Members of this family contain zinc-
finger and bZIP DNA-binding domains. The 
encoded protein specifically binds to CRE as a 
homodimer or a heterodimer with c-Jun or CRE-
BP1, and functions as a CRE-dependent trans-
activator. 
regulation 
of 
transcripti
on, DNA-
templated 
(GO:0045
893) 
DNA 
binding 
(GO:0003
677 
nucleus 
(GO:0005
634) 
(Qi and 
Ding, 
2014) 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
MMP2 matrix 
metallopeptidas
e 2 
9.73 16q12.2 This gene is a member of the matrix 
metalloproteinase (MMP) gene family, that are 
zinc-dependent enzymes capable of cleaving 
components of the extracellular matrix and 
molecules involved in signal transduction. The 
protein encoded by this gene is a gelatinase A, 
type IV collagenase, that contains three 
fibronectin type II repeats in its catalytic site that 
allow binding of denatured type IV and V 
collagen and elastin This may be involved in 
multiple pathways including roles in the nervous 
system, endometrial menstrual breakdown, 
regulation of vascularization, and metastasis. 
bone 
trabecula 
formation 
(GO:0060
346) 
metalloen
dopeptida
se activity 
(GO:0004
222) 
extracellu
lar space 
(GO:0005
615) 
(Mosig 
and 
Martign
etti, 
2013, 
Mosig 
et al., 
2007) 
COL1A
2 
collagen type I 
alpha 2 chain 
9.70 7q21.3 This gene encodes the pro-alpha2 chain of type I 
collagen whose triple helix comprises two 
alpha1 chains and one alpha2 chain. 
skeletal 
system 
developm
ent(GO:0
001501) 
extracellu
lar matrix 
structural 
constituen
t(GO:000
5201) 
extracellu
lar space 
(GO:0005
615) 
(Jiang 
and 
Hao, 
2016, 
Styrkar
sdottir 
et al., 
2016) 
FSTL1 follistatin like 1 9.61 3q13.33 This gene encodes a protein with similarity to 
follistatin, an activin-binding protein. 
bone 
morphoge
netic 
protein 
signalling 
pathway 
(GO:0030
509) 
calcium 
ion 
binding 
(GO:0005
509) 
extracellu
lar space 
(GO:0005
615) 
(Ni et 
al., 
2015) 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
IFI44L interferon 
induced protein 
44 like 
9.61  1p31.1 Exhibits a low antiviral activity against hepatitis 
C virus. 
defense 
response 
to virus 
(GO:0051
607) 
GTP 
binding 
(GO:0005
525) 
cytoplasm 
(GO:0005
737) 
(Woeck
el et al., 
2012a) 
DCN decorin 9.60  12q21.33 This gene encodes a member of the small 
leucine-rich proteoglycan family of proteins. 
Alternative splicing results in multiple transcript 
variants, at least one of which encodes a 
preproprotein that is proteolytically processed to 
generate the mature protein. This protein plays a 
role in collagen fibril assembly. Binding of this 
protein to multiple cell surface receptors 
mediates its role in tumor suppression, including 
a stimulatory effect on autophagy and 
inflammation and an inhibitory effect on 
angiogenesis and tumorigenesis.  
skeletal 
muscle 
tissue 
developm
ent 
(GO:0007
519) 
collagen 
binding 
(GO:0005
518) 
extracellu
lar region 
(GO:0005
518) 
(Goetsc
h and 
Niesler, 
2016, 
Bi et 
al., 
2005) 
IFI16 Gamma-
interferon-
inducible 
protein 16 
9.41  1q23.1 This gene encodes a member of the HIN-200 
(hematopoietic interferon-inducible nuclear 
antigens with 200 amino acid repeats) family of 
cytokines. The encoded protein contains 
domains involved in DNA binding, 
transcriptional regulation, and protein-protein 
interactions. The protein localizes to the 
nucleoplasm and nucleoli, and interacts with p53 
and retinoblastoma-1.  
autophagy 
(GO:0006
914) 
RNA 
binding 
(GO:0003
723) 
membran
e 
(GO:0016
020) 
(Zhang 
et al., 
2007) 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
BLID BH3-like motif 
containing, cell 
death inducer 
9.35  11q24.1 This gene encodes a BH3-like motif containing 
protein involved in cell death. The encoded 
protein may induce apoptosis in a caspase-
dependent manner. 
apoptotic 
process 
(GO:0006
915) 
- cytoplasm 
(GO:0005
737) 
(Li et 
al., 
2014) 
CALD1 caldesmon 1 9.04 7q33 This gene encodes a calmodulin- and actin-
binding protein that plays an essential role in the 
regulation of smooth muscle and nonmuscle 
contraction. The conserved domain of this 
protein possesses the binding activities to 
Ca(2+)-calmodulin, actin, tropomyosin, myosin, 
and phospholipids. This protein is a potent 
inhibitor of the actin-tropomyosin activated 
myosin MgATPase, and serves as a mediating 
factor for Ca(2+)-dependent inhibition of smooth 
muscle contraction. 
muscle 
contractio
n 
(GO:0006
936) 
myosin 
binding 
(GO:0017
022) 
cytoskelet
on 
(GO:0005
856) 
(Mayan
agi and 
Sobue, 
2011, 
Zhang 
et al., 
2012, 
De 
Marchi 
et al., 
2016) 
COL3A
1 
collagen type 
III alpha 1 chain 
8.91 2q32.2 This gene encodes the pro-alpha1 chains of type 
III collagen, a fibrillar collagen that is found in 
extensible connective tissues such as skin, lung, 
uterus, intestine and the vascular system, 
frequently in association with type I collagen. 
Mutations in this gene are associated with 
Ehlers-Danlos syndrome types IV, and with 
aortic and arterial aneurysms. 
skeletal 
system 
developm
ent 
(GO:0001
501) 
extracellu
lar matrix 
structural 
constituen
t 
(GO:0005
201) 
extracellu
lar region 
(GO:0005
518) 
(Chou 
et al., 
2013) 
VIM vimentin 8.82  10p13 This gene encodes a type III intermediate 
filament protein. Intermediate filaments, along 
with microtubules and actin microfilaments, 
make up the cytoskeleton. The encoded protein 
is responsible for maintaining cell shape and 
movemen
t of cell or 
subcellula
r 
componen
structural 
constituen
t of 
cytoskelet
on) 
cytoplasm 
(GO:0005
737) 
(Lian et 
al., 
2009, 
Lian et 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
integrity of the cytoplasm, and stabilizing 
cytoskeletal interactions. This protein is involved 
in neuritogenesis and cholesterol transport and 
functions as an organizer of a number of other 
critical proteins involved in cell attachment, 
migration, and signaling. 
t 
(GO:0006
928) 
al., 
2012b) 
MX1 MX dynamin 
like GTPase 1 
8.64 21q22.3 This gene encodes a guanosine triphosphate 
(GTP)-metabolizing protein that participates in 
the cellular antiviral response. The encoded 
protein is induced by type I and type II 
interferons and antagonizes the replication 
process of several different RNA and DNA 
viruses. 
apoptotic 
process 
(GO:0006
915) 
identical 
protein 
binding 
(GO:0042
802) 
cytoplasm 
(GO:0005
737) 
(Park et 
al., 
2012) 
IFI27 interferon alpha 
inducible 
protein 27 
8.53 14q32.12 Promotes cell death. Mediates IFN-induced 
apoptosis characterized by a rapid and robust 
release of cytochrome C from the mitochondria 
and activation of BAX and caspases 2, 3, 6, 8 
and 9. 
apoptotic 
signalling 
pathway 
(GO:0097
190 
RNA 
polymeras
e II 
activating 
transcripti
on factor 
binding 
(GO:0001
102) 
nucleus 
(GO:0005
634) 
(Gytz 
et al., 
2017) 
GSDM
D 
gasdermin D 8.28  8q24.3  Gasdermin D is a member of the gasdermin 
family. Members of this family appear to play a 
role in regulation of epithelial proliferation. 
Gasdermin D has been suggested to act as a 
tumor suppressor. 
pyroptosis 
(GO:0070
269) 
phosphati
dic acid 
binding 
(GO:0070
300) 
plasma 
membran
e 
(GO:0005
886) 
(Sborgi 
et al., 
2016) 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
OAS2 2'-5'-
oligoadenylate 
synthetase 2 
8.17 12q24.13 This gene encodes a member of the 2-5A 
synthetase family, essential proteins involved in 
the innate immune response to viral infection. 
The encoded protein is induced by interferons 
and uses adenosine triphosphate in 2'-specific 
nucleotidyl transfer reactions to synthesize 2',5'-
oligoadenylates (2-5As). These molecules 
activate latent RNase L, which results in viral 
RNA degradation and the inhibition of viral 
replication.  
type I 
interferon 
signaling 
pathway 
(GO:0060
337) 
metal ion 
binding 
(GO:0046
872) 
cytoplasm 
(GO:0005
737) 
(Woeck
el et al., 
2012b) 
S100A4 S100 calcium 
binding protein 
A4 
8.08  1q21.3 The protein encoded by this gene is a member of 
the S100 family of proteins containing 2 EF-
hand calcium-binding motifs. S100 proteins are 
localized in the cytoplasm and/or nucleus of a 
wide range of cells, and involved in the 
regulation of a number of cellular processes such 
as cell cycle progression and differentiation. 
S100 genes include at least 13 members which 
are located as a cluster on chromosome 1q21. 
This protein may function in motility, invasion, 
and tubulin polymerization. 
positive 
regulation 
of I-
kappaB 
kinase/NF
-kappaB 
signalling 
(GO:0043
123) 
calcium 
ion 
binding 
(GO:0005
509) 
extracellu
lar space 
(GO:0005
615) 
(Erland
sson et 
al., 
2013) 
ALDH3
A1 
aldehyde 
dehydrogenase 
3 family 
member A1 
7.62  17p11.2 Aldehyde dehydrogenases oxidize various 
aldehydes to the corresponding acids. They are 
involved in the detoxification of alcohol-derived 
acetaldehyde and in the metabolism of 
corticosteroids, biogenic amines, 
neurotransmitters, and lipid peroxidation. The 
enzyme encoded by this gene forms a 
cytoplasmic homodimer that preferentially 
response 
to 
hypoxia 
(GO:0001
666) 
3-
chloroally
l aldehyde 
dehydrog
enase 
activity 
(GO:0004
028 
extracellu
lar space 
(GO:0005
615) 
(Wu et 
al., 
2016, 
Yan et 
al., 
2014, 
Gaspar
etto et 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
oxidizes aromatic and medium-chain (6 carbons 
or more) saturated and unsaturated aldehyde 
substrates. It is thought to promote resistance to 
UV and 4-hydroxy-2-nonenal-induced oxidative 
damage in the cornea.  
al., 
2012) 
FBN1 fibrillin 1 7.27  15q21.1 This gene encodes a member of the fibrillin 
family of proteins. The encoded preproprotein is 
proteolytically processed to generate two 
proteins including the extracellular matrix 
component fibrillin-1 and the protein hormone 
asprosin. Fibrillin-1 is an extracellular matrix 
glycoprotein that serves as a structural 
component of calcium-binding microfibrils. 
cellular 
response 
to insulin-
like 
growth 
factor 
stimulus 
(GO:1990
314) 
calcium 
ion 
binding 
(GO:0005
509) 
extracellu
lar region 
(GO:0005
518) 
(Smald
one et 
al., 
2016) 
PARP10 poly(ADP-
ribose) 
polymerase 
family member 
10 
6.61  8q24.3 Poly(ADP-ribose) polymerases (PARPs), such 
as PARP10, regulate gene transcription by 
altering chromatin organization by adding ADP-
ribose to histones. PARPs can also function as 
transcriptional cofactors 
negative 
regulation 
of NF-
kappaB 
transcripti
on factor 
activity 
(GO:0032
088) 
NAD+ 
ADP-
ribosyltra
nsferase 
activity 
(GO:0003
950) 
nucleus 
(GO:0005
634) 
(Kaufm
ann et 
al., 
2015, 
Verheu
gd et 
al., 
2013) 
TMBIM
1 
transmembrane 
BAX inhibitor 
motif 
containing 1 
6.60  2q35 Negatively regulates aortic matrix 
metalloproteinase-9 (MMP9) production and 
may play a protective role in vascular 
remodeling. 
negative 
regulation 
of 
catalytic 
activity 
death 
receptor 
binding 
(GO:0005
123) 
lysosomal 
membran
e 
(GO:0005
765) 
(Shukla 
et al., 
2011) 
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Gene 
Symbol 
Gene Name Fold 
Chan
ge 
Chromoso
me 
Location 
Description Biologica
l Process 
Molecula
r 
Function 
Cellular 
Compone
nt 
Refere
nce 
(GO:0043
086) 
TGFΒI transforming 
growth factor 
beta induced 
6.52 5q31.1 This gene encodes an RGD-containing protein 
that binds to type I, II and IV collagens. The 
RGD motif is found in many extracellular matrix 
proteins modulating cell adhesion and serves as 
a ligand recognition sequence for several 
integrins. This protein plays a role in cell-
collagen interactions and may be involved in 
endochondrial bone formation in cartilage. The 
protein is induced by transforming growth 
factor-beta and acts to inhibit cell adhesion. 
cell 
adhesion 
(GO:0007
155) 
collagen 
binding 
(GO:0005
518) 
plasma 
membran
e 
(GO:0005
886) 
(Bonew
ald and 
Mundy, 
1990, 
Lee et 
al., 
2015) 
IFI6 interferon alpha 
inducible 
protein 6 
6.50  1p35.3 This gene was first identified as one of the many 
genes induced by interferon. The encoded 
protein may play a critical role in the regulation 
of apoptosis. A minisatellite that consists of 26 
repeats of a 12 nucleotide repeating element 
resembling the mammalian splice donor 
consensus sequence begins near the end of the 
second exon. 
type I 
interferon 
signaling 
pathway 
(GO:0060
337) 
protein 
binding 
(GO:0008
234) 
plasma 
membran
e 
(GO:0005
886) 
(Song 
et al., 
2015) 
CTSZ Cathepsin Z 6.48  20q13.32  The protein encoded by this gene is a lysosomal 
cysteine proteinase and member of the peptidase 
C1 family. It exhibits both carboxy-
monopeptidase and carboxy-dipeptidase 
activities. The encoded protein has also been 
known as cathepsin X and cathepsin P. This 
gene is expressed ubiquitously in cancer cell 
lines and primary tumors and, like other 
proteolysi
s 
(GO:0006
508) 
protein 
binding 
(GO:0008
234) 
lysosome 
(GO:0005
764) 
(Liu et 
al., 
2014a) 
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Cellular 
Compone
nt 
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nce 
members of this family, may be involved in 
tumorigenesis. 
ANXA1 annexin A1 6.46  9q21.13 This gene encodes a membrane-localized protein 
that binds phospholipids. This protein inhibits 
phospholipase A2 and has anti-inflammatory 
activity. Loss of function or expression of this 
gene has been detected in multiple tumors. 
response 
to 
estradiol 
(GO:0032
355) 
phospholi
pid 
binding 
(GO:0005
543) 
nucleus 
(GO:0005
634) 
(Ang et 
al., 
2009) 
COL1A
1 
collagen type I 
alpha 1 chain 
5.98  17q21.33 This gene encodes the pro-alpha1 chains of type 
I collagen whose triple helix comprises two 
alpha1 chains and one alpha2 chain. Type I is a 
fibril-forming collagen found in most connective 
tissues and is abundant in bone, cornea, dermis 
and tendon. Mutations in this gene are associated 
with osteogenesis imperfecta types I-IV, Ehlers-
Danlos syndrome type VIIA, Ehlers-Danlos 
syndrome Classical type, Caffey Disease and 
idiopathic osteoporosis.  
osteoblast 
differentia
tion 
(GO:0001
649) 
metal ion 
binding 
(GO:0050
900) 
extracellu
lar space 
(GO:0005
615) 
(Rosser
t et al., 
1995) 
TRAM2 ranslocation 
associated 
membrane 
protein 2 
5.87  6p12.2 TRAM2 is a component of the translocon, a 
gated macromolecular channel that controls the 
posttranslational processing of nascent secretory 
and membrane proteins at the endoplasmic 
reticulum (ER) membrane. 
collagen 
biosynthet
ic process 
(GO:0032
964) 
- integral 
componen
t of 
membran
e 
(GO:0016
021) 
(Liu et 
al., 
2014a) 
SPOCK
1 
SPARC/osteone
ctin, cwcv and 
kazal like 
5.85  5q31.2 This gene encodes the protein core of a seminal 
plasma proteoglycan containing chondroitin- and 
heparan-sulfate chains. The protein's function is 
unknown, although similarity to thyropin-type 
regulation 
of cell 
growth(G
calcium 
ion 
binding 
cytoplasm 
(GO:0005
737) 
(Chen 
et al., 
2016) 
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domains 
proteoglycan 1 
cysteine protease-inhibitors suggests its function 
may be related to protease inhibition.  
O:000155
8) 
(GO:0005
509) 
FKBP10 FK506 binding 
protein 10 
5.70  17q21.2 The protein encoded by this gene belongs to the 
FKBP-type peptidyl-prolyl cis/trans isomerase 
(PPIase) family. This protein localizes to the 
endoplasmic reticulum and acts as a molecular 
chaperone. Alternatively, spliced variants 
encoding different isoforms have been reported, 
but their biological validity has not been 
determined 
chaperone
-mediated 
protein 
folding(G
O:006107
7) 
calcium 
ion 
binding(G
O:000550
9) 
cytoplasm 
(GO:0005
737) 
(Xu et 
al., 
2017) 
EMP1 epithelial 
membrane 
protein 1 
5.12  12p13.1 SOS1 and Ras regulate epithelial tight junction 
formation in the human airway through EMP1 
cell death 
(GO:0008
219 
protein 
binding 
(GO:0008
234) 
plasma 
membran
e 
(GO:0005
886) 
(Sun et 
al., 
2014) 
(Sun et 
al., 
2014) 
S100A2 S100 calcium 
binding protein 
A2 
3.88  1q21.3 The protein encoded by this gene is a member of 
the S100 family of proteins containing 2 EF-
hand calcium-binding motifs. S100 proteins are 
localized in the cytoplasm and/or nucleus of a 
wide range of cells, and involved in the 
regulation of a number of cellular processes such 
as cell cycle progression and differentiation.  
endothelia
l cell 
migration 
(GO:0043
542) 
calcium 
ion 
binding(G
O:000550
9) 
cellular 
componen
t 
(GO:0005
575)  
(Balmai
n et al., 
2003) 
EPB41L
2 
erythrocyte 
membrane 
protein band 4.1 
like 2 
3.78  6q23.1-
q23.2 
Required for dynein-dynactin complex and 
NUMA1 recruitment at the mitotic cell cortex 
during anaphase 
cell 
cycle(GO:
0007049) 
actin 
binding(G
O:000377
9) 
cytoplasm 
(GO:0005
737) 
(Lu et 
al., 
2004) 
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LTBP4 latent 
transforming 
growth factor 
beta binding 
protein 4 
3.66  19q13.2 The protein encoded by this gene binds 
transforming growth factor beta (TGFB) as it is 
secreted and targeted to the extracellular matrix. 
TGFB is biologically latent after secretion and 
insertion into the extracellular matrix, and sheds 
TGFB and other proteins upon activation. 
Defects in this gene may be a cause of cutis laxa 
and severe pulmonary, gastrointestinal, and 
urinary abnormalities 
growth 
hormone 
secretion 
(GO:0030
252) 
transformi
ng growth 
factor 
beta 
binding 
(GO:0050
431) 
extracellu
lar 
exosome 
(GO:0070
062) 
(Lu et 
al., 
2017) 
SLC16A
3 
solute carrier 
family 16 
(monocarboxyli
c acid 
transporters), 
member 3 
3.45 17q25.3 Lactic acid and pyruvate transport across plasma 
membranes is catalyzed by members of the 
proton-linked monocarboxylate transporter 
(MCT) family, which has been designated solute 
carrier family-16. Each MCT appears to have 
slightly different substrate and inhibitor 
specificities and transport kinetics, which are 
related to the metabolic requirements of the 
tissues in which it is found. 
monocarb
oxylic 
acid 
transport 
(GO:0015
718) 
monocarb
oxylic 
acid 
transmem
brane 
transporte
r activity 
(GO:0008
028) 
membran
e 
(GO:0016
020) 
(Tan et 
al., 
2015) 
RUNX2 Runt related 
transcription 
factor 2 
-2 6p21. This gene is a member of the RUNX family of 
transcription factors and encodes a nuclear 
protein with a Runt DNA-binding domain. This 
protein is essential for osteoblastic 
differentiation and skeletal morphogenesis and 
acts as a scaffold for nucleic acids and regulatory 
factors involved in skeletal gene expression. The 
protein can bind DNA both as a monomer or, 
with more affinity, as a subunit of a 
heterodimeric complex.  
protein 
binding 
(GO:0005
515) 
osteoblast 
differentia
tion 
(GO:0001
649) 
cytoplasm 
(GO:0005
737) 
(Komor
i, 2010) 
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XBP1 X-box binding 
protein 1 
-3.64 22q12.1; 
22q12 
This gene encodes a transcription factor that 
regulates MHC class II genes by binding to a 
promoter element referred to as an X box. This 
gene product is a bZIP protein, which was also 
identified as a cellular transcription factor that 
binds to an enhancer in the promoter of the T 
cell leukemia virus type 1 promoter. It may 
increase expression of viral proteins by acting as 
the DNA binding partner of a viral 
transactivator. It has been found that upon 
accumulation of unfolded proteins in the 
endoplasmic reticulum (ER), the mRNA of this 
gene is processed to an active form by an 
unconventional splicing mechanism that is 
mediated by the endonuclease inositol-requiring 
enzyme 1 (IRE1). The resulting loss of 26 nt 
from the spliced mRNA causes a frame-shift and 
an isoform XBP1(S), which is the functionally 
active transcription factor. 
protein 
binding 
(GO:0005
515) 
endoplas
mic 
reticulum 
unfolded 
protein 
response 
(GO:0030
968) 
cytoplasm 
(GO:0005
737) 
(Tohmo
nda et 
al., 
2011) 
NFKBI
A 
NFKB inhibitor 
alpha 
-3.87  14q13.2  This gene encodes a member of the NF-kappa-B 
inhibitor family, which contain multiple ankrin 
repeat domains. The encoded protein interacts 
with REL dimers to inhibit NF-kappa-B/REL 
complexes which are involved in inflammatory 
responses. The encoded protein moves between 
the cytoplasm and the nucleus via a nuclear 
localization signal and CRM1-mediated nuclear 
export. 
NF-
kappaB 
binding 
(GO:0051
059) 
negative 
regulation 
of NF-
kappaB 
transcripti
on factor 
activity 
(GO:0032
088)  
cytoplasm 
(GO:0005
737) 
(Novac
k, 
2011) 
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TRIM3
7 
tripartite motif 
containing 37 
-4.33 17q22 This gene encodes a member of the tripartite 
motif (TRIM) family, whose members are 
involved in diverse cellular functions such as 
developmental patterning and oncogenesis. The 
TRIM motif includes zinc-binding domains, a 
RING finger region, a B-box motif and a coiled-
coil domain. The RING finger and B-box 
domains chelate zinc and might be involved in 
protein-protein and/or protein-nucleic acid 
interactions.  
negative 
regulation 
of NF-
kappaB 
transcripti
on factor 
activity 
(GO:0032
088) 
tumor 
necrosis 
factor 
receptor 
binding 
(GO:0005
164) 
cytoplasm 
(GO:0005
737) 
(Hu 
and 
Gan, 
2017) 
TMEM
64 
Transmembrane 
protein 64 
-4.79 TMEM64 Positively regulates TNFSF11-induced 
osteoclast differentiation. Acts as a regulator of 
TNFSF11-mediated Ca2+ signaling pathways 
via its interaction with SERCA2 which is critical 
for the TNFSF11-induced CREB1 activation and 
mitochondrial ROS generation necessary for 
proper osteoclast generation.  
positive 
regulation 
of 
osteoclast 
differentia
tion 
(GO:0045
672) 
cytosolic 
calcium 
ion 
homeosta
sis 
endoplas
mic 
reticulum 
(GO:0005
783) 
(Kim et 
al., 
2013) 
TPD52L
1 
tumor protein 
D52 like 1 
-5.07 6q22.31 This gene encodes a member of a family of 
proteins that contain coiled-coil domains and 
may form hetero- or homomers. The encoded 
protein is involved in cell proliferation and 
calcium signaling. It also interacts with the 
mitogen-activated protein kinase kinase kinase 5 
(MAP3K5/ASK1) and positively regulates 
MAP3K5-induced apoptosis. Multiple 
alternatively spliced transcript variants have 
been observed.  
positive 
regulation 
of 
apoptotic 
signalling 
pathway 
(GO:2001
235) 
protein 
binding 
(GO:0008
234) 
cytoplasm 
(GO:0005
737) 
(Sathasi
vam et 
al., 
2001) 
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GFRA1 GDNF family 
receptor alpha 1 
-6.07 10q25.3 This gene encodes a member of the glial cell 
line-derived neurotrophic factor receptor 
(GDNFR) family of proteins. The encoded 
preproprotein is proteolytically processed to 
generate the mature receptor. Glial cell line-
derived neurotrophic factor (GDNF) and 
neurturin (NTN) are two structurally related, 
potent neurotrophic factors that play key roles in 
the control of neuron survival and 
differentiation. This receptor is a 
glycosylphosphatidylinositol (GPI)-linked cell 
surface receptor for both GDNF and NTN, and 
mediates activation of the RET tyrosine kinase 
receptor. 
MAPK 
cascade 
(GO:0000
165 
receptor 
binding 
(GO:0005
102) 
plasma 
membran
e 
(GO:0005
886) 
(Konish
i et al., 
2014) 
TFAP2
C 
transcription 
factor AP-2 
gamma 
-6.08 20q13.31 The protein encoded by this gene is a sequence-
specific DNA-binding transcription factor 
involved in the activation of several 
developmental genes. The encoded protein can 
act as either a homodimer or heterodimer with 
other family members and is induced during 
retinoic acid-mediated differentiation. It plays a 
role in the development of the eyes, face, body 
wall, limbs, and neural tube. 
male 
gonad 
developm
ent 
(GO:0008
584) 
DNA 
binding 
(GO:0003
677 
nucleus 
(GO:0005
634) 
(Orso 
et al., 
2004) 
(Cyr et 
al., 
2015) 
KRT8 keratin 8 -6.21 12q13.13 This gene is a member of the type II keratin 
family clustered on the long arm of chromosome 
12. Type I and type II keratins heteropolymerize 
to form intermediate-sized filaments in the 
cytoplasm of epithelial cells. The product of this 
gene typically dimerizes with keratin 18 to form 
- structural 
molecule 
activity 
(GO:0005
198) 
intermedi
ate 
filament 
(GO:0005
882) 
(Wang 
et al., 
2015, 
Le 
Henaff 
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an intermediate filament in simple single-layered 
epithelial cells. This protein plays a role in 
maintaining cellular structural integrity and also 
functions in signal transduction and cellular 
differentiation.  
et al., 
2016) 
NPY1R Neuropeptide Y 
receptor type 1 
-6.39 4q32.2 This gene belongs to the G-protein-coupled 
receptor superfamily. The encoded 
transmembrane protein mediates the function of 
neuropeptide Y (NPY), a neurotransmitter, and 
peptide YY (PYY), a gastrointestinal hormone. 
The encoded receptor undergoes fast agonist-
induced internalization through clathrin-coated 
pits and is subsequently recycled back to the cell 
membrane.  
glucose 
metabolic 
process 
(GO:0006
006) 
pancreatic 
polypepti
de 
receptor 
activity 
(GO:0001
602) 
plasma 
membran
e 
(GO:0005
886) 
(Liu et 
al., 
2015) 
MAL2 mal, T-cell 
differentiation 
protein 2 
-6.63 8q24.12 This gene encodes a multispan transmembrane 
protein belonging to the MAL proteolipid 
family. The protein is a component of lipid rafts 
and, in polarized cells, it primarily localizes to 
endosomal structures beneath the apical 
membrane. It is required for transcytosis, an 
intracellular transport pathway used to deliver 
membrane-bound proteins and exogenous cargos 
from the basolateral to the apical surface. 
myelinati
on 
(GO:0042
552) 
structural 
constituen
t of 
myelin 
sheath 
(GO:0019
911) 
extracellu
lar 
exosome 
(GO:0070
062) 
(Maraz
uela et 
al., 
2004, 
Marazu
ela and 
Alonso, 
2004) 
GREB1 growth 
regulation by 
estrogen in 
breast cancer 1 
-6.72  2p25.1 This gene is an estrogen-responsive gene that is 
an early response gene in the estrogen receptor-
regulated pathway. It is thought to play an 
important role in hormone-responsive tissues 
and cancer. 
- - extracellu
lar 
exosome 
(GO:0070
062) 
(Laviol
ette et 
al., 
2014, 
Hodgki
nson 
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and 
Vander
hyden, 
2014) 
CELSR
2 
cadherin EGF 
LAG seven-
pass G-type 
receptor 2 
-7.11 1p13.3 The protein encoded by this gene is a member of 
the flamingo subfamily, part of the cadherin 
superfamily. The flamingo subfamily consists of 
nonclassic-type cadherins; a subpopulation that 
does not interact with catenins. The flamingo 
cadherins are located at the plasma membrane 
and have nine cadherin domains, seven 
epidermal growth factor-like repeats and two 
laminin A G-type repeats in their ectodomain. 
They also have seven transmembrane domains, a 
characteristic unique to this subfamily. 
Wnt 
signalling 
pathway 
(GO:0016
055) 
calcium 
ion 
binding 
(GO:0005
509) 
plasma 
membran
e 
(GO:0005
886) 
(Hu et 
al., 
2011) 
KRT19 keratin 19 -7.32  17q21.2 The protein encoded by this gene is a member of 
the keratin family. The keratins are intermediate 
filament proteins responsible for the structural 
integrity of epithelial cells and are subdivided 
into cytokeratins and hair keratins. The type I 
cytokeratins consist of acidic proteins which are 
arranged in pairs of heterotypic keratin chains. 
Unlike its related family members, this smallest 
known acidic cytokeratin is not paired with a 
basic cytokeratin in epithelial cells.  
response 
to 
estrogen 
(GO:0043
627) 
structural 
constituen
t of 
cytoskelet
on 
plasma 
membran
e 
(GO:0005
886) 
(Yao et 
al., 
2016) 
ESRP2 epithelial 
splicing 
regulatory 
protein 2 
-8.42 16q22.1 mRNA splicing factor that regulates the 
formation of epithelial cell-specific isoforms. 
Specifically regulates the expression of FGFR2-
IIIb, an epithelial cell-specific isoform of 
regulation 
of RNA 
splicing 
RNA 
binding 
(GO:0003
723) 
nucleus 
(GO:0005
634) 
(Ishii et 
al., 
2014, 
Mizuta
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FGFR2. Also, regulates the splicing of CD44, 
CTNND1, ENAH, 3 transcripts that undergo 
changes in splicing during the epithelial-to-
mesenchymal transition (EMT). 
(GO:0043
484) 
ni et al., 
2016) 
ESR1 estrogen 
receptor 1 
-8.46 6q25.1-
q25.2 
This gene encodes an estrogen receptor, a 
ligand-activated transcription factor composed of 
several domains important for hormone binding, 
DNA binding, and activation of 
transcription.  Estrogen and its receptors are 
essential for sexual development and 
reproductive function, but also play a role in 
other tissues such as bone. Estrogen receptors 
are also involved in pathological processes 
including breast cancer, endometrial cancer, and 
osteoporosis. 
cellular 
response 
to 
estradiol 
stimulus 
(GO:0071
392) 
estrogen 
receptor 
activity 
(GO:0030
284) 
nucleus 
(GO:0005
634) 
(Khalid 
and 
Krum, 
2016) 
LLGL2 LLGL2, 
scribble cell 
polarity 
complex 
component 
-8.47 17q25.1 The lethal (2) giant larvae protein of Drosophila 
plays a role in asymmetric cell division, 
epithelial cell polarity, and cell migration. This 
human gene encodes a protein similar to lethal 
(2) giant larvae of Drosophila. In fly, the 
protein's ability to localize cell fate determinants 
is regulated by the atypical protein kinase C 
(aPKC). In human, this protein interacts with 
aPKC-containing complexes and is cortically 
localized in mitotic cells.  
cell cycle 
(GO:0007
049) 
GTPase 
activator 
activity 
(GO:0005
096) 
cytoplasm 
(GO:0005
737) 
(Sripath
y et al., 
2011) 
MLPH melanophilin -8.69  2q37.3 This gene encodes a member of the exophilin 
subfamily of Rab effector proteins. The protein 
forms a ternary complex with the small Ras-
related GTPase Rab27A in its GTP-bound form 
intracellul
ar protein 
transport 
metal ion 
binding 
(GO:0046
872) 
extracellu
lar 
exosome 
(Westbr
oek et 
al., 
2012) 
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and the motor protein myosin Va. A similar 
protein complex in mouse functions to tether 
pigment-producing organelles called 
melanosomes to the actin cytoskeleton in 
melanocytes, and is required for visible 
pigmentation in the hair and skin. 
(GO:0006
886) 
(GO:0070
062) 
FXYD3 FXYD domain 
containing ion 
transport 
regulator 3 
-9.08 19q13.12 This gene belongs to a small family of FXYD-
domain containing regulators of Na+/K+ 
ATPases which share a 35-amino acid signature 
sequence domain, beginning with the sequence 
PFXYD, and containing 7 invariant and 6 highly 
conserved amino acids. This gene encodes a cell 
membrane protein that may regulate the function 
of ion-pumps and ion-channels. This gene may 
also play a role in tumor progression. 
ion 
transmem
brane 
transport 
(GO:0034
220) 
sodium 
channel 
regulator 
activity 
(GO:0017
080) 
extracellu
lar 
exosome 
(GO:0070
062) 
(Zhu et 
al., 
2010) 
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3.2.4.3.5 Function Enrichment Analysis of the 262 Differentially-Expressed Genes 
in Mg-63 Cells 
Enrichr, a web-accessible programme, was used for Gene Ontology (GO) 
enrichment analysis (Chen et al., 2013, Kuleshov et al., 2016). For such analysis, a p 
value < 0.05 was set as the cut-off for selecting significantly-enriched functional GO 
terms. The results showed that the 262 estrogen responsive, differentially- expressed 
genes identified in Mg-63 were enriched in 128 GO biological process (Lewis et al.) 
terms. 14 out of the 128 GO BP terms enriched are presented in Table 3-8 while the 
reference of each term is summarized in Table 8-4 in the Appendix. Most of the 14 
terms were related to either hormone response or skeletal development including, 
regulation of hormone levels (GO:0010817), hormone metabolic process (GO:0042445), 
muscle system process (GO:0003012), cellular hormone metabolic process 
(GO:0034754), muscle contraction (GO:0006936), response to estrogen (GO:0043627), 
response to estradiol (GO:0032355), regulation of transforming growth factor beta 
receptor signalling pathway (GO:0017015), skeletal system morphogenesis 
(GO:0048705), embryonic skeletal system morphogenesis (GO:0048704), collagen fibril 
organization (GO:0030199), regulation of hormone biosynthetic process (GO:0046885), 
bone trabecula formation (GO:0060346) and negative regulation of hormone 
biosynthetic process (GO:0032353). These gene ontologies showed hormone and 
estrogen related genes with ALDH1A2, ANXA1, COL1A1, ESR1, KRT19, NPY1R, 
PDGFRA, IFI27, and IGF2 under response of estrogen and estradiol. 
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Table 3-8: Functions Enrichment Analysis Result of Mg-63 sequences  
Term P-value 
No. of 
genes 
Members of the panel of 262 
estrogen dependent genes 
Regulation of hormone levels 
(GO:0010817) 
4.67E-05 12 PDGFRA,ANXA1,UGT1A1,ALDH1A2,
CTSZ,LTBP4,CACNA1A,UGT1A3,U
GT1A9,ESR1,UGT1A8,UGT1A7 
Hormone metabolic process 
(GO:0042445) 
4.16E-05 10 PDGFRA,UGT1A1,ALDH1A2,CTSZ,C
ACNA1A,UGT1A3,UGT1A9,ESR1,UG
T1A8,UGT1A7 
Muscle system process 
(GO:0003012) 
0.001089 10 GSTM2,MEF2C,VIPR1,DTNA,CCDC7
8,CALD1,PDE4D,TPM2,KCNMA1,MY
OM2 
Cellular hormone metabolic 
process (GO:0034754) 
3.27E-05 8 PDGFRA,UGT1A1,ALDH1A2,UGT1A
3,UGT1A9,UGT1A8,ESR1,UGT1A7 
Muscle contraction 
(GO:0006936) 
0.003993 8 VIPR1,DTNA,CCDC78,CALD1,PDE4
D,TPM2,KCNMA1,MYOM2 
Response to estrogen 
(GO:0043627) 
0.0199 7 ALDH1A2,ANXA1,COL1A1,ESR1,K
RT19,NPY1R,PDGFRA 
Response to estradiol 
(GO:0032355) 
0.001923 6 COL1A1,ANXA1,IFI27,ALDH1A2,IG
F2,ESR1 
Regulation of transforming 
growth factor beta receptor 
signaling pathway 
(GO:0017015) 
0.002233 6 DAB2,ZEB1,TGFΒI,LTBP4,LDLRAD
4,FBN1 
Skeletal system morphogenesis 
(GO:0048705) 
0.002581 6 PDGFRA,ZEB1,HOXB4,HOXB3,HOX
B6,FGFR1 
Embryonic skeletal system 
morphogenesis (GO:0048704) 
0.004034 5 PDGFRA,ZEB1,HOXB4,HOXB3,HOX
B6 
Collagen fibril organization 
(GO:0030199) 
0.00191 4 COL1A1,COL3A1,COL1A2,COL14A
1 
regulation of hormone 
biosynthetic process 
(GO:0046885) 
0.002755 3 IGF2,CACNA1A,DKK3 
Bone trabecula formation 
(GO:0060346) 
0.004443 2 COL1A1, MMP2 
negative regulation of hormone 
biosynthetic process 
(GO:0032353) 
0.004443 2 CACNA1A,DKK3 
Enriched functions of up and down regulated genes are listed and separated 
into GO terms of biological process category.Bold genes are that among the 
list of 55 Mg-63 genes. 
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3.3 Discussion 
The aim of this chapter was to identify differentially-expressed estradiol- 
responsive genes in cultured osteosarcoma cell lines (Mg-63, TE-85 and Saos-2) by 
RNA Sequencing. This was done in order to identify differential gene changes relevant 
to the development of osteoporosis in postmenopausal women who are more susceptible 
to this disease when estrogen is reduced.  
The results showed that both ER α and ER β mRNA were detected in all three 
osteosarcoma cells, with protein only detected in Mg-63 cells. The results of the present 
experiments are similar to that the previously reported (Lambertini et al., 2003, Solakidi 
et al., 2005, Kurosawa et al., 2002). However, ER α mRNA and protein showed much 
higher level in MCF-7 than that in any of the osteosarcoma cells, which is not 
unexpected, due to very high levels of ER α in the MCF-7 cells (Lewandowski et al., 
2005, Grober et al., 2011, Jonsson et al., 2014). The results also demonstrated that upon 
treatment with β-estradiol, the proliferation rates of the cultured cells were increased in 
Mg-63, TE-85, Saos-2 and MCF-7 compared to the untreated cells. This result is similar 
to other previous reports suggesting that estradiol can stimulate the growth of 
osteosarcoma cells (Lajeunesse, 1994), and TE-85 cells (Ikegami et al., 1994). 
Importantly, the proliferative capabilities of Mg-63 cells has been shown to be positively 
influenced by circulating β-estradiol levels in a dose-dependent fashion (Dohi et al., 
2008). Collectively, it is known that estrogen has a bone-protective effect, mediated via 
the estrogen receptors α and/or β (Khalid and Krum, 2016). Since ER α proteins were 
present in the Mg-63 cells, with a very low amount in TE-85 and Saos-2 cells, this 
suggests that the reason for small number of differentially expressed genes in TE-85 and 
Saos-2 treated cells was due to the low level of ER α proteins in both cell lines. It has 
  Chapter 3 
 
120 | P a g e  
 
been reported that β-estradiol increased osteoblast proliferation through negative 
regulation of Sclerostin (SOST) expression in an indirect manner through interaction 
with BMP2 signalling and that this regulation involves the Wnt/ERα and β-catenin 
pathways (Kim et al., 2015b, Galea et al., 2013a). Thus, because of detecting ER β 
mRNA and protein in all three osteosarcoma cells, these results suggest that ER β might 
be responsible in the proliferation process of osteoblast cells rather than gene expression 
which is mediated by ERα, since also RNA-Seq data, in this study, did not showed that 
ER β was changed in treated osteosarcoma and MCF-7 cells with estradiol compared to 
the non-treated control.  
The alignment of RNA-seq reads to the human reference genome showed that 
88.19 % of the total reads were identical to the human reference genome, a value which 
falls within the accepted range for differential gene expression analysis (Trapnell et al., 
2012, Conesa et al., 2016). Remarkably, overall expression of 262 genes in the Mg-63 
cells and 279 genes in the MCF-7 cell line were altered. This may correspond broadly 
with the ER α receptor status rather than the ER β status of both cells, due to the low 
level of ER β in the MCF-7 cells. Out of 262 genes altered in the Mg-63 cells, 181 genes 
were also significantly alerted in the estrogen-treated MCF-7 cells. These common 
genes were related to regulation of estrogen levels and hormone metabolic process. 
Therefore, it is suggested that these 181 genes were responsive to β-estradiol and the 
remaining 81 genes might be osteosarcoma-specific estradiol responsive mRNAs in 
which both could be involved in the bone turnover pathway.  
In the present experiments, IFI16, Interferon Gamma Inducible Protein 16, showed 
among the highest upregulation, with a change 9.4-fold upon estrogen treatment. IFI16 
has an important role in autoimmune disease, in which a high level of IFI16 is 
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responsible for inducing proinflammatory molecules that lead to apoptosis in endothelial 
cells (Caposio et al., 2007, Gugliesi et al., 2010).Also, transfection of IFI16 into Saos-2 
cells inhibited significantly cell growth and the authors suggested that a certain level of 
IFI16 is important for organizing the proliferation of bone and cartilage tumor cells and 
may be used as an antitumor agent (Zhang et al., 2007). The expression of MMP2 was 
also increasd in estrogen-treated Mg-63 cells compared to non-treated control cells by 
9.7-fold, as it plays a role in the breakdown of extracellular matrix (ECM) which is 
important for embryonic development, morphogenesis, and tissue remodeling (Tallant et 
al., 2010, Nagase and Woessner, 1999). Also it is involved in the degradiation of ECM 
during embryonic bone formation (Sasano et al., 2002, Johansson et al., 1997, Mosig et 
al., 2007), in which silencing of MMP2 led to an increase in  the osteopontin (OPN) and 
bone sialoprotein (BSP) expression (Mosig and Martignetti, 2013).  
The RNA-Seq data showed an increase in the level of TGFβI (Transforming 
Growth Factor Beta Induced) by 6.5 fold due to -estradiol treatment. This gene is an 
important regulator of osteoblast differentiation during endochondral ossification (Thorp 
et al., 1992). The regulation occurs by activating osteoblast recruitment, differentiation, 
and function and inhibiting terminal osteoblast differentiation, bone matrix synthesis, 
and osteocyte apoptosis (Tang and Alliston, 2013). TGFβI protein binds to type I, II and 
IV collagens, which play a role in cell-collagen interactions (Hashimoto et al., 1997). 
Also, TGFΒI inhibits the formation of osteoclast precursor cells and bone resorption 
(Lee et al., 2015). The expression of Annexin A1 (ANXA1) was also shown to be 
increased by a 6-fold change in -estradiol -treated Mg-63 cells. it was found to be 
involved in the regulation of hormone levels and response to estrogen. A previous report 
suggsted that ANXA1 was a tumour suppressor gene since its expression increased 
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when MCF-7 exposure to estrogen  (Ang et al., 2009). ANXA1 can activate NF-κB in 
breast cancer cells mediated by IKK kinase complex suggesting that modulating 
ANXA1 levels has therapeutic potential to suppress breast cancer metastasis (Bist et al., 
2011). This suggests that suppresission of ANXA1 might decrease the activity of NF-κB 
in bone cells result in inhibititing the osteoclastenogenesis process. However, the role of 
ANXA1 on bone cells is not well understood.  
-estradiol increases the expression of VIM, Vimentin, in Mg-63 by 8.8-fold 
compared to control. VIM is type III intermediate filament (IF) protein which makes up, 
with microtubules and actin microfilaments, the dynamic cytoskeleton that regulates cell 
shape, and growth (Olson and Capetanaki, 1989, Capetanaki et al., 1989), enables 
intracellular transport, and supports cell division (Herrmann and Aebi, 2004). VIM 
inhibits endogenous osteocalcin transcription and osteoblast differentiation and inhibits 
the expression of osteoblast marker genes. TGF-β increases VIM expression at the post-
transcriptional level in osteoblast cells resulting in inhibiting the osteoblast 
differentiation (Lian et al., 2009, Lian et al., 2012b). The expression of TMEM64, 
Transmembrane Protein 64, is decreased by -5-fold change in Mg-63 upon estrogen 
treatment. TMEM64 has expression levels inversely related to those of miR-23a/b in 
bone marrow mesenchymal stem cells (BMSCs), which is an osteoblast precursor, from 
aged compared with young mice and humans (Guo et al., 2016) suggesting that 
TMEM64 is the major target of miR-23a/b during BMSC Differentiation (Guo et al., 
2016) suggesting that TMEM64 may play a role in osteoblast maturation. Cathepsin Z 
(CTSZ) was upregulated by 6.5 fold- in -estradiol-treated Mg-63 compared to 
untreated control as well as TRAM2, Translocation associated membrane protein 2, 
which increased by 5.9-fold. The CTSZ was also found to be involved in the regulation 
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of hormone levels and hormone metabolic process by the GO analaysis. Liu et al (2014) 
reported that CTSZ and TRAM2 displayed estradiol dependent induction in human fetal 
osteoblasts transfected with estrogen receptor α, based on case-cohort genome-wide 
association study (GWAS). Furthermore, suppression of these genes in human fetal 
osteoblasts (hFOB)-ERα -containing cell line decreased the expression of other genes in 
pathways associated with osteoporosis risk and/or bone biology such as RANK-
RANKL-OPG (Liu et al., 2014a). RUNX2 increase the osteoblast differentiation and 
function by promoting the transcription of type I collagen, produced by osteoblast, and 
also TRAM2, necessary for effective post-translational processing of this 
macromolecule (Pregizer et al., 2007). Thus, estrogen responsive genes identified in the 
present study have been shown to be involved in bone remodelling.  
In conclusion, all three-osteosarcoma cell lines responded to estradiol by increased 
growth rate compared to non-treated control, this was probably due to an effect through 
ER β. RNA seq result showed that the human osteosarcoma cell line, Mg-63 cells, was 
responsive to estrogen by altering the level of mRNAs and that many genes are affected 
by the hormonal treatment. Some of these genes were shown to be involved in bone 
formation. In the next chapter, RT-qPCR will be used, firstly to confirm the differential 
expression of the RNA-seq-detected genes, and their miRNAs regulators in the three 
cultured osteosarcoma cell lines and secondly, to find out whether they are relevant to 
osteoporosis using osteoclast precursors from clinical blood samples. 
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4 Chapter 4: Identification of Differentially-
Expressed mRNAs/miRNAs in Post-
Menopausal Osteoporosis 
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4.1. Introduction  
Postmenopausal osteoporosis is the most common type of osteoporosis. The 
deficiency of ovarian production of estrogen after the menopause is the major cause of 
rapid bone loss in women (Gallagher and Tella, 2014). In Chapter 3, RNA-sequencing 
identified several genes that were differentially expressed between the cultured 
osteosarcoma cell line Mg-63 treated with -estradiol and non-treated control. Some of 
these genes found to be estrogen responsive or involved in bone turnover based on gene 
ontology analysis. Some of the identified genes were known to be involved in the 
regulation of bone remodelling, for example, DKK3, XAF1, MMP2, COL1A2, IFI44L, 
IFI16, VIM, MX1, PARP10, TGFΒI, CTSZ, COL1A1, TRAM2, TMEM64, KRT8, 
CELSR2 and ESR1. Other genes were involved in estrogen regulation, such as BLID, 
ANXA1, CALD1, CTSZ, TRAM2, EMP1, TFAP2C, GREB1, and ESR1.  
Several studies indicate the importance of miRNAs in monitoring bone 
homeostasis and metabolism (Lian et al., 2012a, Eguchi et al., 2013, Laxman et al., 
2015, Seeliger et al., 2014, Seeliger et al., 2016, Weilner et al., 2015). However, most of 
these studies were carried out using cultured cells or animal model systems (van Wijnen 
et al., 2013) with the exception of few studies in clinical samples from patients who have 
osteoporosis fractures in small pilot experiments. Our group identified circulating of 6 
miRNAs in osteoporosis compare to non-osteoporotic patients (not published yet). 
However, it is not clear that these identified miRNAs were responsive to -estradiol or 
not and can be differentiated between non-osteoporotic and postmenopausal 
osteoporosis women.  
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It is well-known that peripheral blood mononuclear cells (PBMCs) participate in 
osteoclatogenesis by acting as osteoclast precursors (Fujikawa et al., 1996, Matayoshi et 
al., 1996), migrating to bone through the peripheral circulation (Parfitt et al., 1996, 
Parfitt). Then, they differentiate and fuse into immature multinuclear osteoclasts, which 
subsequently become activated to be mature osteoclasts at sites of bone resorption 
(Roodman, 2006). Although it is difficult to collect bone samples in vivo from humans 
for experimentation, PBMCs can be easily collected in large numbers from a blood 
sample. Also, changes in estrogen receptors mRNA in the osteoblast have been reported 
during osteoclast differentiation (Aguirre et al., 2007, Damien et al., 1998). Therefore, 
identified differentially-expressed mRNA/miRNA from RNA-seq and MicroRNA-
PCRArray data were further analysed by RT-qPCR in clinical samples from 
osteoporosis patients to assess potential diagnostic values for osteoporosis. 
4.1 Aim 
The aims of this chapter are to investigate the panel of differentially-expressed 
mRNAs from the Mg-63 cell line, identified by RNA sequencing from Chapter 3, and 
their miRNAs regulators, and their expression in PBMCs of participants was analysed 
by RT-qPCR. The relationship between mRNAs expression change and BMD was also 
examined to investigate their combined association with osteoporosis, and to find out 
whether theses mRNAs could be used as diagnostic and therapeutic biomarkers for 
osteoporosis in the future.  
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4.2. Result 
4.2.1 Identification of Differentially-Expressed mRNAs in 
Osteosarcoma Cell Lines 
The purpose of this part is to check the identified differentially-expressed genes 
from RNA-sequencing (Chapter 3) for expression by the three osteosarcoma cell lines. 
The three cultured osteosarcoma cell lines, Mg-63, TE-85 and Saos-2, represent low, 
moderate and high degree of differentiation, respectively (Pacheco-Pantoja et al., 2011). 
The 55 mRNAs, shown in Table 3-5, were selected and their relative expression levels 
among the cultured cells lines and control MCF-7 cells were determined using RT-qPCR 
by the 2-∆Ct method (Schmittgen and Livak, 2008).   
Among the 55-genes, the mRNAs for 10 of the genes were not detected in any of 
the osteosarcoma cells by the RT-qPCR. These include CREB5, LSP1, CELSR2, 
FXYD3, GFRA1, GREB1, LLGL2, NPY1R, MLPH, and KRT19. Thus, they were 
excluded from any further study. However, 45 genes were found to be expressed at 
different levels in the cultured osteosarcoma cells.    
The expressions of four mRNAs, ALP (Alkaline Phosphatase), CALD1 
(Caldesmon 1), S100A2 (S100 calcium binding protein A2) and RUNX2 (Runt related 
transcription factor 2) were lowest in Mg-63, and highest in Saos-2, while the expression 
of these genes in TE -85 was between that in Mg-63 and Saos-2 (Figure 4-1). The 
expression levels of ALP mRNA in Saos-2 and TE-85 were 1068 and 170-fold higher 
compared to its levels in Mg-63 respectively. The expression levels of CALD1 mRNA 
in Saos-2 and TE-85 were 3.3 and 2.8-fold higher than that in Mg-63, respectively. The 
expression levels of S100A2 mRNA in Saos-2 and TE-85 were 1.9 and 1.5-fold higher 
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than that in Mg-63. RUNX2 was also highly expressed in Saos-2 and TE-85 with levels 
of 150 and 7 respectively than that in Mg-63. The results show increasing levels of these 
mRNAs with increasing maturation of cells, the lowest maturation cells, Mg-63 contains 
lowest levels of these mRNAs and highest maturation cells Saos-2 contains highest 
levels of these mRNAs. The results suggest that these mRNAs might be linked with the 
degree of maturation of the osteosarcoma cells. 
  
Figure 4-1: Levels of mRNAs for differentially expressed genes increase in 
osteosarcoma cell lines 
Relative expression of mRNA was determined by the relative Ct method normalized to 
GAPDH (Data presented as Log 10 of 2 -∆Ct). The figure represents the expression of 
ALP, (B) for CALD1, (C) for S100A2, and (D) for RUNX2. Each bar represents the 
mean and ±SD (n=3). 
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On the other hand, the expression levels of 17 mRNAs showed a decreased in their 
expression from Mg-63 through TE-85 to Saos-2 (Figure 4-2). These mRNAs are, 
BLID (BH3-like motif containing, cell death inducer), COL1A2 (Collagen type I alpha 2 
chain), CTSZ (Cathepsin Z), FBN1 (Fibrillin 1), FSTL1 (Follistatin like 1), GSDMD 
(Gasdermin D), IFI6 (Interferon alpha inducible protein 6), IFI27 (Interferon alpha 
inducible protein 27), IFI44L (Interferon induced protein 44 like), LTBP4 (Latent 
transforming growth factor beta binding protein 4), MX1 (MX dynamin like GTPase 1), 
OAS2 (2'-5'-oligoadenylate synthetase 2), SLC16A3 (Solute carrier family 16 
(monocarboxylic acid transporters), member 3), TFAP2C (Transcription factor AP-2 
gamma), TGFβ1 (Transforming growth factor beta induced), TMIBIM1 
(Transmembrane BAX inhibitor motif containing 1), and VIM  (Vimentin).  
The expression levels of BLID and COL1A2 mRNA in Mg-63 were 25 and 39-
fold higher compared to its levels in Saos-2 respectively, and 3-fold higher for both 
mRNAs in TE-85 that that in Saos-2. The expression levels of CTSZ mRNA in Mg-63 
and TE-85 were 168 and 113-fold higher compared to its levels in Saos-2 respectively. 
The expression levels of FBN1 mRNA in Mg-63 and TE-85 were 31 and 8-fold higher 
than that in Saos-2. The expression levels of GSDMD mRNA in Mg-63 and TE-85 were 
26 and 16-fold higher than that in Saos-2. IFI27 was highly expressed in Mg-63 and TE-
85 with levels of 126 and 3 respectively than that in Saos-2. The expression levels of 
TGFΒI mRNA in Mg-63 and TE-85 were 277 and 18-fold higher than that in Saos-2. 
The expression levels of VIM mRNA in Mg-63 and TE-85 were 10 and 3-fold higher 
than that in Saos-2. The results showed that the levels of these 17 mRNAs exhibited an 
inverse relationship with increasing maturity of the osteosarcoma cells. 
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Figure 4-2: Inversely relationship of mRNAs expression and the maturity of 
osteosarcoma cell lines  
Relative expression of mRNA was determined by the relative Ct method normalized to 
GAPDH (Data presented as Log 10 of 2 -∆Ct). these genes showed a decrease in their 
expression with increased level of maturation. Each bar represents the mean ±SD 
(n=3). 
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The expression levels of 2 mRNAs, ALDH1A1 and XAF1 were higher in Mg-63 
compared to that in TE-85 by 32 and 20-fold respectively, but they were not detected in 
Saos-2 (Figure 4-3A,B). The expression of ESRP2 was higher in TE-85 by 5-fold 
compare to that in Saos-2. However, ESRP2 was not expressed in Mg-63, Figure 4-3C. 
 
Figure 4-3: RT-qPCR of differentially expressed mRNAs in osteosarcoma cell line  
Relative expression of mRNA was determined by the relative Ct method normalized to 
GAPDH (Data presented as Log 10 of 2 -∆Ct). ALDH3A1 and XAF1 were not 
expressed in Saos-2, ESRP2 was not expressed in Mg-3. Each bar represents the mean 
±SD (n=3).  
The expression levels of 12 mRNAs, ANXA1(Annexin A1), COL1A1 (Collagen 
type I alpha 1 chain), COL3A1 (Collagen type III alpha 1 chain), DCN (Decorin), EMP1 
(Epithelial membrane protein 1), EPB41L2 (Erythrocyte membrane protein band 4.1 like 
2), FKBP10 (FK506 binding protein 10), IFI16 (Gamma-interferon-inducible protein 16) 
KRT8 (Keratin 8), MAL2 (Mal, T-cell differentiation protein 2), TMEM64 
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(Transmembrane protein 64), TPD52L1 (Tumor protein D52 like 1), in Mg-63 and Saos-
2 were lower than in TE-85, (Figure 4-4).  
On the other hand, the expression of DKK3 (Dickkopf-related protein 3), MMP2 
(Matrix metallopeptidase 2), NFKBIA (NFKB inhibitor alpha), PARP10 (Poly(ADP-
ribose) polymerase family member 10), SPOCK1 (SPARC/osteonectin, cwcv and kazal 
like domains proteoglycan 1), S100A4 (S100 Calcium Binding Protein A4), TRAM2 
(Translocation associated membrane protein 2), TRIM37 (Tripartite motif containing 
37) XBP1 (X-box binding protein 1) were lower in TE-85 compare to that in Mg-63 and 
Saos-2, Figure 4-5). Thus, different levels of these mRNAs in these different levels of 
maturation, indicating that changes in levels of these mRNAs might be associated with 
the development of osteosarcoma cells.  
Nine mRNAs, ALP, CALD1, BLID, FSTL1, GSDMD, IFI16, IFI44L, S100A2 
and SLC16A3 were detected only in the three osteosarcoma cell lines, but not detected 
in MCF-7 cells. The results suggest that these genes might be bone related estrogen 
responsive genes. Overall, the mRNAs that showed different levels of expression 
between the cell lines, were tested for their response to estrogen. 
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Figure 4-4: Lower expression of mRNAs in Mg-63 and Saos-2 than in TE-85 by 
RT-qPCR 
Relative expression of mRNA was determined by the relative Ct method normalized to 
GAPDH (Data presented as Log 10 of 2 -∆Ct). the expression of these genes showed to 
be higher in TE-85 and lower in Mg-63 and Saos-2. Each bar represents the mean and 
±SD (n=3). 
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Figure 4-5: Lower expression of mRNAs in TE-85 than in Mg-63 and Saos-2 by 
RT-qPCR 
Relative expression of mRNA was determined by the relative Ct method normalized to 
GAPDH (Data presented as Log 10 of 2 -∆Ct). The expression of these genes showed to 
be lowest in TE-85 than that in Mg-63 and Saos-2. Each bar represents the mean and 
±SD (n=3). 
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4.2.2 Identification of Differentially-Expressed Estrogen 
Responsive Genes in Osteosarcoma Cells  
 The effect of estrogen on the expression of the 45 mRNAs expressed in the 
osteosarcoma cells (Section 4.2.1) was tested in osteosarcoma cells using RT-qPCR. 
Nine mRNAs, BLID, FBN1, FSTL1, IFI6, TRAM2, SLC16A3, SPOCK1, TMBIM1, 
and MMP2 exhibited > three-fold lower expression in the three osteosarcoma cell lines, 
Mg-63, TE85 and Saos-2 upon -estradiol treatment compared to the corresponding 
untreated control cells (Figure 4-6 and Table 4-1). -estradiol decreased by >2-fold the 
expression of ALP, COL1A2, COL3A1, EMP1, KRT8, LTBP4, MAL2, TRIM37 and 
TFAP2C mRNAs in all osteosarcoma cells compared to non-treated control (Figure 
4-7). The levels of 8 mRNAs, ANXA1, CTSZ, IFI16, GSDMD, S100A2, TGFΒI, VIM 
and XFA1 mRNAs were highest in Mg-63 cells but lower in TE-85 and Saos-2 cells by 
>2 fold upon estrogen treatment compared to the corresponding non-treated control cells 
(Figure 4-8). The expression levels of DCN and FKBP10 mRNAs, were decreased in 
TE-85 and Saos-2 compared to non-treated control, but not changed in Mg-63 (Figure 
4-9). The RT-qPCR data revealed -estradiol decreased the expression of TMEM64 and 
ESR1 in Mg-63 and TE-85 compared to non-treated controls, but these mRNAs were 
increased in Saos-2 cells (Figure 4-9). RT-qPCR data showed that -estradiol decreased 
the level of 15 mRNAs, ALDH3A1, CALD1, COL1A1, DKK3, ESRP2, EPB41L2, 
IFI27, IFI44L, NFKBIA, MX1, OAS2, PARP10, RUNX2, S100A4, and XBP1, in TE-
85 upon estrogen treatment, but these mRNAs were not changed in Mg-63 and Saos-2 
Figure 4-10.  
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Generally, although these genes showed a different level of expression in the 
osteosarcoma cell lines with different stages of maturation in a normal condition, the 
RT-qPCR data suggest that these genes were negatively responsive to -estradiol. 
Therefore, in view of the association of osteoporosis with reduced estrogen levels in 
patients, it is important to find out if these mRNAs change in clinical samples of post-
menopausal osteoporosis (Section 4.2.4). However, first, the miRNAs associated with 
the expression of these 45 genes were identified. 
  
  Chapter 4 
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Figure 4-6: Effect of β-estradiol on mRNA in the three osteosarcoma cell lines by 
RT-qPCR 
≤3 Fold Change upon -estradiol treatment on osteosarcoma cells, fold changes were 
determined by the relative Ct method normalized to GAPDH (2 -∆∆Ct). Each bar 
represents the mean and ±SD (n=3). 
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Figure 4-7: RT-qPCR result of genes that β-estradiol decrease their expression in 
the all three osteosarcoma cell lines 
Fold Change of genes were determined by the relative Ct method normalized to 
GAPDH (2 -∆∆Ct). Each bar represents the mean and ±SD (n=3).. 
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Figure 4-8: mRNAs that increased in Mg-63 but decreased in TE-85 and Saos-
2upon β-estradiol treatment by RT-qPCR 
Fold Change of genes were determined by the relative Ct method normalized to 
GAPDH (2 -∆∆Ct). Each bar represents the mean and ±SD (n=3). 
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Figure 4-9: The effect of β-estradiol on DCN, FKBP10, TMEM64, and ESR1 by 
RT-qPCR  
-estradiol decrease level of DCN and FKBP10 in TE-85 and Saos-2 but increase in 
Mg-63. Whereas level of TMEM64 and ESR1 were decreased in Mg-63 and TE-85 but 
increased in Saos-2. Fold Change of genes were determined by the relative Ct method 
normalized to GAPDH (2 -∆∆Ct). Each bar represents the mean and ±SD (n=3). 
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Figure 4-10: β-estradiol decreased the level of mRNAs in TE-85 without changed 
in Mg-63 and Saos-2 compared to non-treated control 
Fold Change of genes were determined by the relative Ct method normalized to 
GAPDH (2 -∆∆Ct). Each bar represents the mean and ±SD (n=3). 
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Table 4-1: The effect of estrogen on the expression of genes selected based on 
showing different level in the normal condition. 
 Gene Fold change in 
Mg-63 
Fold change in 
TE-85 
Fold change in 
Saos-2 
Fold change in 
MCF-7 
1 ALDH3A1   1.03 ± 0.03 -3.35 ± 0.17 - -2.86 ± 1.18 
2 ALP -3.41 ± 0.66 -3.86 ± 0.25 -3.42 ± 0.46 - 
3 ANXA1     2.64 ± 0.04 -5.04 ± 1.47 -1.47 ± 0.51 -3.25 ± 0.13 
4 BLID 1.31 ± 0.22 -2.83 ± 1.15 -1.68 ± 0.17 - 
5 CALD1     1.57 ± 0.35 -7.35 ± 0.47 -1.68 ± 0.15 - 
6 COL1A1    -1.23 ± 0.05 -5.75 ± 0.51 -1.63 ± 0.05 3.04 ± 0.57 
7 COL1A2    -1.33 ± 0.34 -5.63 ± 0.28 -2.17 ± 0.06 -3.08 ± 1.39 
8 COL3A1    -1.1 ± 0.08 -8.38 ± 0.29 -1.47 ± 0.18 -0.22 ± 2.97 
9 CTSZ      3.07 ± 0.15 -4.87 ± 0.74 -2.25 ± 1.24 -1.96 ± 0.56 
10 DCN       1.41 ± 0.46 -6.18 ± 1.77 -2.54 ± 0.59 1.15 ± 0.1 
11 DKK3 1.69 ± 0.33 -6.1 ± 1.16 0.13 ± 2.01 -0.03 ± 1.5 
12 ESR1 -2.61 ± 1.95 -5.73 ± 2.76 -5.19 ± 3.17 -2.45 ± 5.24 
13 EMP1 0.24 ± 3.17 -3.98 ± 2.56 -1.1 ± 3.02 -1.79 ± 6.93 
14 EPB41L2 -2.63 ± 1.96 -2.14 ± 0.22 1.51 ± 0.52 -2.44 ± 0.2 
15 ESRP2 - -4.89 ± 1.98 -1.05 ± 0.01 8.32 ± 1.98 
16 FBN1 1.24 ± 0.08 -1.81 ± 0.74 -0.08 ± 1.6 3.26 ± 1.38 
17 FKBP10 -0.05 ± 2.23 -2.39 ± 1.63 -1.94 ± 0.75 0.24 ± 1.91 
18 FSTL1 1.63 ± 0.1 -2.91 ± 0.37 -1.53 ± 0.03 - 
19 GSDMD 5.45 ± 1.07 -1.77 ± 0.07 -1.73 ± 0.5 - 
20 IFI16     2.05 ± 0.5 -5.72 ± 0.87 -1.57 ± 0.18 - 
21 IFI27 0.23 ± 1.95 -5.29 ± 3.1 -1.35 ± 0.45 1.43 ± 0.22 
22 IFI44L 1.97 ± 0.75 -4.17 ± 0.39 -1.29 ± 0.21 - 
23 IFI6 -1.17 ± 0.2 -2.75 ± 0.92 -1.69 ± 0.82 1.56 ± 0.18 
24 KRT8 -6.01 ± 0.71 -2.12 ± 0.14 -2.09 ± 0.05 -1.28 ± 0.08 
25 LTBP4 -2.45 ± 0.78 -1.5 ± 0.19 -2.34 ± 0.05 -1.7 ± 0.66 
26 MAL2 -1.22 ± 0.26 -3.28 ± 2.27 -1.28 ± 3.4 -2.12 ± 1.54 
27 MMP2 1.82 ± 1 -0.93 ± 3.43 -1.77 ± 0.68 -1.6 ± 0.71 
28 MX1 1.22 ± 3.43 -3.3 ± 0.46 -1.85 ± 4.17 2.65 ± 5.5 
29 NFKBIA    1.33 ± 0.16 -7.12 ± 0.87 -1.55 ± 0.3 2.53 ± 0.87 
30 OAS2 1.93 ± 0.15 -7.16 ± 3.06 -0.06 ± 1.62 8.32 ± 1.98 
31 PARP10 0.78 ± 2.93 -4.23 ± 2.98 2.1 ± 0.75 2.47 ± 1.28 
32 RUNX2     1.76 ± 0.87 -6.2 ± 1.45 -1.66 ± 0.04 1.39 ± 0 
33 S100A2 2.21 ± 0.39 -5.48 ± 0.32 -2.13 ± 0.75 - 
34 S100A4    1.58 ± 0.25 -4.96 ± 3.28 -1.55 ± 0.07 -0.26 ± 1.82 
35 SLC16A3 0.08 ± 1.62 -0.94 ± 3.22 -0.33 ± 2.35 - 
36 SPOCK1 1.15 ± 0.05 -1.81 ± 0.89 -2.06 ± 1.48 1.67 ± 0.8 
37 TFAP2C -1.26 ± 0.17 -1.08 ± 0.1 -2.37 ± 0.42 -3.73 ± 0.89 
38 TGFβI 4.1 ± 1.98 -8.18 ± 1.12 -1.69 ± 0.06 1.46 ± 0.28 
39 TMBIM1 1.24 ± 0.08 -1.81 ± 0.74 -0.08 ± 1.6 2.76 ± 2.08 
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 Gene Fold change in 
Mg-63 
Fold change in 
TE-85 
Fold change in 
Saos-2 
Fold change in 
MCF-7 
40 TMEM64    -4.3 ± 1.98 -7.38 ± 1.62 2.03 ± 0.39 1.46 ± 0.19 
41 TRAM2 1.29 ± 0.3 -2.43 ± 0.07 -2.48 ± 0.22 -1.54 ± 0.46 
42 TRIM37    -2.9 ± 1.7 -6.05 ± 0.97 -1.51 ± 0.17 0.07 ± 1.93 
43 VIM       4 ± 1.98 -7.37 ± 1.47 -1.38 ± 0.17 1.22 ± 0 
44 XAF1 3.26 ± 1.64 -4.29 ± 1.31 -1.51 ± 0.22 - 
45 XBP1      1.35 ± 0.25 -5.43 ± 1.21 -1.73 ± 0.07 2.32 ± 0 
Fold Changes of differentially-expressed mRNAs of genes in -estradiol- treated 
osteosarcoma cell lines which were calculated by the relative Ct method 
normalized to GAPDH (2 -∆∆Ct) ±SD (n=3). 
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4.2.3 Potential Target miRNAs in Osteosarcoma Cells 
4.2.3.1 Identification of miRNAs for estradiol responsive mRNAs  
The potential target miRNAs for the identified 45 estrogen responsive genes 
(Section 0) were identified bioinformatically. These miRNAs were identified using 4 
different algorithms (miRanda, miRDB, miRWalk and Targetscan) within the miRWalk 
2.0 database. The results are summarized in Table 4-2. The data show that hsa-miR-100 
may hit 8 of the estrogen responsive mRNAs, ANXA1, COL1A1, COL1A2, COL3A1, 
DCN, ESR1, FBN1, and FSTL1. hsa-miR-196 is reported to regulate 11 genes, ANXA1, 
CALD1, COL1A1, COL1A2, COL3A1, DCN, DKK3, EPB41L2, ESR1, FBN1 and 
FKBP10. COL1A1, CTSZ, EMP1, FKBP10 and FSTL1 can be controlled by has-miR-
1260. Has-miR-1290 might regulate the expression of CALD1, COL3A1, DCN, DKK3, 
EMP1, ESR1, FBN1, FKBP10 and FSTL1. Has-miR-143 can regulate 8 mRNAs, BLID, 
CALD1, COL1A2, CTSZ, EMP1, ESR1, FBN1, and FKBP10. Has-miR-145 can 
regulate 6 mRNAs, BLID, COL1A1, DCN, EMP1, EPB41L2, ESR1. Has-miR-373 can 
regulate 9 mRNAs CALD1, COL1A1, COL1A2, DCN, DKK3, EMP1, EPB41L2, 
ESR1, FSTL1. ANXA1, CALD1, COL1A2, DCN, EMP1, EPB41L2, ESR1, FBN1 and 
FSTL1 can be regulated by has-miR-409. Lastly, FKBP10 might be regulated by has-
miR-99a. 
  
  Chapter 4 
 
145 | P a g e  
 
Table 4-2: Potential target miRNAs of estrogen related genes 
Gene miRNA miRanda miRDB miRWalk Target 
scan 
SUM 
ANXA1 hsa-miR-196a 1 0 1 1 3 
ANXA1 hsa-miR-196b 1 0 1 1 3 
ANXA1 hsa-miR-100 1 1 0 0 2 
ANXA1 hsa-let-7c 1 0 1 0 2 
ANXA1 hsa-miR-409 0 0 1 0 1 
BLID hsa-miR-143 1 0 0 0 1 
BLID hsa-miR-145 1 0 0 0 1 
CALD1 hsa-miR-196a 1 0 1 1 3 
CALD1 hsa-miR-1290 1 0 1 1 3 
CALD1 hsa-let-7c 1 0 1 1 3 
CALD1 hsa-miR-409 1 0 0 1 2 
CALD1 hsa-miR-143 1 0 0 0 1 
CALD1 hsa-miR-373 1 0 0 0 1 
CALD1 hsa-miR-373 1 0 0 0 1 
CALD1 hsa-miR-409 1 0 0 0 1 
COL1A1 hsa-let-7c 1 1 1 1 4 
COL1A1 hsa-miR-196a 1 0 1 1 3 
COL1A1 hsa-miR-1260 1 0 1 1 3 
COL1A1 hsa-miR-100 1 0 1 0 2 
COL1A1 hsa-miR-373 1 0 1 0 2 
COL1A1 hsa-miR-145 1 0 0 0 1 
COL1A2 hsa-miR-196a 1 0 1 1 3 
COL1A2 hsa-let-7c 1 0 1 1 3 
COL1A2 hsa-miR-100 1 0 0 0 1 
COL1A2 hsa-miR-143 1 0 0 0 1 
COL1A2 hsa-miR-373 1 0 0 0 1 
COL1A2 hsa-miR-409 1 0 0 0 1 
COL3A1 hsa-miR-196a 1 1 1 1 4 
COL3A1 hsa-let-7c 1 1 1 1 4 
COL3A1 hsa-miR-100 1 0 1 0 2 
COL3A1 hsa-miR-1290 1 0 0 0 1 
CTSZ hsa-miR-1260 1 0 1 0 2 
CTSZ hsa-miR-143 1 0 0 0 1 
DCN hsa-let-7c 1 0 1 1 3 
DCN hsa-miR-100 1 0 1 0 2 
DCN hsa-miR-373 1 0 1 0 2 
DCN hsa-miR-409 1 0 0 1 2 
DCN hsa-miR-373 1 0 1 0 2 
DCN hsa-miR-196a 1 0 0 0 1 
DCN hsa-miR-1290 1 0 0 0 1 
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Gene miRNA miRanda miRDB miRWalk Target 
scan 
SUM 
DCN hsa-miR-373 0 0 1 0 1 
DCN hsa-miR-373 0 0 1 0 1 
DCN hsa-miR-373 0 0 1 0 1 
DCN hsa-miR-145 0 0 0 1 1 
DKK3 hsa-miR-1290 1 1 1 1 4 
DKK3 hsa-let-7c 1 0 1 1 3 
DKK3 hsa-miR-1290 0 0 1 1 2 
DKK3 hsa-miR-196a 1 0 1 0 2 
DKK3 hsa-miR-373 1 0 1 0 2 
DKK3 hsa-miR-373 0 0 1 0 1 
EMP1 hsa-miR-1290 1 0 1 1 3 
EMP1 hsa-let-7c 1 0 1 0 2 
EMP1 hsa-miR-143 1 0 1 0 2 
EMP1 hsa-miR-373 1 0 1 0 2 
EMP1 hsa-miR-145 1 0 0 1 2 
EMP1 hsa-miR-1260 1 0 0 1 2 
EMP1 hsa-miR-409 1 0 0 0 1 
EPB41L2 hsa-miR-196a 1 0 0 1 2 
EPB41L2 hsa-miR-409 1 0 0 1 2 
EPB41L2 hsa-miR-145 1 0 0 0 1 
EPB41L2 hsa-miR-373 1 0 0 0 1 
ESR1 hsa-miR-196a 1 0 1 1 3 
ESR1 hsa-miR-145 1 0 1 1 3 
ESR1 hsa-miR-373 1 0 1 1 3 
ESR1 hsa-miR-196b 1 0 1 1 3 
ESR1 hsa-miR-409 1 0 1 1 3 
ESR1 hsa-miR-1290 1 0 1 1 3 
ESR1 hsa-miR-373 0 1 1 1 3 
ESR1 hsa-let-7c 1 0 1 0 2 
ESR1 hsa-miR-145 0 0 1 1 2 
ESR1 hsa-miR-373 0 0 1 1 2 
ESR1 hsa-miR-1290 0 0 1 1 2 
ESR1 hsa-miR-143 1 0 1 0 2 
ESR1 hsa-miR-373 1 0 1 0 2 
ESR1 hsa-miR-373 0 0 1 1 2 
ESR1 hsa-miR-1290 0 0 1 1 2 
ESR1 hsa-miR-143 0 0 1 0 1 
ESR1 hsa-miR-373 0 0 1 0 1 
ESR1 hsa-miR-100 1 0 0 0 1 
ESR1 hsa-miR-373 0 0 1 0 1 
ESR1 hsa-miR-143 0 0 1 0 1 
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Gene miRNA miRanda miRDB miRWalk Target 
scan 
SUM 
ESR1 hsa-miR-373 0 0 1 0 1 
FBN1 hsa-miR-100 1 0 1 0 2 
FBN1 hsa-miR-143 1 0 1 0 2 
FBN1 hsa-miR-196a 1 0 0 1 2 
FBN1 hsa-miR-409 1 0 0 1 2 
FBN1 hsa-miR-1290 1 0 0 1 2 
FBN1 hsa-let-7c 1 0 0 0 1 
FKBP10 hsa-miR-1290 1 0 1 1 3 
FKBP10 hsa-miR-1260 1 0 1 1 3 
FKBP10 hsa-let-7c 1 0 1 1 3 
FKBP10 hsa-miR-99a 1 0 1 0 2 
FKBP10 hsa-miR-196a 1 0 0 0 1 
FKBP10 hsa-miR-143 1 0 0 0 1 
FSTL1 hsa-miR-409 1 0 1 1 3 
FSTL1 hsa-miR-100 1 0 1 0 2 
FSTL1 hsa-miR-373 1 0 1 0 2 
FSTL1 hsa-miR-1290 1 0 0 1 2 
FSTL1 hsa-miR-1260 1 0 0 1 2 
FSTL1 hsa-let-7c 1 0 0 0 1 
FSTL1 hsa-miR-373 1 0 0 0 1 
Potentially regulating miRNAs were predicted by 4 different algorithms from 
the miRWalk 2.0 database. 0 indicates not identified, whereas 1 indicates the 
identified miRNA 
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4.2.3.2 The Expression of identified miRNAs in Osteosarcoma Cell 
Lines  
Twelve of the bioinformatically-predicted target miRNAs (previous section) were 
selected because they were identified as differentially expressed between osteopenia and 
osteoporosis compared to non-osteoporosis female (>40 years) serum RNA pools using 
QIAGEN miRNA PCR Array. These 12 miRNAs were hsa-miR-100-5p, hsa-miR-373-
5p, hsa-miR-4516, hsa-miR-99a-5p, hsa-miR-196b-3p, hsa-miR-143-3p, hsa-miR-409-
3p, hsa-miR-145-3p, has-miR-1260, has-miR-1281, has-miR-1290 and hsa-let-7c-5p.  
3 miRNAs, has-miR-143-3p, has-miR-409-3p and has-miR-145were not detected 
in the osteosarcoma cells by RT-qPCR. The levels of four miRNAs, miR-100-5p, miR-
99a-5p, miR-196b-3p and let-7c-5p were lower in the TE-85 cells compared to the Mg-
63 and Saos-2 cells (Figure 4-11). The expression levels of miR-100-5p in Mg-63 and 
Saos-2 were 21.2 and 1.5- fold higher compared to its level in TE-85. Also, the 
expression levels of miR-196b-3p in Mg-63 and Saos-2 were 1.6 and 1.3-fold higher 
than that in TE-85. miR-99a-5p was highly expressed in Mg-63 and Saos-2 with levels 
of 14.6 and 1.2-fold respectively than that in TE-85. The expression levels of miR-let-
7c-5p in Mg-63 and Saos-2 were 56 and 3.6- fold higher compared to its level in TE-85.  
The levels of four miRNAs, miR-373-5p, miR-4516, miR-1260 and miR-1290 
were lower in Saos-2 compared to those in Mg-63 and TE-85( Figure 4-11). The 
expression levels of miR-373-5p in Mg-63 and TE-85 were 1.4 and 4.2- fold higher 
compared to its level in Saos-2. miR-4516 was highly expressed in Mg-63 and TE-85 
with levels of 4-fold than that in Saos-2. Also, the expression levels of miR-1260 in Mg-
63 and TE-85 were 1.3 and 1.4-fold higher than that in Saos-2. The expression levels of 
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miR-1290 in Mg-63 and TE-85 were 1.1 and 2.2- fold higher compared to its level in 
Saos-2.  The levels of miR-1281 were lower in Mg-63 compared to those in TE-85 and 
Sao-2 by 1 and 2.7-fold respectively (Figure 4-11). Overall, the RT-qPCR data showed 
differences in the expression of those miRNAs in the three osteosarcoma cell lines in the 
normal condition.  
 
Figure 4-11: The expression of different miRNAs in osteosarcoma cell lines and 
MCF-7 cells 
The relative expression of 12 selected miRNAs was determined by the relative Ct 
method normalized to SNORD96A (Data presented as Log 10 of 2 -∆Ct). Each bar 
represents the mean and ±SD (n=3). 
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4.2.3.3 Estrogen-responsiveness of miRNAs in Osteosarcoma Cell Lines  
In order to study the effect of -estradiol on the 9 miRNAs tested previously, RT-
qPCR was carried out for the three osteosarcoma cell lines and MCF-7 cells after 
treatment with 1 nM -estradiol compared to the control incubated in the absence of -
estradiol. Relative levels of miRNAs were determined using the 2-∆∆Ct method with 
SNORD96A as a housekeeping control gene. The RT-qPCR data are summarized in 
Figure 4-12 and Table 4-3.  
MiR-100-5p exhibited lower expression in the three osteosarcoma cell lines, Mg-
63, TE85 and Saos-2 upon estrogen treatment compared to the control non-treated those 
osteosarcoma cells (< ± two-fold change). -estradiol increase the expression of miR-
373-5p and miR-let-7c-5p in TE-85 by 3.6 and 3.8-fold respectively compared to non-
treating control, but these miRNAs were not changed in Mg-63 and Saos-2. However, -
estradiol increase the expression of miR-4516 and miR99a-5p in Mg-63 by 3.6 and 4.7-
fold respectively compared to non-treating control, but these miRNAs were not changed 
in TE-85 and Saos-2. The level of miR-196b-3p were increased in Mg-63 and Saos-2 by 
2 and 3-fold, but decreased in TE-85 by 2-fold upon estrogen treatment compared to the 
control non-treated. The RT-qPCR data revealed that -estradiol decrease the expression 
of miR-1260 in Mg-63 and TE-85 compared to non-treating control by 3.8 and 3.7-fold 
respectively, but this miRNA was not changed in Saos-2 cells. RT-qPCR data showed 
that -estradiol decrease the level of miR-1290 in TE-85 and Saos-2 compared to non-
treating control by 2.6 and 4.6-fold respectively, but this miRNA was not changed in 
Mg-63. The expression level of miR-1281 was decreased upon -estradiol treatment 
compared to non-treated control only in Saos-2 by 2-fold. Therefore, although these 
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miRNAs were differentially expressed between the three osteosarcoma cells, they were 
also found to be estrogen related miRNAs. Thus, in the reduced estrogen in the 
postmenopausal osteoporosis women, the level of these miRNAs will change which will 
then provide an explanation of the gene changes seen in the mRNAs because these 
miRNAs were originally selected as being regulators of the differentially-expressed 
mRNAs. 
 
Figure 4-12: RT-qPCR result of treated osteosarcoma cell line and MCF-7 with 
1nM β-estradiol of some miRNAs 
Fold Change of genes were determined by the relative Ct method normalized to 
SNORD96A (2 -∆∆Ct). Each horizontal line represents the mean and ±SD of triplicated 
counting. 
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Table 4-3: The effect of β-estradiol on the expression of miRNAs in 
osteosarcoma cell lines  
ID miRNAs Fold change 
in Mg-63 
Fold change 
in TE-85 
Fold change 
in Saos-2 
Fold change 
in MCF-7 
1 hsa-miR-100-5p  1.16 ± 0.17 -1.83 ± 0.27 -1.62 ± 0.15 -1.49 ± 0.03 
2 hsa-miR-373-5p  1.25 ± 0.33 3.66 ± 0.93 1.26 ± 0.26 -1.49 ± 0.03 
3 hsa-miR-4516    3.58 ± 1.17 1.10 ± 0.09 1.4 ± 0.04 3.68 ± 0.79 
4 hsa-miR-99a-5p  4.74 ± 2.9 -1.36 ± 0.21 -1.58 ± 0.37 -1.89 ± 0.03 
5 hsa-miR-196b-3p 1.93 ± 0.14 -1.94 ± 1.08 3 ± 0.5 1.63 ± 0.61 
6 hsa-miR-1260 -3.8 ± 1.05 -3.65 ± 0.5 -1.44 ± 0.14 2.43 ± 0.66 
7 hsa-miR-1281 1.12 ± 0.13 1.01 ± 0.01 -2.04 ± 0.7 2.95 ± 1.3 
8 hsa-miR-1290 1.19 ± 0.23 -2.56 ± 0.5 -4.64 ± 0.91 3.13 ± 0.88 
9 hsa-let-7c-5p -1.76 ± 0.48 3.76 ± 0.06 -1.18 ± 0.22 3.25 ± 0.39 
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4.2.4 Identification of Differentially Expressed 
mRNAs/miRNAs in Osteoporosis Clinical Specimens 
The major objective of this part is to find out if the β-estradiol related 
mRNAs/miRNAs identified in the cells lines change in postmenopausal osteoporosis 
compared to non-osteoporotic controls caused by reduced estrogen. The level of 
expression of the estrogen related mRNAs/miRNAs identified in the osteosarcoma cells 
above were studied by RT-qPCR in individual peripheral blood mononuclear cells 
(PBMC), which are osteoclast precursor cells (Fujikawa et al., 1996), obtained from 
participants in a blood sample. These participants were recruited from referrals to the 
Radiology Department for a bone density scan at the Royal Liverpool University 
Hospital. Bone mineral density (BMD) and T-Score were obtained. Blood samples were 
taken and PBMCs were isolated (Material and Methods, Section 2.9). Participants were 
categorised into three groups, based on their T-Score. A non-osteoporotic (NOPC) group 
having T score >-1.0, an osteopenia (OPA) group with T score <-1.0 and >-2.5 and an 
osteoporosis (OPS) group with T score ≤-2.5.   
A total of 100 participants were recruited, 82 participants were female and 18 were 
male as summarized in Table 4-4. The cut-off age was 40 years, so the 3 participants 
below 40 was excluded. There was no significant age mean difference between the three 
study groups, (p value = 0.078). Thirteen percent of the recruits were non-osteoporotic 
(10 female and 3 male), sixty five percent of the participants were osteopaenia (54 
female and 11 male) and twenty two percent were osteoporosis (18 female and 4 male). 
Total RNA was prepared from PBMC cells isolated from blood samples, and subjected 
to RT-qPCR as described in (Material and Methods, Section 2.10). RT-qPCR analysis 
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was carried out with GAPDH levels used as an internal control for real-time PCR. All q-
PCR data were logarithmically transformed. 
Table 4-4: Characteristics of clinical samples (F=82, M= 18) 
Condition Sex (No) 
Age (year) 
mean± SD 
No. of 
Fracture 
(%) 
BMD 
g/cm2 
Mean± 
SD 
T-Score 
Lumbar Spine 
(L2-L4) Mean 
± SD 
Non-
osteoporotic 
F (n=10) 68 ± 9.8 3 (30%) 1 ± 0.1 0.8 ± 1.5 
M (n=3) 45.3 ± 25.7 1 (30%) 0.3 ± 0.6 0.3 ± 0.6 
Total (n=13) 59.2 ± 19.9 4 (30%) 0.8 ± 0.4 0.7 ± 1.3 
Osteopenia 
F (n=54) 63.9 ± 10.3 25 (50%) 0.8 ± 0.2 -1.2 ± 0.9 
M (n=11) 65.5 ± 13.4 3 (30%) 0.8 ± 0.3 -0.7 ± 1.4 
Total (n=65) 64.2 ± 10.7 28 (40%) 0.8 ± 0.2 -1.1 ± 1 
Osteoporosis 
F (n=18) 68.8 ± 14.1 8 (40%) 0.7 ± 0.2 -2.6 ± 0.9 
M (n=4) 67.3 ± 10.2 1 (30%) 0.6 ± 0.1 -2.6 ± 1 
Total (n=22) 68.05±12.1 9 (35%) 0.7±0.2 -2.6 ± 0.95 
4.2.4.1 Differentially Expressed mRNAs Associated with Osteoporosis 
Patients 
To find out whether any of the 45 mRNAs identified (Section 4.1.3) as β-estradiol 
related genes in osteosarcoma cell were differentially expressed in PBMC cells of 
patients in the three patient groups above, a pilot experiment on 4 female samples from 
each group was carried out by RT-qPCR. Out of the 45 mRNAs, 9 mRNAs (ALDH3A1, 
BLID, CALD1, COL1A1, COL1A2, COL3A1, IFI27, TFAP2C and S100A2) were not 
detected in the PBMC samples and 22 genes showed a Ct of >30. Thus, these 31 genes 
were excluded from further study. The remaining 14 genes showed Ct value of less than 
30 on the 4 PBMC samples. These genes were ANXA1, CTSZ, VIM, IFI16, TMEM64, 
TRIM37, TGFβI, TRAM2, GSDMD, KRT8, NFKBIA, S100A4, XBP1 and RUNX2.  
The mean expression of all 14 mRNAs were compared in each patient between the 
three groups. One-way ANOVA (Bonferroni's multiple comparisons test) was used to 
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compare the mean of the expression of each gene between the three groups, NOPC, 
OPA and OPS. The RT-qPCR 2-∆Ct data were logarithmically transformed (Log10) since 
it provides a symmetrical data to show more accurate and relevant interpretation 
(Schmittgen and Livak, 2008).  
The expression levels of ANXA1 mRNA were much lower in osteoporotic 
patients compared with non-osteoporotic control and osteopenia patients (ANOVA p = 
0.029, Figure 4-13). There was a significantly difference between non-osteoporotic 
group and osteoporosis group (Bonferroni’s p = 0.021). The levels of XBP1 mRNA 
were much lower in osteoporotic patients compared with osteopenia patients and non-
osteoporotic controls (ANOVA p = 0.0001, Figure 4-13), and there was a significant 
decrease in the expression of XBP1 mRNA in the osteoporosis compared to the non-
osteoporotic control (Bonferroni’s p = 0.0013). The differences of S100A4 mRNA 
expression between the three groups showed a significant changed (ANOVA p = 0.0003, 
Figure 4-13). The q-PCR data showed that there was no change in osteopenia samples 
but a significant decrease in the osteoporosis sample once compared to non-osteoporotic 
samples (Bonferroni’s p = 0.023). The levels of VIM mRNA were significantly lower in 
the osteoporosis group compared to non-osteoporotic participants and osteopenia 
patients (ANOVA p= <0.0001, Figure 4-13) and there was a significant decreased in the 
expression of VIM in the osteoporosis patient non-osteoporotic (Bonferroni’s p = 0.042). 
The results revealed that the levels of two mRNAs, ANXA1, and XBP1 in PBMCs were 
much lower in osteoporosis patients compared with osteopenia patients and non-
osteoporotic group (ANOVA p = 0.029, p = 0.0001, respectively).  
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Figure 4-13: Decreased mRNAs expression in PBMCs of osteoporosis patients 
RT-qPCR data showed that the expression of ANXA1, XBP1, S100A4 and VIM were 
significantly lower in OPS compared to NOPC. box-and-whisker plots showed the 
expression of mRNA in non-osteoporotic, osteopenia and osteoporosis groups. p value 
was calculated using one-way ANOVA. Box plots showing 25th, 50th, and 75th 
percentiles (horizontal bars) and minimum to maximum ranges (error bars). Dots 
indicate outliers 
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The levels of CTSZ mRNA were much higher in osteoporotic patients compared 
with osteopenia patients and non-osteoporotic controls (ANOVA p = 0.0007, Figure 
4-14). The significant difference increases in CTSZ mRNA level occurred between 
CTSZ expression in the non-osteoporotic and the osteopaenia groups and between the 
non-osteoporotic and osteoporosis groups was increased significantly (Bonferroni’s p = 
0.046 and 0.0004, respectively). The levels of GSDMD mRNA were higher in 
osteoporosis patients compared with osteopenia patients and the non-osteoporotic 
control (ANOVA p = 0.0019, Figure 4-14). There was a significant increase in GSDMD 
mRNA expression levels in the osteopaenia and osteoporosis samples compared to that 
in the non-osteoporotic samples (Bonferroni’s p = 0.004, 0.0011 respectively). The 
levels of TMEM64 mRNA were higher in both osteopenia and osteoporosis patients 
compared to non-osteoporotic control (ANOVA p = 0.0002). There was significantly 
increased (Bonferroni’s p = 0.0002 and p = 0.027, Figure 4-14) in the expression of 
TMEM64 mRNA in the osteopaenia and osteoporosis samples compared to that in the 
non-osteoporotic samples. The levels of TRAM2 mRNA was significantly higher in the 
osteopenia and osteoporosis patients compared to that in the non-osteoporotic control 
(ANOVA p = 0.016, Figure 4-14). The levels of TRIM37 mRNA was significantly 
higher in the osteoporosis patients compared to that in the non-osteoporotic control 
(ANOVA p = 0.029, Figure 4-14). The results also showed that the levels of three 
mRNAs, CTSZ, GSDMD and TMEM64 in PBMC were significantly increased in both 
osteopaenia and osteoporosis compared to the non-osteoporotic group (ANOVA p = 
0.0007, p = 0.0019, and p = 0.0002 respectively). 
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Figure 4-14: An increase of mRNAs expression in PBMCs of osteoporosis patients 
RT-qPCR data showed that the expression of CTSZ, GSDMD, and TMEM64 were 
significantly higher in OPS compared to NOPC. box-and-whisker plots showing the 
expression of mRNA in non-osteoporotic, osteopenia and osteoporosis groups. p value 
was calculated using one-way ANOVA. Box plots show 25th, 50th, and 75th 
percentiles (horizontal bars) and minimum to maximum ranges (error bars). Dots 
indicate outliers 
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4.2.4.2 Differentially Expressed miRNAs Associated with Osteoporosis 
Patients 
To find out whether any of the 9 miRNAs (Section 4.1.3) identified as -estradiol 
related miRNAs in osteosarcoma cells were differentially expressed in PBMC cells of 
patients in the three patient groups, a pilot experiment on 4 female samples from each 
group was carried out by RT-qPCR. Two out of nine differentially expressed miRNAs 
identified from pilot experiments were excluded, has-miR-1281 had Ct >31, and has-
miR-let-7c-5p did not showed any changed expression between the three groups, 
(ANOVA p = 0.42). The remaining 7 miRNAs showed Ct value that were less than 30 
on the 4 PBMC samples were tested on all participants’ samples. These miRNAs are 
hsa-miR-100-5p, hsa-miR-373-5p, hsa-miR-4516, hsa-miR-99a-5p, hsa-miR-196b-3p, 
has-miR-1260, and has-miR-1290.  
The RT-qPCR data revealed that the levels of miRNA-99a-5p were lower in 
osteoporosis patients compared with osteopenia patients and non-osteoporotic control 
(ANOVA p = 0.027, Figure 4-15A). A significantly difference was shown between the 
non-osteoporotic group and the osteoporosis group (Bonferroni’s p = 0.026). Similarly, 
the expression of miR-100-5p was lower in osteoporotic patients compared with 
osteopenia patients and non-osteoporotic controls (ANOVA p = 0.0002, Figure 4-15A). 
There was also significantly difference shown between non-osteoporotic group and 
osteoporosis group, (Bonferroni’s p = 0.015). RT-qPCR data showed that the level of 
hsa-miR-373-5p in non-osteoporotic participants was significantly different between that 
in osteopaenia and osteoporosis patients (ANOVA p = 0.0003), but no change was seen 
between non-osteoporotic control and osteoporosis patients (p > 0.9, Figure 4-15A).  
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Overall, the results revealed that the levels of two miRNAs, miRNA-99a-5p, and 
miR-100-5p in PBMCs were much lower in osteoporosis patients compared with 
osteopenia patients and non-osteoporotic group (ANOVA p = 0.027, p = 0.0002 
respectively). 
On the other hand, the RT-qPCR data showed that the expression levels of miR-
196b-3p was much higher in osteoporotic patients compared with osteopenia patients 
and non-osteoporotic controls (ANOVA p = <0.0001, Figure 4-15B). There was a 
significant increase in miR-196b-3p mRNA expression in the osteopaenia and 
osteoporosis samples compared to that in the non-osteoporotic samples (Bonferroni’s p 
= 0.0008, p<0.0001).  Moreover, the expression level of hsa-miR-1260 and hsa-miR-
1290 were higher in osteoporosis patients compared with osteopenia patients and the 
non-osteoporotic control (ANOVA p = 0.0072 and p=0.0004, respectively, Figure 
4-15B). The expression level of hsa-miR-1260 and hsa-miR-1290 in osteoporosis 
participants was significantly higher compared to those in non-osteoporotic participants 
(Bonferroni’s p = 0.0062 and 0.0058 respectively, Figure 4-15B). Thus, the results 
revealed that the levels of three miRNAs, miRNA-196b-3p, miR-1260 and miR-1290 in 
PBMCs were much higher in osteoporosis patients compared with osteopenia patients 
and non-osteoporotic group (ANOVA p = <0.0001, p = 0.0072 and p = 0.0004 
respectively). 
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Figure 4-15: Relative miRNA expression in PBMCs  
RT-qPCR data showed that (A) the expression of miRNA-99a-5p, miRNA-100-5p, and 
miRNA-373-5p were significantly lower in OPS compared to NOPC. (B) the expression 
of miRNA-196b-3p, miRNA-1260 and miRNA-1290 were significantly higher in OPS 
compared to NOPC. box-and-whisker plots showed the expression of miRNA in non-
osteoporotic, osteopenia and osteoporosis groups. p values were calculated using one-way 
ANOVA. Box plots showing 25th, 50th, and 75th percentiles (horizontal bars) and 
minimum to maximum ranges (error bars). 
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4.2.4.3 mRNA/miRNAs Associated with Low BMD 
Pearson correlation coefficient between relative expression level and lumber spine 
(L2-L4) T-score was calculated and tested. This was performed to verify if the levels of 
any particular mRNAs/miRNA correlated with the T-score in all the PBMC samples. 
Linear regression was run on each mRNA expression and T-score level to obtain the 
T-score correlated gene lists.  
The correlation analysis revealed that the levels of CTSZ and GSDMD mRNAs in 
the PBMC samples significantly correlated inversely with participants’ T-scores (Figure 
4-16A, p = 0.0002 and 0.022, respectively). No other mRNA expression showed any 
significant association with the level of the T-score (Table 4-5). Therefore, the 
decreased level of only CTSZ and GSDMD indicates that they are associated with the 
reduction in bone density with osteoporosis. 
The correlation analysis also demonstrated that the level of hsa-miR-100-5p, 
hsa-miR-196b-3p and has-miR-1290 expression in PBMC samples was significantly 
associated with the level of the T-score as illustrated in Figure 4-16B, (p value = 
0.035, 0.0004, and 0.047). However, the other miRNAs did not show any significant 
correlation between the expression level of miRNA in the PBMC of participants and 
their T-score. Although dysregulation of miR-100-5p and miR-196b-3p showed a 
significant correlation with the participants’ T-score, they are not correlated with the 
progression of the osteoporosis. Therefore, the decreased level of only miR-1290 is 
suggested to be associated with the development of osteoporosis.  
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Figure 4-16: T-score-associated mRNAs/miRNAs expression in PBMC samples  
Regression line showing the correlation between (A) mRNA and (B) miRNAs 
expression level and T-Score Lumbar Spine (L2-L4) in female participants. The black 
line denote the regression lines for samples and the 2 dots lines represent the 95% CI. 
Only those mRNA/miRNAs showing significant correlations are shown 
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Table 4-5:Correlation of mRNAs/miRNAs expression and participants’ T-
score  
mRNAs/miRNAs Pearson r P value 
ANXA1 -0.084 0.45 
CTSZ -0.4 0.0002 
VIM -0.013 0.91 
TMEM64 -0.019 0.86 
TRIM37 -0.152 0.17 
TGFΒI -0.133 0.23 
TRAM2 -0.202 0.065 
GSDMD -0.249 0.022 
NFKBIA -0.078 0.48 
S100A4 0.032 0.77 
XBP1 0.038 0.73 
miR-373-5p 0.168 0.127 
miR-100-5p 0.264 0.016 
miR-4516 -0.068 0.538 
miR-99a-5p 0.160 0.146 
miR-196b-3p -0.376 0.0004 
miR-1260 -0.204 0.062 
miR-1290 -0.272 0.013 
Pearson-r value in the title represents the Pearson correlation coefficient 
between gene expression and BMD level across all samples 
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4.2.4.4 Diagnostic Value of mRNAs/miRNAs in Osteoporosis 
AUC is the area under the receiver operating characteristic (ROC) curve. It is a 
graphical plot that provides the reflection of how good a test is at distinguishing 
between patients with disease and those without disease (Zweig and Campbell, 1993, 
Akobeng, 2007). There are 4 possible categories that describe the AUC values. A test 
with an area greater than 0.9 has high accuracy, while 0.7–0.9 indicates moderate 
accuracy, 0.5–0.7, shows low accuracy and <0.5 indicates a poor accuracy (Akobeng, 
2007). To assess the potential diagnostic value of the significantly regulated 
mRNAs/miRNAs, a ROC curve analysis was performed for the relative expression of 
the all mRNAs/miRNAs tested in the participants’ PBMC. The associated AUC was 
used to confirm the diagnostic value of each mRNA/miRNA. The results are 
summarized in Figure 4-17A-E and Table 4-6. The sensitivity and specificity 
associated with the optimal cut‐off points are shown also in Table 4-6. 
The AUC discrimination was significantly separated for mRNAs CTSZ, IFI16, 
TMEM64, TRAM2, and GSDMD. All of these five-discrimination displayed the 
moderate accuracy. The diagnostic value for TRAM2 and CTSZ in clinical samples 
for osteoporosis patient was 0.866 and 0.806 respectively, with p value of 0.0002 and 
0.002, respectively. The sensitivity and specificity of TRAM2 were 86, 80 % 
respectively. However, the specificity was highest in CTSZ at 90% but the sensitivity 
was lower at 74%. Although the AUC of TMEM64 and GSDMD were significantly 
discriminatory, their specificity was very low, 60 and 50 % respectively. Therefore, 
the result suggests that only CTSZ has diagnostic value for osteoporosis. 
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The ROC curve analysis indicates that the level of hsa-miR-196b-3p might be a 
potential biomarker for distinguishing osteoporosis participants from non-osteoporotic 
participants’, AUC = 0.853, p = 0.0003. The sensitivity and specificity of discriminating 
hsa-miR-196b-3p in PBMC samples were 78% and 80% respectively. However, the rest 
of the mRNA/miRNA levels were not significantly separated and had a low accuracy 
rate. Thus, the result suggests that only hsa-miR-196b-3p might have a diagnostic 
value for osteoporosis. 
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Figure 4-17: ROC curves of mRNAs/miRNA for osteoporosis. 
ROC curves generated from the logarithmically transformed relative expression of 
these mRNAs/miRNA from the participants’ PBMCs tested. the result showed AUC 
corresponding to at least moderate accuracy. 
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Table 4-6: Diagnostic value of mRNAs/miRNAs for Osteoporosis 
mRNAs/miRNAs 
Area 
Under 
Curve 
95% 
Confidence 
Interval 
p 
value 
Sensitivity Specificity Accuracy 
Lower 
Bound 
Upper 
Bound 
ANXA1 0.659 0.463 0.855 0.105 85% 60% low 
CTSZ 0.806 0.714 0.898 0.002 74% 90% moderate 
VIM 0.647 0.517 0.778 0.132 69% 60% low 
IFI16 0.763 0.668 0.858 0.007 72% 90% moderate 
TMEM64 0.730 0.563 0.896 0.019 86% 60% moderate 
TRIM37 0.518 0.375 0.660 0.857 50% 50% low 
TGFΒI 0.614 0.447 0.780 0.246 69% 70% low 
TRAM2 0.866 0.770 0.961 0.0002 86% 80% moderate 
GSDMD 0.791 0.625 0.956 0.003 88% 50% moderate 
KRT8 0.616 0.425 0.806 0.238 59% 80% low 
NFKBIA 0.517 0.381 0.653 0.863 49% 70% low 
S100A4 0.497 0.342 0.652 0.972 51% 70% poor 
XBP1 0.401 0.263 0.538 0.310 45% 50% poor 
RUNX2 0.649 0.531 0.766 0.129 57% 70% low 
miR-373-5p 0.685 0.558 0.812 0.058 57% 90% low 
miR-100-5p 0.444 0.273 0.615 0.567 45% 50% poor 
miR-4516 0.640 0.477 0.802 0.153 73% 50% low 
miR-99a-5p 0.604 0.378 0.830 0.288 66% 60% low 
miR-196b-3p 0.853 0.731 0.975 0.0003 78% 80% moderate 
miR-1260 0.586 0.386 0.787 0.377 58% 50% low 
miR-1290 0.555 0.374 0.736 0.576 64% 50% low 
Data were evaluated via a cut‐off point which jointly maximises both 
sensitivity and specificity. Bold data showed the significant AUC 
discriminated.   
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4.3. Discussion 
In this chapter, a panel of differentially expressed mRNA/miRNAs identified by 
RNA sequencing in Chapter 3 were analysed using cultured osteosarcoma cells and 
clinical samples by RT-qPCR. This was in an attempt to identify candidate 
mRNAs/miRNAs associated with osteoporosis patients.  
Transmembrane Associated Membrane Protein 2 (TRAM2) is an estradiol-
responsive protein in human fetal osteoblast cells based on case-cohort genome-wide 
association study (GWAS). TRAM2 suppression changed the expression of genes in 
pathways associated with osteoporosis risk and/or bone biology such as RANK-
RANKL-OPG (Liu et al., 2014a). It has been shown to be a key activator of alpha1(I) 
collagen promoter; a downstream target of the master osteoblast differentiation factor 
RUNX2 (Pregizer et al., 2007). In concordance with reported findings, our data 
confirmed its response to -estradiol in the three osteosarcoma cells and showed a 
significant increase in TRAM2 mRNA expression in postmenopausal osteoporosis 
through osteopenia as opposed to the non-osteoporotic group (P = 0.016). Also, TRAM2 
exhibited the strongest AUC discrimination at 0.866, with 86% and 80% sensitivity and 
specificity, respectively.  
Transmembrane protein (TMEM64) is a positive regulator of osteoclast formation 
in mice bone marrow macrophages (BMMs). Knockdown of TMEM64 blunted the 
activity of osteoclast differentiation markers NFATc1, OSCAR, CTSK and 
PPARGC1B, and RANKL. Consistently, cells overexpressing TMEM64 showed a 
significant reduction in osteogenic markers including ALP, OCN, COLLA, OSX, and 
RUNX2 (Kim et al., 2013, Jeong et al., 2015). The expression pattern of TMEM64 
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mRNA PBMCs obtained from osteoporosis patients, as opposed to control PBMCs, 
revealed a dramatic increase with a p-value of 0.0006. Moreover, the accuracy of the 
diagnostic potential TMEM64 mRNA levels stands at an AUC value of 0.730 and a p-
value of 0.019, which further corroborates previous findings that identify TMEM64 as a 
negative osteogenic protein.     
Annexin A1 (ANXA1) mRNA displayed as an β-estradiol responsive gene by 
increasing the expression in Mg-63 by 3.30-fold and decreasing in TE-85 by -5.04-fold 
once treating with 1 nM and compare the expression against that non-treating control. 
The expression of ANXA1 mRNA in PBMCs was significantly decreased compared to 
non-osteoporotic female participants’ (p = 0.029, Figure 4-14A). Several studies 
demonstrated the anti-inflammatory effects of Annexin 1 (ANXA 1), a calcium-
dependent phospholipid-linked protein (Serhan et al., 2008, Vago et al., 2012, Lim and 
Pervaiz, 2007). Particularly, ANXA1 silencing reduces the rate of osteoclast formation 
in both arthritis and monocyte-derived human macrophages by promoting IL-6 release 
(Kao et al., 2014). Furthermore, ANXA1 has been shown to play a key role in bone 
formation in rat osteoblasts in primary cell cultures. ANXA1 enhances PTH-mediated 
cAMP stimulation by binding calcium ions that act as a second messenger relaying the 
PTH signal intracellularly (Suarez et al., 1993). In accordance with published work, our 
results detected reduced expression of ANXA1 in postmenopausal osteoporosis 
compared to non-osteoporotic participans’. This is in full agreement with the reported 
role of ANXA1 favoring osteoclast formation.  
ANXA1 has been identified as a target for regulatory miRNAs 196a and 196b, 
with inversely proportional expression levels detected in a variety of cancer cell lines, in 
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4 cells line of each esophageal, breast, and endometrial origin (Luthra et al., 2008). 
Similar correlation was also found in 10 esophgeal adenocarcinoma cell line and the data 
of paired normal/tumor tissues from additional 10 patients (Luthra et al., 2008). 
Investigations here revealed that the expression levels of ANXA1 and has-miRNA-
196b-3p are inversely proportional in PBMCs, osteosarcoma cells, and MCF-7 cell line. 
This further confirms that ANXA1 is inversely correlated with has-miRNA-196b-3p. 
Also, two studies found that miRNA 196a inversely regulate the proliferation in human 
adipose-derived stem cells (hASCs); which are bone marrow-derived mesenchymal stem 
cells and subsequently differentiate into osteoblast (Gir et al., 2012, Kim et al., 2009). 
This may correlate with this study where miRNA-196b-3p level were higher in 
osteoporosis PBMC cells which result in increased osteoclast activity. Also, as miRNA-
100-5p is a predicted to target ANXA1, for the first time, the data confirmed that the 
level of miRNA-100-5p is correlated with that in ANXA1 in the PBMCs samples which 
is lower in osteoporosis compared to that in non-osteoporotic and osteopenia samples. 
miR-100 was significantly response to β-estradiol with a higher level in Mg-63 
cells compared to TE-85, Saos-2, and MCF-7 compared to the control of each cell. Also, 
female osteoporosis patients had significantly lower PBMC miR-100-5p expression 
levels in comparison with control samples (p = 0.0002), which also correlated with the 
patients’ T-score. The study by Zeng (2012) and colleagues revealed a revers association 
between miR‐100 and osteogenic differentiation through its target gene BMPR2 in 
human adipose-derived mesenchymal stem cells (hASCs) in vitro (Zeng et al., 2012). 
Also, there was a significant upregulation of miR-100 expression in serum and bone 
tissue of osteoporotic patients compared with non-osteoporotic fracture (Seeliger et al., 
2014). These results suggest that an increase in miRNA-100 expression in mature or 
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precursor osteoblasts, or a decrease in osteoclast precursors may be a hallmark of 
osteoporosis. This is mediated through either blunting osteoblast differentiation or 
promoting osteoclast differentiation. Therefore, taken together, the increase of miRNA-
100 expression in mature or precursor osteoblasts, or a decrease in osteoclast precursors 
may cause bone loss and osteoporosis either by increase the osteoclast differentiation or 
decrease the osteoblast differentiation.  
Consistent with miR-100 expression patterns, The RT-qPCR data showed miR-99a 
was significantly upregulated in Mg-63 cells. Also, it showed that significant  
downregulation of miR-99a-5p expression in PBMC of the osteoporotic samples 
compared to the non-osteoporotic samples, although the accuracy of the distribution was 
low, AUC = 0.604. Franceschetti et al. (2014) reported that microRNA-99b and 
microRNA-365 are highly increased during osteoclastogenesis. Transfection-mediated 
inhibition of miR-99b led to diminished size and number of osteoclasts, indicating an 
indispensable role of miR-99b in osteoclast formation (Franceschetti et al., 2014). 
Altogether, our results strongly suggest that, disregarding subspecies variation, miR-99 
may be involved in osteoclast formation. 
Cathepsins are a family of serine, cysteine, and aspartyl protease enzymes 
involved in cell turnover (Santamaria et al., 1998). Members of the family have been 
implicated in number of pathologies including cancer, neurodegenerative disorders, and 
arthritis (Santamaria et al., 1998, Mohamed and Sloane, 2006). Of particular relevance 
to our studies, the association of cathepsins with bone remodelling in osteoclasts has 
been established (Holzer et al., 2005, Lang et al., 2004, Han et al., 2009, Wilson et al., 
2009).  
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Furthermore, the role of CTSZ in bone disease has not been sufficiently investigated 
until recently. Staudt et al. (2010) reported that CTSZ secretion is detected in primary 
osteoblasts and osteoblastic cell lines CAL72 and Mg-63 (Staudt et al., 2010). In 
agreement with previous studies, we show here that the expression level of CTSZ is 
inversely proportional to the maturity of cultured osteosarcoma cells, (Figure 4-3). T he 
in alltreatment estradiol disregulated uponthat CTSZ is  qPCR data also showed-RT 
7 cells-three groups of osteosarcoma and MCF  as compared to untreated controls of each 
cell type.CTSZ mRNA expression in PBMC samples was significantly upregulated in 
osteopenia and postmenopausal osteoporosis in comparison to non-osteoporotic 
participants’ (p = 0.0011, Figure 4-14) . Moreover, a significant correlation was detected 
between CTSZ mRNA expression levels in PBMCs and the participants’ T-score (p = 
0.0002). As evidenced by an AUC value of 0.806, CTSZ was among the strongest 
diagnostic value through AUC discrimination measurment with sensitivity of 74% and 
specificity of 90%. 
Altogether, it was possible to show that mRNAs/miRNA are associated with the 
pathogenesis of osteoporosis and may play important roles in the detection and 
classification of osteoporotic diseases. Some of the identified mRNA/miRNA showed 
significant difference in distinguishing between non-osteoporotic and osteoporotic 
female patients. However, it should be pointed out that more studies are necessary to 
further investigate biological role of the mRNA/miRNA in the bone cells. Similarly, the 
data here suggest an integral role played by CTSZ in bone resorption. This is 
accomplished by inducing osteoclastic differentiation of PBMCs, possibly through 
promoting their transendothelial migration. Hence, manipulating CTSZ-mediated 
activation of PBMCs may be a promising target for drug development. In order to 
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achieve that, the biological role of CTSZ in osteosarcoma cells will be investigated as 
describe in the next chapter. 
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5 Chapter 5: The Role of Cathepsin Z in 
Osteosarcoma Cells
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5.1. Introduction  
Human cathepsin Z (CTSZ) (also known as cathepsin X, CTSX, and cathepsin P, 
CTSP) is a lysosomal cysteine proteinase and member of the cathepsin protease family 
(Santamaria et al., 1998), which includes other cysteine cathepsins, namely cathepsins 
B, C, F, H, K, L, O, S, V, W and Z (Santamaria et al., 1998). CTSZ protein exhibits both 
carboxy-monopeptidase and carboxy-dipeptidase activities and are found in all animals 
as well as other organisms (Santamaria et al., 1998). Some of these cathepsins are 
expressed highly in specific cell types such as CTSK in osteoclasts and CTSS in 
immune cells (Mohamed and Sloane, 2006). The cysteine cathepsin proteases function 
predominantly as intracellular endopeptidases in endolysosomal vesicles (Mohamed and 
Sloane, 2006), where most become activated in the acidic environment of the lysosome 
(Jedeszko and Sloane, 2004).  Cathepsin also function extracellularly through the 
degradation of the extracellular matrix such as cathepsin K which is the major 
therapeutic target for osteoporosis (Fonovic and Turk, 2014). The organic bone matrix is 
degraded by not only cathepsin K, but also by matrix metalloproteinases or other 
cathepsins (Goto et al., 2003)  
The expression of CTSX was found in monocytes, macrophages and dendritic 
cells (Kos et al., 2005) and in tumour cells of prostate (Nägler et al., 2004),  gastric 
carcinoma (Buhling et al., 2004), and in aging mouse brain cells, glial cells and was also 
reported in patients with Alzheimer disease (Wendt et al., 2007). CTSX enzyme was 
found to be secreted from non-hematopoietic bone marrow cells and found 
predominantly on the surface of primary human osteoblasts (Staudt et al., 2010) but the 
biological function of CTSZ remains unknown. The expression of cathepsins B, L and X 
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were downregulated during differentiation of myeloid-derived suppressor cells 
(MDSCs) from macrophage to osteoclast in mice bearing highly metastatic tumours 
which might inhibit osteoclastogenesis by decreasing the fusion of osteoclast precursor 
through cleavage of proteins needed for membrane fusion (Edgington-Mitchell et al., 
2015).  
In Chapter 4, the expression of cathepsin Z mRNA (CTSZ) was found to be 
decreased based on the maturity level of the cultured cells. Expression of CTSZ mRNA 
was also found to be significantly upregulated in PBMC isolated from clinical 
specimens from osteopaenia and postmenopausal osteoporosis patients compared to 
specimens from non-osteoporotic control. The expression of CTSZ mRNA was shown 
to be significantly correlated with T-score of the participants. ROC analysis of the CTSZ 
were among the highest sensitivity and specificity of the regulated genes tested on the 
PBMCs of female non-osteoporotic, osteopenia and osteoporosis postmenopausal 
participants’ samples. Thus, it is important to find out the biological role of CTSZ that 
might be related to the development of osteopenia/osteoporosis. The aim of this chapter 
is to understand the biological role of CTSZ in which will be approached by: 
• Finding out whether the cultured osteosarcoma cells produce CTSZ protein. 
• Suppressing the expression of CTSZ by RNA interference in cultured 
osteosarcoma cells.  
• Investigating the consequential effect of CTSZ suppression on the proliferation, 
migration, and invasion of cultured osteosarcoma cells. 
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5.2. Result 
5.2.1 Detection of Cathepsin Z protein in the Cultured 
Osteosarcoma Cells 
In Chapter 4, RT-qPCR results showed that the levels of CTSZ mRNA exhibited 
an inverse relationship with increasing maturity of osteosarcoma cells. i.e. the levels of 
CTSZ mRNA were the highest in Mg-63 cells, but lowest in Saos2, while the levels of 
CTSZ in TE-85 was between that in Mg-63 and Saos2 cells (Chapter 4, Section 0). 
In this chapter, initially, the protein levels of CTSZ in the cultured osteosarcoma 
cells and MCF-7 are determined by western blot using antibodies for CTSZ (R&D 
System, UK). β-actin antibody was used as a housekeeping control to standardise 
between samples (Figure 5-1). A single 34 kDa band corresponding to the molecular 
weight of CTSZ (Pecar Fonovic and Kos, 2015), was detected in the Mg-63 and TE-85 
cells, but was undetectable in the Saos-2 and MCF-7 cells. Quantitative analysis showed 
that the level of CTSZ protein in Mg-63 was 3.8 times higher than that in the TE-85. 
These results are consistent with the relative levels of CTSZ mRNA in the Mg-63 and 
TE-85 cell lines (Chapter 4, Section 4.2.1). The detection of low levels of CTSZ mRNA 
in the Saos-2 and MCF-7 cells, but no protein detection, arises for the better sensitivity 
of RT-qPCR over western blotting. Mg-63 and TE-85 cells were used for the 
suppression of CTSZ protein. 
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Figure 5-1: Detection of CTSZ protein in the cultured osteosarcoma cells 
and MCF-7. 
(A) Representative western blot analysis of CTSZ protein levels in cell 
lines. CTSZ was detected in only the Mg-63 and TE-85 at 34 KDa. 
However, CTSZ protein was not identified in Saos-2 and MCF-7. β-Actin 
was used as an internal control. (B) Densitometric analysis of CTSZ 
protein levels in Mg-63 and TE-85 was calculated. The expression of 
CTSZ protein in the Mg-63 cells was 3.8 times more than in the TE-8 
cells. Each bar represents the mean ±SD (n=3).  
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5.2.2 Suppression of Cathepsin Z Expression by RNA 
Interference 
5.2.2.1 SiRNA probes for Cathepsin Z 
The full-length cDNA sequence of CTSZ and protein sequence are shown in (Figure 
5-2). Small-interfering RNA (siRNA) was used to knockdown CTSZ mRNA level in 
Mg-63 and TE-85 cells in order to assess whether suppression of CTSZ mRNA 
expression can inhibit CTSZ protein in the Mg-63 and TE-85 cells. 4 target positions on 
the CTSZ cDNA were selected as highlighted in Figure 5-3 and Table 5-1.  
siRNA 1 (CAGATACAACCTTGCCATCGA) located between 984 and 1004, 
siRNAi 2 (ATCGAGGAGCACTGTACATTT) located between 1000 and 1020, siRNAi 
3 (TCGGATCAACATCAAGAGGAA) located between 435 and 455 and lastly siRNA 
4 (ACCGGAGGCATCTATGCCGAA) located between 802 and 922. Silencer® 
Negative Control (Ambion, Inc., USA) was used to check for off-target effects or 
toxicity of transfection reagents or of the siRNA itself.  
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Figure 5-2: Full-length mRNA sequence of CTSZ 
The figure showed the full-length cDNA sequence, the accession number 
is NM_001336.3. The gray highlighted nucleotide showed the CDS, 
between 127-1038. 6 exons showed with different colours as well as 4 
siRNAs used in this study 
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Table 5-1: List of siRNA primer sequences used 
siRNA  Target 
Gene  
Target sequence Company Catalog no. 
siRNA 1 
CTSZ 
CAGATACAACCTTGCCATCGA Qiagen SI03064495 
siRNA 2 ATCGAGGAGCACTGTACATTT Qiagen SI03048087 
siRNA 3 TCGGATCAACATCAAGAGGAA Qiagen SI00025536 
siRNA 4 ACCGGAGGCATCTATGCCGAA Qiagen SI00025529 
 
 
 
Figure 5-3: Nucleotide sequences of CTSZ mRNA.  
4 siRNA sequences and their positions used in this study to supress CTSZ 
expression are coloured purple. 
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5.2.2.2 Test Time Course of siRNA Transfection on Osteosarcoma Cells 
Initial experiments were directed towards finding out whether incubation of the 
cells with transfection complexes for 24 or 48 h was necessary to achieve a reduction in 
CTSZ mRNA levels. Mg-63 cells were used for these experiments (Figure 5-4 and Table 
5-2). The expression of CTSZ on negative control, and siRNA-treated Mg-63 cells were 
compared with the expression of CTSZ on scrambled siRNA using one-way ANOVA. 
Quantitative analysis showed that the levels of CTSZ mRNA in scrambled control and 
Mg-63 treated with transfection reagent alone were similar to that in the parental Mg-63 
cells. For cells incubated with transfection reagent for only 24 h (Figure 5-4A), there 
was an insignificant decrease in expression of CTSZ mRNA when compare to the 
scrambled siRNA (p = 0.795). However, for cells treated with CTSZ siRNA 
oligonucleotides the expression of CTSZ mRNA was decreased by around 60 % when 
compared to the scramble siRNA (p = 0.0019, 0.002, 0.0013 and 0.0012 for siRNA 1, 2, 
3 and 4 respectively).  
After 48 h (Figure 5-4, B), the levels of CTSZ mRNA transfected with CTSZ-
siRNA were significantly reduced relative to the parental control (p = 0.008), but were 
not significantly different to the scrambled control (p >0.05) and the transfection 
reagents only (p >0.05), which were similarly reduced. This shows that after 48 h, the 
transfection reagent itself is causing a reduction in the expression of CTSZ mRNA and 
not the siRNA. Thus, 24 h was used in future siRNA experiments due to toxicity of 
transfection reagent after 48 h. 
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Figure 5-4: RT-qPCR results for Mg-63 cells treated with SiRNAs for 24 
and 48 h. 
CTSZ silencer and negative control were added to the confluent cells after 
which, cells were harvested after 24 (A) or 48 h (B). Relative expression 
of CTSZ mRNA was determined by 2-CT method, normalized to GAPDH. 
Each bar represents the mean ±SD (n=2). Negative controls and infected 
Mg-63 by CTSZ siRNAs were compared to the parental Mg-63 which was 
set as 100 using one-way ANOVA. 
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Table 5-2: RT-qPCR results for optimization the time course of the 
transfection reagent and siRNAs of CTSZ in Mg-63 for 24 and 48 h. 
Incubation 
time 
Dunnett's multiple 
comparisons test 
Mean Difference to 
the scrambled 
siRNA (%) 
P Value 
24 h 
Parental vs. Scramble 14.42 0.3418 
Reagent only vs. Scramble -12.08 0.7955 
siRNA1 vs. Scramble -57.04 0.0019 
siRNA2 vs. Scramble -56.23 0.0020 
siRNA3 vs. Scramble -60.81 0.0013 
siRNA4 vs. Scramble -61.05 0.0012 
48 h 
Parental vs. Scramble 55.99 0.0078 
Reagent only vs. Scramble -27.08 0.1833 
siRNA1 vs. Scramble -18.33 0.4717 
siRNA2 vs. Scramble -20.72 0.3703 
siRNA3 vs. Scramble -15.66 0.6025 
siRNA4 vs. Scramble 2.6 0.9997 
Cells infected with negative control and silencer CTSZ siRNAs were 
compared to the parental cells using one-way ANOVA, (Dunnett's multiple 
comparisons test). The mean difference was calculated by the percentage of 
decreased expression to the parental. 
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5.2.2.3 Effect of siRNA on the Level of CTSZ mRNA in Osteosarcoma 
Cell Line Mg-63 and TE-85 
To assess the extent of suppression of CTSZ mRNA in Mg-63 and TE-85 cells, 
mRNA was isolated from parental, transfected with scrambled siRNA and CTSZ-siRNA 
transfected Mg-63 and TE-85 cells, followed by revers transcription. The relative levels 
of CTSZ mRNAs were analysed by quantitative RT-qPCR using GAPDH as a housekeeping 
control, Figure 5-5 (A) for Mg-63 and Figure 5-5 (B) for TE-85.  
The results showed that the levels of CTSZ mRNA in Mg-63 cells transfected with 
scrambled control siRNA and treated with transfection reagent only were similar to that 
in the parental untreated Mg-63. However, the level of CTSZ mRNA was significantly 
reduced compared to scrambled control in all CTSZ-siRNAs (p < 0.0001) 54, 50.5, 49.5 
and 54.25 % in cells transfected with CTSZ-siRNA 1, 2, 3, or 4, respectively.   
Additionally, the level of CTSZ mRNA expression in TE-85 was significantly 
decreased in cells transfected with siRNAs 2 and 4 by 44.8 and 43.8% relative to the 
scrambled control cells (p = 0.02 and 0.022, respectively), but not significantly by 37 
and 40.9 % for SiRNAs 1 and 3 compared to the scrambled control (p= 0.055, and 0.06, 
respectively).  
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Figure 5-5: The effect of CTSZ mRNA suppression in Mg-63 and TE-85 
cells using CTSZ-siRNAs 
CTSZ silencer and control SiRNAs were added to confluent cells, after 
which the cells were harvested after 24 h. Data represent the relative 
expression of CTSZ determined by the relative Ct method normalized to 
GAPDH for Mg-63 (A) and TE-85 (B). Each bar represents the mean and 
±SD (n=3).  
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5.2.2.4 Effect of siRNA on the Level of CTSZ Protein in Osteosarcoma 
Cell Lines Mg-63 and TE-85. 
Since the CTSZ protein was only found in Mg-63 and TE-85 cells, the suppression 
of CTSZ protein was then measured in these cells. Western blot analysis of the 
knockdown CTSZ protein expression in Mg-63 cells is shown in Figure 5-6 and Table 
5-3, which summarizes the percentage changed statistically with the expression of CTSZ 
protein in the parental of Mg-63 set as 100.  
A single CTSZ band of 34 kDa was detected in parental Mg-63, negative controls, 
and CTSZ-siRNA transfected cells. The levels of CTSZ protein expression in CTSZ-
siRNAs transfected Mg-63 cells were reduced compared to the parental control cells 
(Figure 5-6 A). Densitometric analysis showed that the level of CTSZ protein in Mg-63 
cells treated with CTSZ-siRNA 1, 2, 3 and 4 was significantly reduced by 29 (p = 
0.0034), 34 (p = 0.001), 52 (p <0.0001) and 72 % (p <0.0001), respectively compared to 
the scrambled control (one-way ANOVA, Dunnett's multiple comparisons test). The 
negative controls using reagent-only showed a small non-significant 8% decrease in 
CTSZ protein level (p = 0.054) compared to scrambled control.  
The levels of CTSZ protein in scrambled control and TE-85 treated with 
transfection reagent alone were similar to that in the parental TE-85 cells, (Figure 5-7). 
The relative levels of CTSZ protein in TE-85 cells transfected with CTSZ-siRNA 2, 4, 1 
and 3 were decreased by 60.2, 49.2, 43.8 and 41.8 % respectively compared to that in 
the scrambled control. The most efficient suppression was achieved in TE-85 by siRNA-
2, up to 60 % (p = 0.0001) compared to scrambled control. Thus, Mg-63-CTSZ siRNA4 
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and TE-85-CTSZ-siRNA 2 showing the highest effect of the CTSZ suppression were 
used for the function tests. 
 
 
Figure 5-6: The effect of CTSZ-siRNA on the levels of CTSZ protein in 
Mg-63 cells. 
(A) Representative western blot analysis of CTSZ levels in Mg-63 
transfected with non-small interfering control or small interfering CTSZ. 
Cells were harvested after 24 h of treatment. β-Actin was used as an 
internal control. (B) Densitometric analysis of CTSZ protein levels in 
Parental or treated with CTSZ-siRNA. All experiments were repeated 
three times, and data are expressed as mean ± SD (n=3). ns= not 
significant, p value ** < 0.01, **** < 0.0001, = significant 
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Figure 5-7: CTSZ protein expression was decreased by siRNA knockdown 
in TE-85 cells. 
CTSZ protein expression was evaluated by (A) western blotting with 
lysates from cells that were treated with a 24 h transfection with siRNAs 
or negative control. (B) The relative intensities of the bands on the western 
blot were analyzed using Image lab Software. Columns indicate the ratio 
of CTSZ intensity to β-Actin intensity that was measured in three 
independent experiments. ns= not significant, p value *** < 0.001, **** < 
0.0001, = significant 
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Table 5-3: Suppression of CTSZ protein expression by siRNA knockdown in 
Mg-63 and TE-85 cells.  
Dunnett's multiple 
comparisons test 
Mean Difference to the 
Scramble cells (%) 
P Value 
Mg-63 
Parental vs. Scramble 10.5 0.4949 
Reagent only vs. Scramble -20.4 0.0502 
siRNA1 vs. Scramble -29.3 0.0046 
siRNA2 vs. Scramble -33.7 0.0014 
siRNA3 vs. Scramble -51.7 0.0001 
siRNA4 vs. Scramble -72.1 0.0001 
TE-85 
Parental vs. Scramble 11.2 0.5303 
Reagent only vs. Scramble -5.3 0.9578 
siRNA1 vs. Scramble -43.8 0.0003 
siRNA2 vs. Scramble -60.2 0.0001 
siRNA3 vs. Scramble -41.8 0.0005 
siRNA4 vs. Scramble -49.2 0.0001 
Each of cells transfected with negative control and silencer CTSZ siRNAs 
were compared to the scramble cells using one-way ANOVA (Dunnett's 
multiple comparisons test). The expression of CTSZ protein in untreated Mg-
63 and TE-85 was set as 100. The mean difference was calculated by the 
percentage of decreased expression compared to the scrambled control.  
  Chapter 5 
 
192 | P a g e  
 
5.2.3 Silencing of Cathepsin Z Inhibit the proliferation, 
Invasion, and Migration of Mg-63 and TE-85 
5.2.3.1 Effect of CTSZ-siRNAs on the Proliferation of Mg-63 and TE-
85 Cells 
The effect of CTSZ suppression on the proliferation of Mg-63 and TE-85 was 
assessed by MTT assay. A standard curve for each cell line was generated to correlate 
the optical density of formazan with the cell number as shown in Figure 5-8. Linear 
regression indicated a linear correlation (R2 for Mg-63 and TE-85 cells both 0.99) 
between absorbance signal, at 570 nm, and cell number ranging from 6.25×103 to 
2.5×105 cells in the volume of the assay. Thus, the values of absorbance at 570 nm 
showed a strong correlation with the number of cells seeded from that range. Then, 5000 
cells from parental, control and siRNAs transfected of Mg-63 and TE-85 cell line were 
seeded and the absorbance was measured over a 6-day period. The optical density values 
obtained from the plate reader were converted to cell numbers, which were extrapolated 
from the standard curve.  
Overall, growth rate of parental cells and transfectants displayed a very similar 
growth pattern (Figure 5-9). Statistical analysis using two-way ANOVA (Dunnett's 
multiple comparisons test) (Table 5-4) showed no significant difference at any time 
point, including day 6, between parental, reagent only and scrambled siRNA 
transfectants control for both Mg-63 and TE-85 (P>0.05). By the 4th day, cell numbers 
were significantly decreased by 44 % in Mg-63 treated with CTSZ-siRNA4 (P= 0.0034).  
On the 5th day, the cell number was significantly reduced for those cells treated with 
CTSZ-siRNA 4, 2, 3 and 1 by 36, 33, 30 and 23 %, respectively, compared to the 
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scrambled siRNA control. By day 6, the Mg-64 cells expressing the 4 siRNAs all 
showed a significant decrease in the cell number (Table 5-4) with Mg-64-CTSZ-siRNA4 
showing the greatest inhibitory effect on growth rate of 40%.  SiRNA 4 was the most 
effective siRNA at reducing CTSZ levels (72% reduction). 
Transfectant TE-85 with all CTSZ-siRNAs showed a significant decrease in cell 
number starting from day 4, and by day 6 cell numbers were decreased by 45, 25, 20% 
and 20% for CTSZ-siRNA 2, 4, 1 and 3 transfected cells, respectively (p = 0.0001). In 
this case, siRNA 2 was also the most effective at reducing the growth rate.  In TE-85 
cells, siRNA2 was the most effective at reducing the level of CTSZ protein, thus in both 
Mg-63 and TE-85 cells, reduction of CTSZ protein is associated with a significant 
reduction in growth rate. This interpretation is strengthened by the observation that plots 
of % reduction in CTSZ protein and reduction in growth rate showed a linear 
relationship, with R2 values for Mg-63 and TE-85 of 0.78 and 0.96, respectively (Table 
5-4). 
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Figure 5-8: The relationship between colour development and cell number 
in the MTT assay of cell growth of Mg-63 and TE-85 cells. 
Using linearity, standard curves were established for Mg-63 cells (A) and 
TE-85 cells (B) as described in Materials and Methods. The curve equation 
and regression of each standard curve is presented on the diagrams. Each 
point represents mean ±SD (n=3). 
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Figure 5-9: the impact of CTSZ suppression on the proliferation rate of 
transfectant cells. 
The growth rate of untransfected parental, scrambled and CTSZ-siRNAs 
transfectants of Mg-63 (A) and TE-85 (B) cells during a 6- day 
experimental period and samples subjected to MTT assay. The cell count 
for each sample was determined from a calibration curve. Data showed as 
mean ±SD (n=3).   
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Table 5-4: The effect of suppressed CTSZ on the growth rate of Mg-63 and 
TE-85 at the end points of proliferation assay 
 Mg-63 TE-85 
Dunnett's multiple 
comparisons test 
Changes to 
parental 
(%) 
P value 
Changes 
to 
parental 
(%) 
P value 
Parental vs. Scrambled -8 0.6 0 0.99 
Reagent only vs. 
Scrambled 4 0.98 3 0.94 
siRNA1 vs. Scrambled 12 0.04 20 0.0005 
siRNA2 vs. Scrambled 21 0.007 45 0.0001 
siRNA3 vs. Scrambled 18 0.04 20 0.0004 
siRNA4 vs. Scrambled 40 0.0001 25 0.0001 
The percentage of cell counts on day 6 is shown compared to the scrambled 
control. P values were obtained by two-way ANOVA (Dunnett's multiple 
comparisons test). 
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5.2.3.2 Effect of CTSZ-siRNAs on the Invasion of Mg-63 and TE-85 
Cells through Matrigel. 
The impact of CTSZ -siRNAs on invasiveness of osteosarcoma cells Mg-63 and 
TE-85 was assessed by a transwell chemotactic invasion assay using a BD BioCoatTM 
MatrigelTM. The invaded cells were counted in four random fields using light 
microscope at 400 × magnification as shown in Figure 5-10. One-way ANOVA (with 
post hoc Dunnett's multiple comparisons test) was used to compare the mean of the 
transfectant cells with the scrambled control while parental cells were set as 100 as 
shown in Figure 5-11 and Table 5-5.  
The invasion of parental Mg-63 cells and transfection reagent-only cells have 
similar penetration rates (P = 0.81 and 0.44, respectively compared to scramble). Cell 
transfected with CTSZ-siRNA showed a decreased rate of invasiveness compare to the 
scrambled siRNA (P = 0.0001). The maximum depletion of invasion among the CTSZ-
siRNAs was by siRNA-4 at 69.9 % (p = 0.0001). The second highest reduction was 
shown in CTSZ-siRNA-2 with 63.6 % (p = 0.0001). While CTSZ-siRNA-3 and 1 
showed lower but still significant reductions in the rates of invasion of 58.6 and 57.6 % 
(p value of both = 0.0001). 
The penetration rate of parental TE-85 cells and transfection reagent-only cells 
showed the same rate of invasiveness once compared to the scrambled siRNA (P = 0.998 
and 0.94, respectively). TE-85 transfected with CTSZ-siRNAs showed a significant 
reduction in the rate of invasiveness compared to that in the scrambled. The highest 
reduction was revealed to be in CTSZ-siRNA-2 by 65.1 % (P= 0.0001). The second 
highest reduction was shown in CTSZ-siRNA-3 by 43.2 % (P= 0.0001), While CTSZ-
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siRNA-1 and 4 showed significantly lower rates of the invasion of 26 and 21 %, 
respectively, P= 0.0014 and 0.011, respectively. Overall, the invasion of cells was 
decreased when the level of CTSZ was reduced.  
Table 5-5: The impact of CTSZ silencing on invasion rates of Mg-63 and TE-
85 cells. 
Cell 
line 
Dunnett's multiple 
comparisons test 
The difference rate of the 
invasion mean compared 
to scramble 
P Value 
Mg-63 
Parental vs. Scramble 4.91 0.8126 
Reagent only vs. Scramble -7.388 0.4395 
siRNA1 vs. Scramble -57.64 0.0001 
siRNA2 vs. Scramble -63.55 0.0001 
siRNA3 vs. Scramble -58.62 0.0001 
siRNA4 vs. Scramble -69.95 0.0001 
negative vs. Scramble -90.15 0.0001 
TE-85 
Parental vs. Scramble 2.617 0.9977 
Reagent only vs. Scramble -5.183 0.9410 
siRNA1 vs. Scramble -26.03 0.0014 
siRNA2 vs. Scramble -65.08 0.0001 
siRNA3 vs. Scramble -43.22 0.0001 
siRNA4 vs. Scramble -21.35 0.0110 
negative vs. Scramble -90.08 0.0001 
The mean difference is the percentage of cells invaded compared to the 
parental cells and analysed statistically using one-way ANOVA, (Dunnett's 
multiple comparisons test). Results were obtained from two separate 
experiments. 
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Figure 5-10: Suppression of Cathepsin Z inhibits the invasion of (A) Mg-63 
and (B) TE-85 cell line. 
Cell invasion were tested using MatrigelTM Invasion Chambers. 
a,b,c,d,e,f,g and h represent Parental cells, Scramble, Reagent only, 
siRNA1, siRNA2, siRNA3, siRNA4 and negative control respectively. 
Cells in siCTSZ group showed a much lower penetration rate than cells in 
Parental or the scrambled control. Cells were counted with a microscope at 
magnification X400 from 4 different fields in 2 experiments.   
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Figure 5-11:Suppression of Cathepsin Z partially inhibits the invasion of 
(A) Mg-63 and (B) TE-85 cell lines. 
Cell invasion were tested using MatrigelTM Invasion Chambers. Cells in 
the siCTSZ group showed a much lower penetration rate than cell in 
parental or control cells and importantly the scrambled control. Bars 
represent mean and ± SD of 4 high power fields (n=2). Serum-free medium 
in the lower chamber was set up as negative control for each cell line. 
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5.2.3.3 Effect of CTSZ-SiRNAs on the Migration of Mg-63 and TE-85 
Cells. 
To evaluate the functional effect of CTSZ knockdown on the migration of the 
cells, wound healing assays were performed. The migration of the cells, on the two 
edges of the scratch, were monitored for 72 h or until cell-cell contact was reached the 
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scratch wound was closed as shown in Figure 5-12 and 
 
Figure 5-13. Two-way ANOVA (Dunnett's multiple comparisons test) was used to 
assess the migration rate for the three-time points, 0, 24 and 48 h, and compared to the 
mean of the scrambled control width as shown in Figure 5-14 and Table 5-6.  
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The results showed that transfectants with any of the four CTSZ-siRNAs did not 
exhibit any significant difference in wound closure when compared to the scrambled 
control in 24 h either in Mg-63 or TE-85 cells (All P > 0.05).  
 On the other hand, after 48 h, silencing of CTSZ in Mg-63 with any of the four 
siRNAs showed significant reductions in the rate of migration over 48 h compared with 
the scrambled siRNA control. The migration of cells with siRNA-4, which had the 
lowest level of CTSZ, displayed the highest unclosed width of 82 % (p <0.0001) 
compared to the scrambled control. It also showed that the migration of cells transfected 
with CTSZ-siRNA-2 has the second highest unclosed width of 78 % (p < 0.0001). 63 
and 42.3% of the migration rate were shown in Mg-63 with siRNA1 and 3 with p values 
of 0.0001 and 0.0017, respectively.  
TE-85 cells transfected with CTSZ-siRNAs exhibited a significantly reduced 
migration rate over 48 h compared with scrambled control. The highest significant 
migration rate was in cells suppressed by CTSZ-siRNA-2 by 23.9 % (p = 0.0015). 
Furthermore, the migration rate showed a significant decreased in TE-85 with siRNA3, 
1 and 4 (p = 0.0047, 0.011 and 0.0135, respectively). Overall, the migration of cells was 
decreased with reduced level of CTSZ. 
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Figure 5-12: In vitro scratch wound healing assay of Mg-63 cells after 
silencing CTSZ expression  
Representative images of wound healing with control and different 
transfectants in 0, 24, 48 and72 h after the transfection of siRNA Mg-63. 
Cells were wounded and monitored with microscope every 24 h. Images 
were captured using a 4x objective lens, were photographed with an 
ToupTek ToupView and the width of the wound between the two edges 
was measured in triplicate using Image J software. 
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Figure 5-13: In vitro scratch wound healing assay of TE-85 cells after 
silencing CTSZ expression  
Representative images of wound healing with control and different 
transfectants in 0, 24, 48 and72 h after the transfection of siRNA TE-85 
cells. Cells were wounded and monitored with microscope every 24 h. 
Images were captured using a 4x objective lens, were photographed with 
an ToupTek ToupView and the width of the wound between the two edges 
was measured in triplicate using Image J software.  
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Table 5-6: The impact of CTSZ silencing on migration rates of transfected 
Mg-63 and TE-85 at 48 h. 
The mean difference is the distance percentage change compared to the 
scrambled control and analysed using two-way ANOVA, (Dunnett's multiple 
comparisons test) to yield P values. Results were obtained from three 
separate experiments. 
  
 Dunnett's multiple 
comparisons test 
Mean difference to 
the scrambled 
control (%) 
P Value 
Mg-63 
Parental vs. Scrambled 2.56 0.9996 
Reagent only vs. Scrambled 23.53 0.1469 
siRNA1 vs. Scrambled 62.82 0.0001 
siRNA2 vs. Scrambled 78.40 0.0001 
siRNA3 vs. Scrambled 42.31 0.0017 
siRNA4 vs. Scrambled 81.86 0.0001 
TE-85 
Parental vs. Scrambled 2.54 0.9957 
Reagent only vs. Scrambled -1.3 0.9997 
siRNA1 vs. Scrambled 19.76 0.0109 
siRNA2 vs. Scrambled 23.94 0.0015 
siRNA3 vs. Scrambled 21.60 0.0047 
siRNA4 vs. Scrambled 19.27 0.0135 
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Figure 5-14: The Effect of siRNAs Directed at CTSZ mRNA on the closure 
of the wound in a scratch wound healing assay using Mg-63 (A) or TE-85 
(B) cells. 
The mean difference is the distance in micrometre change throughout 48 h. 
The bars show the width of the scratch width of the wound of parental, and 
Transfectant cells after 0, 24 h and 48h of incubation and by 72 h the 
closure of the wound was completely stop. Data are presented as mean ± 
SD (n=3).   
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5.3. Discussion 
CTSZ mRNA was found to be expressed in the cultured osteosarcoma cells and its 
functional tests were investigated in vitro. Mg-63, TE-85 and Saos-2 represent 
immature, moderately mature and mature osteoblast cells respectively (Pacheco-Pantoja 
et al., 2011). The RT-qPCR results indicate that CTSZ mRNA expression was inversely 
decreased with the maturation level of osteosarcoma cells. This suggest that CTSZ could 
be secreted from different cells (Kos et al., 2005, Nägler et al., 2004, Buhling et al., 
2004, Wendt et al., 2007). The expression of CTSZ mRNA and protein were consistent 
with each other in Mg-63 and TE-85. However, in Saos-2 cells, CTSZ mRNA was only 
expressed at a low amount but its protein levels were not detectable by western blot 
(Figure 5-1). Whilst consistent in showing low level most likely reason for the 
difference is that the method for detection of mRNA (i.e. PCR) is much more sensitive 
than the method for detecting protein (i.e. Western blotting) (Koussounadis et al., 2015, 
Greenbaum et al., 2003) 
The effect of suppressing CTSZ mRNA and protein was carried out in the Mg-63 
and TE-85 cell lines using RNAi. The result showed that expression levels of CTSZ 
mRNA and protein was significantly reduced in the CTSZ-siRNAs transfected cells 
compare to scrambled control for both Mg-63 and TE-85. Therefore, taken together, the 
knockdown of CTSZ expression at the level of mRNA was generally correlated with a 
similar degree of knockdown of CTSZ protein as in agreement with previous studies 
(Abreu et al., 2009, Edfors et al., 2016)   
As an initial stage to understanding the biological role of CTSZ in osteosarcoma 
cells, it was evaluated whether reduction in the level of CTSZ resulted in a reduction in 
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cell migration, invasion and proliferation of these cells. Overall, the proliferation, 
invasion and migration of cells were decreased with the reduced level of CTSZ. There 
was a clear and significant reduction of growth rate in CTSZ-siRNA transfectants cells 
compared to scramble control at day 6. Knockdown of CTSZ significantly reduced the 
number of cells invading through the Matrigel-coated membrane. Although there was no 
change in cell migration after 24 h, it was found that the wound closure rate was faster in 
the parental cells and scrambled control significant than in siRNA transfectants at 48 h, 
(Figure 5-14). Further statistical analysis was performed in order to assess the 
correlation between growth rate and migration/invasion. The rate of the growth in 
transfectant Mg-63 was significantly correlated with migration and invasion. Similarly, 
the proliferation of TE-85 transfectant showed a significantly correlation with migration 
and invasion (P= 0.009 and 0.024 respectively). These results suggest that CTSZ is 
involved in all three cellular activities-invasion, migration and proliferation. Given that 
the observed reduction in invasion (24h), and migration (48h) precede that of 
proliferation (6 days), the finding indicate that CTSZ-siRNA-induced inhibition of 
invasion and migration is independent of its effect on the proliferation and the reduction 
in growth rate at 24 and 48 hours was insufficient to account for the reductions in 
migration/invasion observed (Tremel et al., 2009). Likewise, it is comprehensible to 
suggest that cellular migration may be a prerequisite for proliferation. Also. The blunted 
invasion is in agreement with the protease activity of CTSZ.  
It was clear that there was a reduction of all function tests when CTSZ was 
suppressed using RNAi in Mg-63 and TE-85 cells. Nevertheless, Mg-63-CTSZ siRNA4 
and TE-85-CTSZ-siRNA 2 showing the highest effect of the CTSZ suppression on the 
function tests. In other words, different siRNAs have efficiently on different cells. The 
  Chapter 5 
 
210 | P a g e  
 
result here was consistent with other studies recently. Kraus et al indicated that 
suppression of CTSX induced cellular senescence and inhibited cell proliferation, and 
the cellular transmigration/ invasion in mouse embryonic fibroblasts (MEF) cells and 
neonatal normal human dermal fibroblasts (NHDF) (Kraus et al., 2011). In another 
study, antisense oligonucleotide suppression of CTSX protein revealed that cellular 
invasion of gastric adenocarcinoma cells infected with H. pylori was significantly lower 
compared with that in uninfected (Krueger et al., 2005). It was also reported that a lack 
of CTSX protein reduced the migration in neuroblastoma cells, and hence CTSX was 
suggested to play a role in migration of the SK-NBE2 cells (Gangoda et al., 2015). 
Recently, CTSZ gene was found to be estradiol-dependent, based on case-cohort 
genome-wide association study (GWAS) (Liu et al., 2014a). Furthermore, the 
suppression of CTSZ mRNA showed that the expression was changed in pathways 
associated with risk for bone fracture in postmenopausal breast cancer patients treated 
with aromatase inhibitors (AIs) for 5 years (Liu et al., 2014a). In concordance with the 
present experiment, overexpression of CTSZ in human hepatocellular carcinoma cell 
line (HCC cells) substantially enhanced the invasiveness, and significantly increased cell 
migration ability in a wound healing assay (Wang et al., 2011). Similarly, Jevnikar et al 
reported that overexpression of CTSX significantly raised transmigration and invasion 
of T lymphocytes compared with that of the wild-type cells through uncoated and 
ICAM1- coated polycarbonate membranes in a Transwell migration model. Matrigel-
coated polycarbonate membrane. Therefore, they suggested that CTSX might be an 
important factor enabling T lymphocytes to function effectively as migratory cells 
during the immune response (Jevnikar et al., 2008)  
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Overall, the rate of expression of CTSZ is directly proportional to proliferation, 
invasion and migration of cells. Thus, these data suggest that CTSZ is involved in other 
cellular mechanism besides proteolysis. However, it is possible that proteolysis might 
play a role in proliferation, migration and invasion. CTSZ plays role in migration, 
invasion and proliferation of the osteosarcoma cells, Mg-63 and TE-85. This indicates 
that CTSZ may be a target protein that controls the migration, invasion and proliferation 
of bone cells. These results indicate that CTSZ may be an important molecular 
biomarker in early diagnosis and prediction of treatment response and prognosis of 
osteoporosis. 
.
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Chapter 6: Final Discussion and Future Work
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6.1 Final Discussion 
Osteoporosis is a metabolic bone disorder characterized by low bone mass and 
increased incidences of fragility fracture (Ensrud and Crandall, 2017), particular in post-
menopausal women where estrogen deficiency plays an important role in bone 
homeostasis (Feng and McDonald, 2011). The regulation of bone formation and bone 
resorption is mediated through estrogen receptors α and/or β (Fitzpatrick, 2006).  Many 
studies have previously reported the possible ways that estrogen could regulate genes in 
osteoblast cells (Krum et al., 2008, Kassem et al., 1996, Chen et al., 2002). However, 
since most of these studies were carried out using cultured cells or animal model 
systems (van Wijnen et al., 2013), the occurrence of estrogen deficiency as related to 
bone homeostasis in postmenopausal women is not well understood. Thus, it is 
important to investigate hormone and hormone responsive molecules associated with the 
development of osteoporosis in that population.  
In this study, as summarized in Figure 6-1, a hormone responsive cell model 
system was established using osteosarcoma [osteoblast-like] cell lines, Mg-63, TE-85 
and Saos-2 cells, where Mg-63 is identified as the cell line being the least mature, Saos-
2 as the most differentiated and TE-85 may have a level of maturity somewhere between 
Mg-63 and Saos-2 (Pacheco-Pantoja et al., 2011). Both ER α and β mRNAs and proteins 
were expressed in Mg-63 cells, which is in full agreement with previous reports 
(Lambertini et al., 2003, Solakidi et al., 2005, Kurosawa et al., 2002). However, the 
levels of ER α proteins were much lower in both osteosarcoma cells, TE-85 and Saos2 
cells, compared to that in Mg-63 cells. The ER β protein was detected in all three 
osteosarcoma cell lines and showed similar levels to those of MCF-7 cells. Thus, the 
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probable reason for fewer differentially expressed hormone-responsive genes being 
identified in TE85 and Saos2 cells is there being insufficient amount of ER α proteins in 
both these cell lines for 17-β-estradiol to form homo-dimers of ERα or hetero-dimers 
with ERβ to interact with specific DNA sequences to activate transcription (Khalid and 
Krum, 2016). 
To assess the RNA Seq quality of each sample, mapping of the sequencing data 
was performed. The alignment of RNA-seq reads to the human reference genome 
showed that around 88 % of the total reads were identical to the human reference 
genome. The result here indicates good quality reads and theabsence of contamination 
based on RNA-seq criteria. It has been reported that in a typical experiment, it is 
possible to align 60 -90 % of the reads to the reference genome, since accurate 
differential analysis depends on appropriately spliced read alignments which indicate 
good quality reads and the absence of contamination (Trapnell et al., 2012, Conesa et al., 
2016). 
A panel of differentially expressed hormone responsive genes were identified 
using RNA sequencing from established osteosarcoma cell line, Mg-63 cells after  
estradiol treatment. 154 genes were up-regulated and 108 genes were down-regulated 
compared to non-treated controls. Some of these genes are known to be involved either 
in the regulation of bone remodelling, or in responding to estrogen. About 181 (65 %) of 
these genes were also significantly altered in the estrogen-treated MCF-7 cells. 
Therefore, these genes are suggested to be responsive to β-estradiol (Wang et al., 2007). 
The remaining 81 genes distinctly expressed in the Mg-63 cells, were not differentially 
expressed by -estradiol in the MCF-7 cells, possibly reflecting the different origins of 
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the cells, i.e. bone and breast cells (Deroo et al., 2009) and suggests that these 81 genes 
might be bone-specific, estrogen-responsive genes/mRNAs.   
A panel of 55 differentially-expressed hormone-responsive genes identified by 
RNA sequencing were validated initially using cultured osteosarcoma cells by RT-
qPCR. The results showed that 45 out of 55 genes (around 82%) were detected at altered 
levels in the cultured osteosarcoma cells indicating that changes in levels of these 
mRNAs might be associated with the development of osteosarcoma cells.  
It is noted that among identified estrogen responsive genes from this study, both 
CTSZ and TRAM2 genes were also reported to be associated with risk for bone fracture 
in a case-cohort genome-wide association study (GWAS) using samples from 1071 post-
menopausal women patients treated with aromatase inhibitor (Liu et al., 2014a). This 
GWAS study confirms the relationship between estrogen and CTSZ and TRAM2 gene 
expression. 
The estrogen receptor 1 gene (ESR1) and the RUNX2 gene, found differentially 
expressed in the present study, have also been identified in 3 different large international 
GWAS reports (Richards et al., 2008, Styrkarsdottir et al., 2008, Estrada et al., 2012). 
One GWAS comprised 2094 UK and 6463 Western European subjects (Richards et al., 
2008), a second GWAS comprised 10,026 Icelandic, 2269 Danish, and 1491 Australian 
subjects (Styrkarsdottir et al., 2008), and a third GWAS comprised 80,000 BMD and 
130, 000 fracture cases and controls of European and east Asian origin (Estrada et al., 
2012). This suggests that ESR1 and RUNX2 are widely associated with risk factors for 
osteoporosis. Although the remaining genes identified from this study have not been 
reported in GWAS, this could be due to the natural complexity of osteoporosis, 
variations in hormone levels, fracture history, and the heterogeneity of different 
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populations, age and ethnicity of the subjects of the studies (Mendoza et al., 2012). 
Furthermore, GWAS analyses identify genome variations, but not gene expression levels 
(Liu et al., 2014a), whereas the present study focuses directly on expressed mRNA 
levels. 
Upon further analysis, it was revealed that some of the validated genes were 
associated with the development of osteoporosis in clinical samples, PBMCs, using RT-
qPCR. The levels of ANXA1, S100A4, and XBP1 mRNAs were significantly decreased 
in PBMCs associated with a reduced T-score in osteoporotic patients (p = 0.0291, 
0.00034, 0.0001, respectively). Particularly, it was found previously that suppression of 
ANXA1 decreases the formation of osteoclast in both arthritis and monocyte-derived 
human macrophages by promoting IL-6 release (Kao et al., 2014). Also, ANXA1 has 
been shown to be a bone formation modulator in rat osteoblasts in primary cell cultures 
through enhancing PTH-mediated cAMP stimulation by binding calcium ions that act as 
a second messenger relaying the PTH signal intracellularly (Suarez et al., 1993). 
Potential target miRNAs of ANXA1 mRNA were identified using 4 different algorithms 
(miRanda, miRDB, miRWalk and Targetscan) within the miRWalk 2.0 database. 
miR100-5p and miR-196b-3p showed to be target miRNAs for ANXA1. In PBMCs, 
ANXA1 mRNA was positively regulated by miR100-5p (p = 0.0002), and negatively 
regulated by miR196b-3p (p < 0.0001). ANXA1 has previously been identified as a 
target for regulatory miRNAs 196a and 196b, with inversely proportional expression 
levels detected in a variety of cancer cell lines (Luthra et al., 2008). Also, Gir et al 
(2012) and Kim et al (2009) showed that miRNA 196a inversely regulates the osteoblast 
precursor (Gir et al., 2012, Kim et al., 2009). This is in concordance with the reported 
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role of ANXA1 favoring osteoclast formation, evident by the reduced expression of 
ANXA1 in postmenopausal osteoporosis compared to non-osteoporotic participants’. 
Cathepsins are a family of serine, cysteine, and aspartyl protease enzymes 
involved in cell turnover (Santamaria et al., 1998). Members of the Cathepsin family 
have been found to be involved in serious clinical conditions including cancer, 
neurodegenerative disorders, and arthritis (Santamaria et al., 1998, Mohamed and 
Sloane, 2006), and the association of cathepsins with bone remodelling in osteoclasts is 
well established (Holzer et al., 2005, Lang et al., 2004, Han et al., 2009, Wilson et al., 
2009). However, the role of CTSZ in bone disorder has not been sufficiently 
investigated until Liu et al confirm the presence of CTSZ to be estradiol-dependent, 
based on case-cohort GWAS and suggested that suppression of CTSZ mRNA result in 
changing in pathways associated with risk for bone fracture in postmenopausal breast 
cancer patients (Liu et al., 2014a). Our data indicate that the expression of CTSZ mRNA 
showed an inverse relationship to the maturity degree of osteosarcoma cells. Also, the 
levels of CTSZ mRNA were much higher in PBMC of osteoporotic patients compared 
with osteopenia patients and non-osteoporotic controls (p = 0.0007). Increasing levels of 
CTSZ mRNA in PBMC significantly correlated with the reduced bone mineral density 
T-score in osteoporosis patients (p = 0.0002). ROC analysis for CTSZ mRNA showed 
an AUC of 0.806 and p = 0.002, suggesting that CTSZ mRNA might have utility for 
further development as a biomarker for osteoporosis in post-menopausal women. 
Furthermore, through a follow-up cellular functional study, suppression of CTSZ 
mRNA/protein expression using RNAi significantly inhibited invasion, migration and 
proliferation of Mg-63 and TE-85 cells. Kraus et al indicated that suppression of CTSZ 
inhibited cell proliferation, and the cellular transmigration/ invasion in mouse embryonic 
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fibroblasts (MEF) cells and neonatal normal human dermal fibroblasts (NHDF) (Kraus 
et al., 2011). Also, in concordance with the present experiment, it was found that 
overexpression of CTSZ in human hepatocellular carcinoma cell line (HCC cells) and T 
lymphocytes significantly raised the transmigration and invasion compared with that of 
control cells (Wang et al., 2011, Jevnikar et al., 2008) 
 Taken together, these results suggest that CTSZ might be a target protein that 
modulates the migration, invasion and proliferation of bone cells. To our knowledge, 
this is the first report of the presence of CTSZ mRNA and protein in cultured 
osteosarcoma cells, and the first demonstration of an association between CTSZ and 
osteoporosis in clinical samples. The elevated CTSZ mRNA expression level, as 
detected in low BMD participants, probably stimulate more PBMC, osteoclast 
precursors, migration/invasion through blood vessel walls to bone resorption surface in 
vivo. This is where they differentiate into higher number of mature osteoclasts 
eventually leading to enhanced bone resorption (i.e. osteoporosis). These findings 
indicate that CTSZ may be an important molecular biomarker for both the in early 
diagnosis of osteoporosis as well as prediction of treatment response and prognosis.  
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Figure 6-01: Project summary and findings. 
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6.2 Future study  
To fully establish this study following further studies are needed: 
➢ Although there are many pathways through which osteoclast can be activated, 
the results presented in this thesis clearly indicate CTSZ is a major inducer of 
bone loss in osteoporosis in post-menopausal women. Nevertheless, further 
larger studies will be required to identify the exact pathways and targets, such as 
Wnt signalling pathway through which inhibiting CTSZ with the biologic agents 
could bring about such outcome. 
➢ Some in-vivo studies are needed to assess the ability of suppressed CTSZ to 
reduce the migration and invasion abilities of osteoclast cells and the ability of 
PBMCs to form osteoclast cells and the possibility of using it as a treatment 
target.  
➢ Other identified estrogen-responsive genes, such as ANXA1, GSDMD, 
TMEM64, miR-196b-3p and miR-100-5p, need to be tested with large number of 
clinical samples to have a clear picture about molecular mechanism underlying 
estrogen deficiency in postmenopausal osteoporosis women    
➢ As part of the national research programme in the Kingdom of Saudi Arabia, part 
of the current work will be expanded to include osteoporosis in postmenopausal 
women patients from that country since this disease has a high prevalence in that 
area with, potentially, additional more risk factors, particularly lifestyle. 
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8.1 Laboratory Equipment 
Table 8-1 Equipment used in this project 
No. Equipment Manufacture and Model 
1 -80° Freezer ESCO Lexicon ULT 
Freezer 
2 Automated Cell counter  ScepterTM, MILLPORE, 
UK 
3 BIO-RAD T100 Thermocycler. Bio-Rad Laboratories 
Ltd., UK 
4 BioRad ChemiDOCTM digital imager Bio-Rad Laboratories 
Ltd., UK 
5 CryoPure Tube 1.8 mL STARLAB Ltd, UK 
6 ESCO Class II BS Cabinet AC2-4G1SP Biological 
safety cabinet class II. 
ESCO, UK 
7 Gel power pack Power PacTM HC, BIO-RAD, UK 
8 Gel Transfer Trans-Blot®Turbo Transfer System, BIO-RAD, UK 
9 Genies2 Vortex mixer Scientific Laboratory 
Supplies Ltd 
10 Microcentrifuge SCF2 Fisher Scientific UK 
11 Nikon Diaphot inverted microscope/D50 camera Nikon 
12 PCR hood PCR Workstation 
13 Qubit® Protein Assay Kit using the Qubit® Flurometer 
2.0 
Invitrogen Ltd, Paisely, 
UK 
14 Roche Lightcycler® 96 Real-Time PCR System. Roche Diagnostics Ltd, 
UK 
15 SPECTROstar Nano LabTech, Germany 
16 Thermo Heraeus Megafuge 16R Centrifuge 
(Refrigerated) 
ThermoFisher, UK 
17 Thermo Scientific Heraeus Fresco Centrifuge 17R 
(Refrigerated) 
ThermoFisher Ltd, UK 
18 Thermo Scientific NanoDrop™ 2000 spectrophotometer ThermoFisher Ltd, UK 
19 ThermoBloc, FALC Lurano, ITALY 
20 Waterbath Grant, JB Aqua 18 Plus 
21 -80° Freezer ESCO Lexicon ULT 
Freezer 
 
  
  Appendix 
 
256 | P a g e  
 
Table 8-2 Consumables used in this study 
No. Material  Manufacture and Model 
1 1.5mL ultra High Recovery (UHR) Microcentrifuge 
Tube  
STARLAB Ltd, UK 
2 2.0mLultra High Recovery (UHR) Microcentrifuge Tube STARLAB Ltd, UK 
3 6/12/24 well tissue culture plates Techno Plastic Products 
4 96-well real time PCR plates Starlab 
5 CryoPure Tube 1.8 mL STARLAB Ltd, UK 
6 Disposable serological pipette tips Starlab 
7 Filter Tip (Sterile), 0.5-10µl Fisher Scientific Ltd, UK 
8 Filter Tip (Sterile), 2-20µl Fisher Scientific Ltd, UK 
9 Filter Tip (Sterile), 100-1000µl Fisher Scientific Ltd, UK 
10 Greiner Bio-One 10 mLLeucosep® tube, sterile for 3-8 
mLblood 
 Greiner bio-one Ltd, UK 
11 SARSTEDT S-Monovette® 9mLK3E, Potassium EDTA STARLAB Ltd, UK 
12 STARLAB 15 mLPolypropylene Centrifuge Tubes STARLAB Ltd, UK 
13 STARLAB 50 mLPolypropylene Centrifuge Tubes STARLAB Ltd, UK 
14 TC-25, TC-75 flasks STARLAB Ltd, UK 
15 Filtropur S 0.45 syringe filter SARSTEDT, UK 
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8.2 Materials for Blood Collection and Molecular 
Biology  
Table 8-3 Chemical and reagent used in this project 
No. Chemical and Reagent Manufacture 
1 Charcoal Stripped Fetal Bovine Serum,  Sigma-Aldrich Company Ltd., UK 
2 Chloroform [Sigma] (>99.5% Purity, 119.38 
g/mol (mW)) 
Sigma-Aldrich Company Ltd., UK 
3 Dimethyl sulfoxide (DMSO), Sigma-Aldrich Company Ltd., UK 
4 Dulbecco’s Modified Eagle’s Medium, Sigma-Aldrich Company Ltd., UK 
5 Ethyl alcohol, Pure ≥95% [Sigma] Sigma-Aldrich Company Ltd., UK 
6 Fetal Bovine Serum (FBS), Sigma-Aldrich Company Ltd., UK 
7 Ficoll-Paque Premium 1.077g/ml GE Healthcare Life Sciences, UK 
8 HiPerFect® Transfection Reagent QIAGEN Ltd, UK. 
9 L-Glutamine solution, Sigma-Aldrich Company Ltd., UK 
10 MEM Non-essential Amino Acid Solution 
(100×), 
Sigma-Aldrich Company Ltd., UK 
11 Methanol Sigma-Aldrich Company Ltd., UK 
12 miScript II RT Kit QIAGEN Ltd, UK. 
13 miScript SYBR Green PCR Kit QIAGEN Ltd, UK. 
14 Penicillin-Streptomycin, Sigma-Aldrich Company Ltd., UK 
15 Pure-ethanol molecular biology grade Sigma-Aldrich Company Ltd., UK 
16 PureLink® RNA Mini Kit Ambion by life technology, UK 
17 Qubit® Protein Assay Kit Ambion by life technology, UK 
18 RIPA Lysis and Extraction Buffer ThermoFisher, UK 
19 RNaseZap® Solution Life Technologies Ltd, UK 
20 Roswell Park Memorial Institute (RPMI) 
without L-glutamine 
Sigma-Aldrich Company Ltd., UK 
21 RT2 First Strand Kit QIAGEN Ltd, UK. 
22 RT² SYBR Green qPCR Mastermix QIAGEN Ltd, UK. 
23 Shandon™ Kwik-Diff™Stains ThermoFisher, UK 
24 SuperSignal™ West Femto Chemiliminescent 
Substrate 
ThermoFisher, UK 
25 Thiazolyl Blue Tetrazolium Bromide Sigma-Aldrich Company Ltd., UK 
26 Trizol® Reagent Life Technologies Ltd, UK 
27 Trypsin-EDTA solution Sigma-Aldrich Company Ltd., UK 
28 β-Mercaptoethanol  BIO-RAD, UK 
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8.3 Gene Ontology Reference 
Table 8-4: ontology reference of identified genes in Mg-63 using cufflinks 
software by Earlham Institute 
 GO class   Genes  Reference   Evidence  
Androgen metabolic process ESR1 GO_REF:0000107 IEA 
Angiotensin maturation CTSZ Reactome:R-HSA-2022381 TAS 
Bone morphogenesis MEF2CA ZFIN:ZDB-PUB-030304-
18|PMID:12588850 
IMP 
Bone trabecula formation COL1A1 GO_REF:0000107 IEA 
 
MMP2 GO_REF:0000107 IEA 
Cartilage development involved 
in endochondral bone 
morphogenesis 
COL1A1 GO_REF:0000107 IEA 
Cellular response to estradiol 
stimulus 
ESR1 RGD:1600115 IEA 
 
MMP2 RGD:2325711|PMID:19861308 IMP 
 
UGT1A1 GO_REF:0000107 IEA 
Collagen fibril organization COL14A1 PMID:2187872 NAS 
 
COL1A1 GO_REF:0000107 IEA 
 
COL1A2 GO_REF:0000107 IEA 
 
COL3A1 GO_REF:0000107 IEA 
Embryonic cranial skeleton 
morphogenesis 
PDGFRA GO_REF:0000107 IEA 
Embryonic skeletal system 
morphogenesis 
HOXB3 GO_REF:0000107 IEA 
 
HOXB4 RGD:1600115 IEA 
 
HOXB6 GO_REF:0000107 IEA 
 
MEF2C MGI:MGI:3714538|PMID:17420000 IMP 
 
ZEB1 GO_REF:0000107 IEA 
Endochondral ossification COL1A1 GO_REF:0000107 IEA 
 
MEF2C RGD:1600115 IEA 
Estrogen metabolic process PDGFRA GO_REF:0000107 IEA 
 
UGT1A1 PMID:8780690 TAS 
Growth hormone secretion LTBP4 PMID:9660815 TAS 
Insulin secretion ANXA1 GO_REF:0000107 IEA 
Muscle contraction CALD1 Reactome:R-HSA-445355 TAS 
 
MYOM2 PMID:7505783 TAS 
 
TPM2 Reactome:R-HSA-445355 TAS 
 
VIPR1 PMID:8390245 TAS 
Muscle filament sliding TPM2 Reactome:R-HSA-390522 TAS 
Negative regulation of cartilage 
condensation 
MMP2 PMID:17604018 IMP 
Negative regulation of hormone 
biosynthetic process 
CACNA1A GO_REF:0000107 IEA 
Positive regulation of gene 
expression 
ESR1 PMID:21047992 IDA 
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Positive regulation of parathyroid 
hormone secretion 
FGFR1 GO_REF:0000107 IEA 
Positive regulation of steroid 
hormone biosynthetic process 
IGF2 MGI:MGI:4417868|GO_REF:0000096 ISO 
Prolactin secretion ANXA1 GO_REF:0000107 IEA 
Regulation of aldosterone 
metabolic process 
KCNMA1 PMID:8973172 ISA 
Regulation of cardiac muscle cell 
contraction 
PDE4D GO_REF:0000024 ISS 
Regulation of cardiac muscle 
contraction by regulation of the 
release of sequestered calcium ion 
GSTM2 PMID:17023043 IC 
Regulation of hormone secretion ANXA1 PMID:19625660 IMP 
Regulation of insulin secretion CACNA1A Reactome:R-HSA-422356 TAS 
Regulation of skeletal muscle 
contraction by regulation of 
release of sequestered calcium ion 
GSTM2 PMID:17023043 IC 
Relaxation of cardiac muscle GSTM2 PMID:21323602 TAS 
Response to estradiol ALDH1A2 GO_REF:0000107 IEA 
 
ANXA1 GO_REF:0000107 IEA 
 
COL1A1 GO_REF:0000107 IEA 
 
ESR1 RGD:2313676|PMID:9528993 IEP 
 
IFI27 RGD:68731|PMID:11356686 IEP 
 
IGF2 RGD:2311518|PMID:18946176 IEP 
 
PDGFRA RGD:2292171|PMID:14724432 IEP 
Retinoic acid biosynthetic process ALDH1A2 MGI:MGI:4417868|GO_REF:0000096 ISO 
Retinoic acid metabolic process ALDH1A2 GO_REF:0000024 ISS 
 
UGT1A1 PMID:20308471 IC 
 
UGT1A3 PMID:20308471 IC 
 
UGT1A7 PMID:20308471 IC 
 
UGT1A8 PMID:20308471 IC 
 
UGT1A9 PMID:20308471 IC 
Retinol metabolic process ALDH1A2 GO_REF:0000041 IEA 
Skeletal muscle contraction CCDC78 PMID:22818856 IMP 
Skeletal system morphogenesis COL1A1 MGI:MGI:3710444|PMID:17440987 IGI 
 
FGFR1 PMID:15863030 TAS 
 
HOXB4 RGD:1624291 ISO 
 
MMP2 RGD:1624291 ISO 
 
PDGFRA RGD:1624291 ISO 
Smooth muscle contraction PDE4D GO_REF:0000107 IEA 
Smooth muscle contraction 
involved in micturition 
KCNMA1 PMID:11641143 IDA 
Striated muscle contraction DTNA PMID:10767327 TAS 
 
MYOM2 GO_REF:0000033 IBA 
Response to estrogen ESR1 PMID:11581164 IDA 
 PDGFRA RGD:2292171|PMID:14724432 IEP 
 KRT19 GO_REF:0000107 IEA 
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Cellular response to estrogen 
stimulus 
ESR1 GO_REF:0000107 IEA 
 
 
 
 
 
 
 
